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nigrostriatal pathway in a rat model of PD. Immunohistochemistry, FSCV, and behavioral tests were
conducted to assess the ability of the micro-TENNs to reconstruct the pathway, release dopamine in the
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discrete somatic and axonal regions could be fabricated to span nigrostriatal pathway in rats. Our worked
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cytoarchitecture, extend dopaminergic neurites into the host tissue, and release an appropriate concentration
of dopamine. In conclusion, this dissertation showed proof of concept for using dopaminergic micro-TENNs
to reconstruct the nigrostriatal pathway and laid the groundwork for future optimization studies necessary for
clinical translation. This strategy has the potential to provide a transformative solution to replace lost
neuroanatomy and alleviate the cause of motor symptoms for patients afflicted by PD.
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ABSTRACT
TISSUE ENGINEERED NIGROSTRIATAL PATHWAY
FOR TREATMENT OF PARKINSON’S DISEASE
Laura Anne Struzyna
Daniel Kacy Cullen, Ph.D.

Parkinson’s disease is a progressive neurodegenerative disease that affects 1-2% of
people over 65, causing significant morbidity across a prolonged and escalating disease
course. The classic motor deficits of Parkinson’s disease (PD) are caused by degeneration
of dopaminergic neurons in the substantia nigra pars compacta (SNpc), resulting in the loss
of their long-distance axonal projections that modulate the striatum. Contemporary
treatments only minimize the symptoms of this disconnection, as there is no approach
currently capable of replacing the nigrostriatal pathway. In this dissertation, we applied
micro-tissue engineering techniques to create living, implantable micro-tissue engineered
neural networks (micro-TENNs) that mimic the architecture and function of the
nigrostriatal pathway. These constructs consisted of dopaminergic neurons with long
axonal tracts encased within hydrogel micro-columns; lumen extracellular matrix (ECM),
growth factors, and end targets were varied to optimize cytoarchitecture and neurite length.
Immunocytochemistry, fast scan cyclic voltammetry (FSCV), and imaging analysis were
used to investigate the functional characteristics of the constructs in vitro, including their
ability to release dopamine and integrate with a population of striatal neurons. Finally, the
constructs were transplanted to span the nigrostriatal pathway in a rat model of PD.
v

Immunohistochemistry, FSCV, and behavioral tests were conducted to assess the ability of
the micro-TENNs to reconstruct the pathway, release dopamine in the striatum, and
improve motor deficits. This work confirmed that dopaminergic micro-TENNs
demonstrating discrete somatic and axonal regions could be fabricated to span nigrostriatal
pathway in rats. Our worked showed that they had the machinery to release dopamine,
recycle dopamine, and functionally integrate with striatal neurons in vitro. In vivo studies
established that transplanted micro-TENNs could maintain their cytoarchitecture, extend
dopaminergic neurites into the host tissue, and release an appropriate concentration of
dopamine. In conclusion, this dissertation showed proof of concept for using dopaminergic
micro-TENNs to reconstruct the nigrostriatal pathway and laid the groundwork for future
optimization studies necessary for clinical translation. This strategy has the potential to
provide a transformative solution to replace lost neuroanatomy and alleviate the cause of
motor symptoms for patients afflicted by PD.
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CHAPTER 1: INTRODUCTION
1.1 Overview
Parkinson’s disease (PD) is a progressive neurodegenerative disease that affects 12% of people over 65.1,2 The classic motor symptoms of PD are caused by selective
degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc),
resulting in a loss of their long-projecting axonal inputs to the striatum. Unfortunately,
current treatment strategies can only minimize the symptoms of this disconnection, not
directly replace the crucial nigrostriatal pathway. The purpose of this dissertation is to
advance the first regenerative medicine strategy enabling the direct reconstruction of the
nigrostriatal pathway, which is preferentially vulnerable in Parkinson’s disease (PD). We
will develop novel custom-built micro-tissue engineered neural networks (micro-TENNs)
comprised of dopaminergic neurons and long-projecting axonal tracts and transplant them
to physically replace lost neurons and their axonal connections to the striatum in rat models
of PD. Our overarching hypothesis is that preformed micro-TENNs will survive,
synaptically integrate, and thereby physically reconstruct the nigrostriatal pathway to
restore motor function in models of nigrostriatal disconnection. If successful, microTENNs will provide a transformative solution to replace lost neuroanatomy and alleviate
the cause of motor symptoms for patients afflicted by PD.
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1.2 Background
1.2.1 The Challenge of Central Nervous System Regeneration
The extraordinary computational capabilities of the human brain rely on vast axonal
connections spanning long distances that form sophisticated neural circuits and enable
profound parallel processing, often referred to as the connectome.3 Degeneration and
disconnection of these axonal pathways as well as localized neuronal degeneration
frequently occur in many central nervous system (CNS) disorders, including traumatic
injury, stroke, PD and others.4–8 Unfortunately, in the CNS, functional regeneration rarely
occurs. CNS neurogenesis is restricted to a few distinct domains such as the subventricular
zone and the dentate gyrus of the hippocampal formation.9–11 In the majority of the CNS,
natural regeneration of long axon pathways does not occur, mainly due to endogenous
inhibition of axon growth, absence of directed guidance to far distant targets, and loss of
intrinsic capacity for long outgrowth in mature neurons.4–8,12,13 The lack of neurogenesis
and correctly targeted axonal re-growth are key limitations in endogenous CNS
regeneration and repair, thereby resulting in diminished recovery and continued functional
deficits.

1.2.2 Principles of Tissue Engineering in the Nervous System
Tissue engineering is a branch of regenerative medicine that combines aspects of
biomaterial scaffolds and cell delivery techniques to promote regeneration and functional
restoration following injury or disease.14 Cell delivery strategies may replace lost cells in
2

cases where endogenous cells are insufficient or dysfunctional and may utilize primary,
stem, differentiated, genetically engineered, autologous, allogeneic, or heterologous
cells.15–22 Living cells possess the ability to secrete thousands of neurotrophic factors and
may actively modulate pro-regenerative cues such that they remain optimal for axon
guidance and sprouting, myelination, and the restoration of complex 3-D tissue structures.
While cell-based strategies provide several key advantages for promoting neuroregeneration, there are also significant drawbacks to this approach. Living cells may elicit
an immune response from host tissue leading to inflammation or rejection of the graft,
depending on the source and phenotype of the cells.23 This response can be circumvented
through the use of autologous cells from the patient. Additionally, whereas glial cells elicit
a vigorous immune response and show poor attrition upon transplantation, constructs
consisting of pure neurons appear to be well tolerated by the immune system and survive
at least several months.24–26 Certain undifferentiated stem cells also may be immune
privileged and only elicit a delayed or significantly attenuated immune response.27
Although undesirable, immunosuppression can be utilized to mitigate an immune response.
Interestingly, in some cases adjunct immunosuppression has actually been shown to
accelerate axonal regeneration and functional restoration.28 An additional challenge with
cell-based techniques is that increasing the regenerative capacity of the cellular
environment may lead to excessive or aberrant regeneration, such as over-proliferation of
host cells as well as formation of deleterious axonal connections. Although the challenge
of aberrant regeneration is not limited to cell-based strategies, regenerative constraints may
be necessary in certain applications. However, the nervous system does maintain
3

tremendous capacity for plasticity, creating the possibility of effective use of novel
connectivity.
Biomaterials provide 3-D structure for host cell infiltration, differentiation, and
organization, and may also serve as a means for drug administration (e.g., controlled
release).14,29 Biomaterials are generally fabricated from synthetic or naturally occurring
polymers and are sometimes loaded or coated with soluble factors to promote neural
regeneration.15,30,31 Such therapies alone are limited in recreating and maintaining the
optimal concentrations of soluble factors and presentation of structural cues for
regeneration; they weakly simulate the conditions that exist during embryonic development
when neurogenesis and axogenesis first occur. At present, biomaterial scaffolds can only
deliver a relatively small number of factors involved in regeneration, and, although
controlled release of soluble factors is a common objective, acellular scaffolds are not
currently capable of modulating secreted factors based on the progression and state of the
regenerative process.15,30,32 As such, the mechanisms and efficacy of numerous acellular
constructs have not successfully translated to in vivo environments despite being
“optimized” in vitro, suggesting that endogenous processes and signals may override the
regenerative effects of many contemporary acellular biomaterials.
In combining biomaterial and cell replacement strategies, tissue engineering
techniques consist of three-dimensional (3-D) environments capable of influencing cell
(native and/or implant) behavior such as phenotype, architecture, migration, and survival.
This architecture may be precisely engineered to match the structure and properties of the
tissue for integration: to provide directionality for infiltration from implant to host, vice4

versa, or both.17–22,33,34 Tissues may be synthesized to promote desired cellular
organizations or mechanical properties (e.g. rigidity or elasticity) that are directionally
dependent (anisotropic).35 Likewise, gradients of factors, such as growth factors and
signaling molecules, may be used within tissue engineered scaffolds to generate anisotropic
features.31 The permissive microenvironment or proper matching of mechanical features
created by some biomaterial hydrogels may also improve graft survival by influencing
inflammatory reactions and minimizing the foreign body response.36 In the CNS, both cell
replacement and tissue engineering strategies are being vigorously pursued to facilitate
regeneration of native tissue and/or to directly restore lost function based on permanent
structural integration.16–19,37–39 While these techniques offer the advantage of being
“personalized”, i.e. fabricated using a patient’s own cells to treat their specific neurological
affliction, it may be desirable in other cases to have generalized scaffolds available “off the
shelf.” This prospect creates several challenges associated with the scale-up and storage of
live constructs, as well as the quality control measures following production and
immediately prior to implantation.40 These challenges are shared with all emerging
regenerative medicine and tissue engineering strategies for living grafts and organ
replacement, and thus there are a number of companies focused on various strategies to
address these issues.40,41

1.2.3 Significance of Parkinson’s Disease
PD is a progressive neurodegenerative disease that causes significant morbidity
across a prolonged and escalating disease course. PD is characterized by resting tremor,
5

bradykinesia (slowness of movement), rigidity, and other symptoms that decrease quality
of life, ultimately leading to significant disability via the inability to control motor function
(akinesia).1,42 In the U.S., 50,000-60,000 cases are diagnosed each year with over 1 million
people diagnosed in total.1 As the disease affects 1-2% of people over 65, its prevalence is
expected to double in the next 20 years.1,2 The cost of PD is estimated to be nearly $35
billion per year in the U.S. alone.43 Recent studies have estimated that arresting PD
progression would result in net monetary benefits of almost $450,000 per patient, and if
PD progression was slowed by 20%, a benefit of over $75,000 per patient would be
realized.43

1.2.4 Neuropathology of Parkinson’s Disease
The motor symptoms of PD are caused by the selective loss of dopaminergic
neurons in the substania nigra pars compacta (SNpc) projecting to the dorsal striatum,
which is composed of the caudate and putamen (see Figure 1.1 for an overview of the
relevant neuroanatomy). SNpc degeneration is thought to result from the formation of
Lewy bodies and Lewy neurites, inclusions in cytoplasm and processes, respectively.44 The
primary components of Lewy pathology are filaments of a-synuclein, a neuronal protein
normally found in synaptic terminals.45 Lewy pathology also occurs outside of the SNpc
and striatum, including in the olfactory bulb, medulla, pons, spinal cord and peripheral
autonomic system, and in later stages of PD, the midbrain, amygdala, hippocampus, and
several other cortical regions.46,47 At the time of motor symptom onset, at least 60% of
SNpc cells have degenerated.44 There are several theories as to why dopaminergic neurons
6

are preferentially impacted, but many believe that a combination of factors including
structure, function, and metabolic needs make dopaminergic neurons particularly
vulnerable to the pathophysiology of PD.48
Non-motor symptoms associated with PD affect nearly the entire body,
encompassing a wide range of manifestations including, sensory, autonomic, sleep,
neuropsychiatric disorders, sensory deficits, irregular sleep cycle patterns, cognitive
decline, depression, anxiety, apathy, psychosis, and various autonomic bodily functions.49–
51

Although PD is commonly associated with motor symptoms, some non-motor

symptoms, such as sensory deficits and irregular sleep cycle patterns, might present before
the onset of the classic motor symptoms of PD, while others manifest at later stages, such
as cognitive decline and neuropsychiatric disorders.52 Widespread a-synuclein pathology
is often observed throughout the central and peripheral nervous systems in regions
associated with the presentation of non-motor symptoms, however the exact mechanism
remains unclear.53 Growing evidence has implicated diffuse brain atrophy and
neurotransmitter depletion (e.g. noradrenergic, serotonergic, and cholinergic) in multiple
interconnected CNS pathways, specifically between the striatum, prefrontal cortex, limbic
system, and spinal cord, in the manifestation of non-motor symptoms of PD.54
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Figure 1.1: Overview of Basal Ganglia Neuroanatomy. A schematic overview of the
primary motor circuits in the basal ganglia, the indirect (left) and direct (right) pathways.
Note, contralateral connections are to separate indirect and direct pathways. Crossing sides
do not imply decussation. Excitatory connections are depicted in green with triangle end,
inhibitory connections are depicted in red with "T" end. Not all connections are depicted,
including but not limited to, all connections from thalamus to cortex, all connections from
cortex to striatum, connections to/from caudate nucleus (tail), connections from cortex to
brainstem, and inputs to SNpc (pictured in the inset). Inset: a schematic overview of inputs
to SNpc found in literature. The PPN is located caudal to the substantia nigra and inputs
are depicted as such. Inputs from the caudate nucleus (tail) are not pictured, and all inputs
from the cortex are not pictured. Merging of signals from the cortex or caudate/putamen
are done for illustrative purposes. D1; D1 receptors; D2; D2 receptors; DA, dopamine;
ENK, enkephalin; GLU, glutamate; NUC, nucleus; PPN, pedunculopontine nucleus; SP,
substance P; SUB, substantia.
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1.2.5 Importance of the Nigrostriatal Pathway and Implications of Its Loss
As SNpc neurons send long axonal projections to the striatum, the stereotypical
neurodegeneration that occurs in PD deprives the striatum of crucial dopaminergic inputs
and thereby interrupts important motor feedback pathways. The nigrostriatal pathway is a
major component of the basal ganglia, the interconnected structures within the brain
involved in motor control (Figure 1.1). The main structures in the basal ganglia circuitry
are the dorsal striatum (caudate nucleus and putamen), the core of the nucleus accumbens,
the globus pallidus, the subthalamic nucleus, and the substantia nigra. The primary input
target of the basal ganglia is the striatum, which integrates the incoming sensorimotor
information via projections from the neocortex, intralaminar nuclei of the thalamus, and
midline nuclei of the midbrain. Output projections from the internal segment of the globus
pallidus (GPi) and pars reticulata of the substantia nigra (SNpr) are modulated by two basal
ganglionic circuits, which are referred to as the “direct” and “indirect” pathways.55 The
direct pathway serves to increase movement with inhibitory projections from the striatum
to the SNpr and GPi. The indirect pathway serves to decrease movement with inhibitory
projections to the external segment of the globus pallidus (GPe), which in turn sends
inhibitory projections to the subthalamic nucleus (STN) that sends excitatory projections
to the GPi and SNpr.56–59 These pathways are antagonistic: the direct pathway leads to
motor facilitation, and the indirect pathway suppresses unwanted motor movement (motor
cessation).
As such, a main component of the basal ganglia motor circuit is the nigrostriatal
pathway with dopaminergic projections originating from neurons in the SNpc. The
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projections comprise the highly dense axonal arborization found mostly in the striatum
with some collateral arborization in the GPe. Dopamine-releasing axons in the nigrostriatal
pathway synapse onto GABAergic medium spiny neurons in the striatum. In the direct
pathway, the terminals synapse to D1-receptors, and in the indirect pathway, the terminals
synapse to D2-receptors. Dopamine release activates the direct D1-receptor-mediated
pathway that ultimately facilitates motor movement. In non-pathologic conditions, the
cortex activates the indirect pathway with a smaller contribution of inhibition through
SNpc dopamine release on D2-receptor cells in the striatum. In PD, the degeneration of
SNpc dopamine neurons shifts the balance of direct and indirect pathways. The net result
of both pathways is inhibitory cells in the GPi/SNpr are more active to create a stronger
inhibition of the thalamus that culminates in less activation of the motor cortex.
The diagram of the indirect and direct pathways (Figure 1.1) is meant to
approximate the primary pathways for motor movement, and includes an insert containing
an important aspect often left out of published pathway diagrams: input to the SNpc, which
modulate basal ganglia activity, thus closing the feedback loop (Figure 1.1) Indeed, the
literature indicates the presence of a wide array of inputs into the SNpc including
GABAergic from the caudate/putamen, glutamatergic from the cortex and STN,
glutamatergic and cholinergic from pedunculopontine nucleus, and GABAergic input from
the SNpr.60–67 It is probable that these inputs to the SNpc are vital for highly functioning
motor feedback circuits.66,67
The striatum is further organized into two distinct compartments comprised of
dendrite and local axon collaterals known as the striosomes and the matrix.68 The matrix
10

compartment relays information from sensorimotor input and output neurons to the GPi
and SNpr via the direct and indirect pathways. Striosomes, also known as patch
compartments, are widely distributed regions within the striatum comprising
approximately 15% of the volume in the striatum. The striosome compartments form an
interconnected 3-D labyrinthine network within the striatum. Striosome neurons are
thought to modulate the entire dorsal striatum via their inhibitory afferents to the
dopaminergic neurons in the SNpc (not pictured in Figure 1.1).
Long-projecting axons from SNpc neurons exhibit an exquisite arbor in the striatum
to release dopamine at highly dense varicosities along the axon, which are organized en
passant with neighboring neuronal compartments. Dopamine has a rapid half-life, which
limits its sphere of influence. However, the highly dense arborization of dopaminergic
neurons provides overlapping and redundant innervation of the striatum, which leads to
increased temporal and spatial effects compared with what can be achieved from a single
dopaminergic neuron.69 Detailed anatomical work in rodents showed that a single
dopaminergic neuron innervates, on average, 2.7% of the neurons in one striatum (e.g.,
~75,000 out of 2,790,000 striatal neurons in one hemisphere of the rodent brain).68
Moreover, because of the redundant overlapping arborization, it is estimated that a single
striatal neuron is under the influence of 95-194 dopaminergic neurons from the SNpc.
Consequently, this highly redundant organization might contribute to the clinical
presentation of PD; patients only develop symptoms of Parkinsonism following an
extensive loss of dopaminergic neurons (>60%).48,68–71 The complexity and nuances of the
basal ganglia circuitry and the widespread innervation of a single nigrostriatal axon, let
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alone all nigrostriatal inputs, warrant thoughtful consideration regarding techniques for
adequate circuit reconstruction.

1.2.6 Historic and Current Treatments for Parkinson’s Disease
As far back as the 1940s, the advent of the stereotactic head frame allowed the
targeting of subcortical structures with great precision.72 Surgeons discovered
serendipitously that ablation or lesion therapy could modulate brain activity and ameliorate
the symptoms of PD.73,74 However, the discovery of levodopa (or other dopamine agonists)
led to a shift away from surgical therapy to chronic pharmaceutical treatment.75,76 These
agents attempt to compensate for the underproduction of dopamine due to cell loss.42 In
the early 1990’s, Laitinen et al. reintroduced the posteroventral pallidotomy and reported
significant improvements for all motor complications of PD.42 During pre-thalamotomy
mapping studies, high-frequency electrical stimulation ameliorated PD symptoms, leading
to the development of deep brain stimulation.77 By the mid-1990’s, DBS of the GPi and
STN was also shown to be effective. Indeed, in appropriately selected patients where
levodopa-related complications are disabling, modulation of brain function via DBS of the
GPi or STN has been shown to be superior to continued medical management.78–80 In many
cases, pharmacological treatments are the first step in treatment, followed by DBS as a
second step. Often, DBS patients continue levodopa or other pharmacological treatments,
although often at a lower dose.
Although these treatments have led to significant improvements in movement
disabilities and improved the quality of life for patients with PD, they are treating
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symptoms resulting from the loss of dopaminergic input to the striatum rather than
resolving the underlying neurodegeneration. In addition, there are often unwanted side
effects. For instance, DBS stimulation may detrimentally impact cognition and speech.81
Moreover, any current treatment regimen—pharmaceutical management, DBS, or a
combination of the two—often fails to give the same clinical benefit over time. The lack
of long-term efficacy is generally attributed to one of two issues: (1) the advent of adverse
side effects (e.g. dyskinesias, motor fluctuations, behavioral addictions, and/or impulse
control disorders), or (2) the further degeneration of nigrostriatal neurons decreasing
clinical benefits.82 As such, even with state-of-the-art management, the average duration
from minimal disability to confinement to bed or wheelchair is approximately 13 years.43
New pharmaceutical therapies that focus on neuroprotection are being developed,
although to date, there are no proven therapies to slow progression of disease.83 In addition,
these treatments would not restore innervation to the striatum, as they would not replace
SNpc dopaminergic neurons that had degenerated before the onset of motor symptoms.44
Therefore, a method to diagnose PD pathology before the onset of motor symptoms would
be necessary for these pharmacological methods to maintain motor function.84 Although
there is growing evidence that non-motor symptoms have a key impact on quality of life,
only a few large randomized clinical trials have focused on management of non-motor
symptoms.49 Dopaminergic agonists are effective for treatment of few of the non-motor
symptoms, but might also increase the likelihood for some patients to experience adverse
events, such as somnolence, dizziness, hallucinations, and nausea.85
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Gene therapies to relieve PD symptoms have recently reached clinical trials
evaluating the efficacy and safety of delivering vectors with genes encoding for
overexpression of (1) glutamic acid decarboxylase in the subthalamic nuclei to increase the
GABA basal tone, (2) enzymes to increase endogenous striatal dopamine synthesis or
conversion of L-dopa to dopamine, and (3) neurturin—a ligand similar to GDNF that has
been shown to enhance survival and outgrowth of dopaminergic neurons.86–90 To date, out
of these gene therapy clinical trials, only the vector with the gene encoding for increased
production of glutamic acid decarboxylase has demonstrated beneficial motor function.91
Therefore, while gene therapy might be a promising strategy, development of an effective
treatment requires more research.
Prior to the 1970s, it was widely believed that restorative treatments for
neurodegenerative diseases of the CNS were not possible. However, two articles published
in the same year demonstrated that fetal mesencephalic grafts rich in dopaminergic neurons
could ameliorate Parkinsonism symptoms in rodent models.92,93 Since then, many others
have examined the potential of fetal graft implants to produce dopamine in the
striatum.94,95,104–113,96,114–116,97–103 As of 2004, over 350 patients had received cell
replacement therapies, and in many cases, patients were tapered off drugs and witnessed a
decrease in motor symptoms.99 Successful fetal tissue grafts have survived over two
decades in some patients despite ongoing PD pathology.98,117 Indeed, long-term survival of
grafted dopaminergic neurons with extensive putamenal dopaminergic innervation was
reported in PD patients at postmortem.113–115 In addition,
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F-fluorodopa imaging

demonstrated robust dopaminergic uptake within the striatum. Clinical trials have indicated
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beneficial results from cellular grafts when methods sustain a novel population of at least
80,000 dopaminergic neurons, although, in a recent study, motor benefits were observed
with only 40,000 neurons surviving after 24 years.113,118
Although inconsistent, clinical improvements, such as decreased motor symptoms,
were observed in some cases; however, widespread clinical adoption of tissues grafts has
been stymied by several notable limitations. A subset of patients had adverse side effects
or no significant improvements.99 Moreover, grafts were sourced from fetal tissue, and the
variability of source tissue likely contributed to some trials showing limited to no efficacy.
Additionally, multiple fetal donors (typically 3-5) must be pooled to source a sufficient
number of cells for one patient, which may contribute to the heterogeneity of outcomes and
likely indicates a lack of material for widespread clinical usage. This is exacerbated by
ethical concerns associated with fetal tissue that make access difficult in some instances,
thereby limiting procedures. Also, trials have had varied preparation, storage, and
immunosuppression regimes that may have affected the health of the grafts, again creating
a source of variability and likely affecting efficacy. Thus, fetal grafts have inherent issues
with consistency and requirements for immunosuppression.119
Another concern is that the majority of these studies involved cellular graft
implantations in the striatum, not the SNpc- the location of dopaminergic neurons naturally
providing input to the striatum. Whereas cells implanted into the striatum may create new
“factories” for dopamine, these cells do not receive their normal inputs to control their
activity, potentially resulting in dysregulated dopamine release and related side effects. As
discussed previously, the SNpc receives a wide range of inputs, and these inputs are
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thought to be important for restoring the full motor circuit.66,67 The tradeoffs between
different options for placement of cells/grafts is covered in more depth below, but complete
function of the motor control system relies on well-controlled feedback loops that fine-tune
dopamine levels. Although significant progress has been made, fetal tissue grafts do not
appear to present a viable or sustainable strategy to repair the nigrostriatal pathway and
replicate both the outputs and inputs for dopamine regulation to the striatum from the SNpc.
However, success of fetal grafts in PD patients demonstrates the potential for dopaminergic
neuron transplants to provide long-term benefits, provided there are improvements in
cell/tissue supply, consistency, and ideally, actual recreation of the nigrostriatal pathway.

1.3 Design Goals to Restore the Nigrostriatal Pathway
1.3.1 Design Criteria
The pioneering work from the 1970s and 1980s demonstrated the potential for
allografted fetal grafts to restore the nigrostriatal pathway in patients with PD. These
studies also paved the way to establish design criteria for cell-based therapies prior to
clinical trials including:
(a) Long-term survival of dopaminergic neurons with robust fiber outgrowth into the
host striatum in an adult rodent brain92
(b) Synaptic integration with the host rodent brain (i.e. receiving local inputs from the
host brain and forming connections with host striatal end target)120,121
(c) Adequate dopamine release in a controlled fashion122
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(d) Amelioration of motor deficits in rodent models of PD123
Previous studies provide putative requirements for constructs to recapitulate the
nigrostriatal pathway in humans, originating in the SNpc and terminating in the striatum.
Initially, for proof of concept studies in rats, the literature suggests a requirement of ≥1200
morphologically healthy dopaminergic neurons with a unidirectional axonal architecture
and ≥5-6 mm in length that result in dopamine release in the range of 50-100 nM in the
striatum for functional benefits to be seen.124,125 Based on human fetal graft studies, these
numbers translate to 40,000-80,000 healthy dopaminergic neurons, unidirectional axonal
architecture of ≥3-5 cm in length, and dopamine release of ≥7 ng/mg of tissue for
nigrostriatal pathway restoration in humans. To restore the entire nigrostriatal pathway
with appropriate inputs and outputs remains a considerable challenge, as implantation of
only dissociated cells cannot restore the key anatomic features of damaged pathways—
notably long axon tracts projecting to proper anatomical structures. Key considerations
include: (1) cell source and (2) location of the transplant (see Figure 1.2).

1.3.2 Cell Source Considerations
While fetal graft studies in PD have demonstrated integration and functional
recovery, the limited supply and inconsistency of these grafts have led researchers to
consider other cell sources. Building upon the knowledge gained from the fetal transplant
trials, a successful grafting strategy would likely require the use of authentic dopaminergic
neurons resembling those found in the SNpc of healthy patients. Indeed, advancement of
cell culture techniques has led to the generation of dopaminergic-like neurons from
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embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), expanded neural
precursor cells (NPCs), mesenchymal stem cells (MSC), and direct neuronal
reprogramming.
ESCs derived from the inner cell mass of early-stage embryos have the capability
for self-renewal and pluripotency, providing a potentially unlimited source of any cell type.
The development of differentiation protocols to generate ESC-derived dopaminergic
neurons led to promising proof of concept experiments demonstrating survival in an adult
rodent brain following transplantation. However, early protocols also reported incomplete
differentiation, leading to tumor formation and neural overgrowth. Similar to fetal grafts,
limited tissue availability and ethical concerns led to alternative techniques to derive
transplantable dopaminergic neurons. Indeed, the discovery that human fibroblasts could
demonstrate pluripotency led to the development of iPSCs, which opened the possibility
for a patient-specific cell source that avoided the ethical issues associated with ESCs.
Furthermore, advancements in developmental neurobiology led to the discovery that
dopaminergic neurons are derived from floor plate cells, which resulted in novel molecular
differentiation techniques for generating more “authentic-like” dopaminergic neurons
resembling those found in the SNpc. These refined differentiation protocols, used with both
ESCs and iPSCs, have obviated the earlier issues with tumorgenicity and enabled longdistance targeted striatal innervation. Indeed, human ESC-derived tyrosine hydroxylase
(TH+) dopaminergic neurons are capable of performing equivalently to human ventral
mesencephalic tissue post transplantation by extending neurites into the host brain up to 3
mm from the graft and ameliorating behavioral deficits in a rodent model.126 In a recent
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report, intranigral human ESC-derived ventral mesencephalic progenitors were capable of
directed outgrowth to the striatal and forebrain structures in rodent and non-human primate
(NHP) models of PD, paving the way for future clinical trials aiming for complete circuitry
repair.127
NSCs expanded from ESCs and iPSCs have been investigated by many laboratories
as a potential alternative cell source for use in cell replacement treatments of PD due to
their multipotent and self-renewing properties. Unlike ESCs and iPSCs, NSCs have limited
differentiation capability and are fated towards a brain cell phenotypes, such as neurons,
astrocytes, and oligodendrocytes, reducing the likelihood for tumor growth.129,130 NSCs
provide neuroprotection, decrease immunoreactivity, and secrete neurotrophic factors,
including glial-derived neurotrophic factors and brain-derived neurotrophic factors.
Several studies have demonstrated the potential of using NSCs for neural repair of damaged
pathways.131–133 Previous work has also shown that NSCs can differentiate into
dopaminergic-like cells, survive transplantation, integrate with the host architecture, and
improve functional recovery.134 Although recent reports have established novel cell sorting
techniques to increase purification of “authentic-like” dopaminergic neurons, expansion of
NSCs has remained challenging and will likely require further refinement to scale up the
yield for clinical trials.135 Moreover, further safety and efficacy pre-clinical studies are
necessary to reduce the likelihood for graft and/or differentiation failure.137,138
MSCs are multipotent, non-hematopoietic stem cells capable of self-renewal that
typically arise from bone marrow and differentiate into adipocytes, osteoblasts, and
chondroblasts, and have been reported to elicit an anti-inflammatory effect.139–142 As
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elevated neuroinflammatory responses have been implicated in neurodegenerative
diseases, there has been increased interest in MSCs as a potential cell source candidate due
to their immunomodulatory effect.144 Indeed, MSCs have demonstrated the capability to
differentiate into astrocyte-like cells that secrete neurotrophic factors and ameliorate the
motor deficits in a rodent model of PD.145 In addition to immunomodulation, MSCs and
MSCs differentiated into a neuron-like phenotype reportedly migrated across the corpus
callosum to a 6-OHDA lesioned SNpc and striatum when initially transplanted in the
contralateral hemisphere.146 However, it was unclear whether the cells were attracted to the
lesion itself or the acute inflammation at the injection site.147
Direct neuronal reprogramming has recently become an interesting cell source
candidate with the potential for generating dopaminergic neurons from somatic cells, such
as fibroblasts and astrocytes, by adding transcription factors for cell lineage
conversion.56,57,148–152 This strategy could provide an unlimited number of autologous
dopaminergic neurons reprogrammed from a patient’s own somatic cells, alleviating the
ethical concerns and limited tissue availability of fetal cells, and minimizing the
complications associated with allogenic transplants. Although reprogramming has
historically used viral vectors, recent advancements in microRNA technology has led to
the development of alternative transcription factor delivery methods that have been
reported to increase the conversion efficiency in vitro and in vivo. Such techniques have
been shown to effectively convert somatic cells into functional dopaminergic neurons and
ameliorate motor symptoms in a model of PD.152
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Cellular engineering strategies may also be advantageous for cell transplants, with
such genetic manipulation being employed in vitro prior to in vivo implantation. For
instance, specific genetic alterations may be beneficial to improve the survival, integration,
and efficacy of transplants. One type of modification could be to limit immunogenicity and
thereby improve the survival and integration of the cells.153,154 However, cell-based or
tissue engineered constructs (either allogeneic or autologous) may eventually succumb to
the underlying pathology and degenerate similar to native tissue. Although the
susceptibility of transplanted cellular constructs to the typical progression of PD pathology
is still unclear, previous research has shown that dopaminergic neurons from tissue grafts
can survive up to 18-24 years in vivo despite ongoing degeneration of the native
dopaminergic system.113 However, in some patients with long-term survival of fetal
mesencephalic grafts, α-synuclein-positive Lewy bodies were found in 1-5% of
transplanted dopaminergic neurons at 12-22 years and 12% in one patient at 24 years post
transplantation.105,113 Thus, the development of PD-resistant neurons might be necessary
to overcome this vulnerability, improve the construct lifespan, and prevent α-synuclein
aggregation by augmenting the genes implicated in autophagy or α-synuclein
clearance.157,158 Furthermore, genetically enhanced dopaminergic neurons engineered to
increase dopamine production and/or release could minimize the number of surviving cells
necessary to restore dopamine levels in the striatum, thus maximizing the likelihood for
successful innervation of the striatum, and potentially halting the evolution of PD
symptoms.
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1.3.3 Cell Location Considerations: Striatum
Cell-based transplantation strategies have primarily focused on using intra-striatal
dopaminergic grafts to restore the physiological levels of dopamine within the striatum. As
noted above, cells implanted into the striatum may create new “factories” for dopamine,
but they do not receive the full suite of normal inputs that finely tunes dopaminergic
production and delivery in the striatum. Intra-striatal transplantation of dopaminergic
neurons into NHP models of parkinsonism have demonstrated extensive neurite outgrowth
in the striatum and increased dopamine uptake near the graft, resulting in significant
amelioration of the cardinal motor symptoms of PD.159–163 Despite these improvements,
inconsistent functional recovery in animal models and human studies has been reported,
likely due to variation in graft composition, low dopaminergic neuron survival, poor
neurite extension, minimal graft volume, differing immunosuppressant regimes, and/or the
inhibitory microenvironment.109,128,164–167

1.3.4 Cell Location Considerations: Substantia Nigra Pars Compacta
Intranigral transplantation studies have largely failed because long-distance axonal
regrowth to the correct target(s) within the CNS is limited.168–170 Despite the development
of various approaches to increase neurite outgrowth, these strategies have only attained
sub-centimeter scale growth, which would be insufficient to span the nigrostriatal pathway
in the human brain (i.e. SNpc to striatum is at least 3 cm).126,160,171–174 Furthermore, the
lack of targeted outgrowth can result in the innervation of aberrant targets. Although the
ideal location for cell transplantation is the SNpc, the use of intranigral transplants must be
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combined with supplementary techniques to achieve targeted axonal outgrowth
demonstrating clinically relevant regenerative distances. Such supplementary techniques
are discussed below.

1.3.5 Cell Location Considerations: Nigrostriatal Pathway
Successful striatal innervation in humans and NHPs from grafts transplanted into
the SNpc will require targeted axonal outgrowth on the order of centimeters.123,185,186
Bridging the nigrostriatal pathway with growth factors or cells may alter the inhibitory
microenvironment and provide a supportive conduit for regenerating axons that effectively
guides immature axons from the SNpc to the DA-depleted striatum. Early “bridging”
studies reported using embryonic striatal tissue as a “stepping stone” to effectively enable
targeted outgrowth from axons grafted in the SNpc towards the graft, and ultimately the
host striatum.176 While this strategy appeared promising, in primate studies the attraction
was greatly diminished with increasing distance between the striatal “stepping stone” and
the SNpc graft, and the preferential attraction to the striatal “stepping stone” prevented
outgrowth beyond the graft to the intended host striatum.172
In one series of reports, injection of the excitotoxin kainite from the midbrain to the
striatum created a trophic environment capable of promoting outgrowth from fetal
mesencephalic grafts transplanted in the SNpc to reinnervate the striatum, which increased
baseline striatal dopamine release and reduced motor behavioral deficits.181,182 However,
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kainate is an excitatory neurotoxin, thus significantly limiting the fetal mesencephalic graft
+ kainate bridging strategy as a potential regenerative strategy for patients with PD.183
Following this approach, a similar strategy has been investigated using cell linederived neurotrophic factor (GDNF) as an attractant for guiding transplanted axons from
the SNpc to the striatum. Administering a track of GDNF from the fetal graft in the SNpc
to striatum facilitated outgrowth and improved rotational behavior in lesioned rats.184 This
strategy was adapted in a NHP model of PD that utilized viral-vector mediated
overexpresion of GDNF in the striatum, enabling outgrowth from a fetal graft in the SNpc
towards the striatum. In this study, only a few grafted dopaminergic axons innervated the
striatum; however, these findings demonstrated neurotrophic supplementation could
enable targeted long-distance axonal outgrowth.173
Lastly, a strategy utilizing dual dopaminergic transplants along the basal ganglia
circuitry has been reported to enable complex movement patterns in models of
PD.110,169,187–190 Fetal dopaminergic grafts implanted into both the striatum and the SNpc
provided trophic support to otherwise denervated host neurons, prevented widespread
degeneration from second-order neuron neurotransmitter depletion, and thereby increased
the number of potential targets for regenerating axons from dopaminergic neurons
transplanted in the SNpc. In a small pilot study, this approach resulted in significant longterm clinical improvement of motor function in patients.110,111,191 In comparison to grafts
implanted solely into the striatum, the researchers believed the double grafts enabled
superior reinnervation of basal ganglia structures, which contributed to improved
functional recovery.110,187,188,190 While intriguing as a regenerative strategy for PD, further
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research is necessary to understand the exact mechanism behind the impressive functional
recovery.

Figure 1.2 Overview of Regenerative Medicine-Based Repair Strategies for PD. A
schematic overview of the possible repair strategies for the nigrostriatal pathway. The
figure depicts the same circuit diagram schematic shown in Figure 1.1 with circuit
connections removed. The top left inset includes the various cell sources used. The red,
green, and yellow arrows indicate the various locations that cells have be implanted. The
inset to the right shows a pre-formed construct solution to restore the nigrostriatal pathway,
including dopaminergic cell bodies in the SNpc, the inputs to those dopaminergic cells
from other neural structures, and their long axonal outputs to the striatum. NUC, nucleus;
SUB, substantia.
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1.4 Approach
1.4.1 Overview
Our approach would uniquely address gaps in current technologies to restore the
nigrostriatal pathway by simultaneously replacing neurons and long-distance axonal tracts.
Micro-tissue engineered neural networks (micro-TENNs) are living 3-D neural constructs
that recapitulate lost neuroanatomy and consist of a discrete neuronal population with longprojecting axonal tracts encased in miniature tubular hydrogels. These constructs are less
than one-fourth of the diameter of DBS leads and can extend up to several centimeters in
length.19–21,33,192,193 The exterior hydrogel shell contains an interior extracellular matrix
(ECM) core optimized to support neuronal survival and neurite extension in vitro, yet
gradually degrades over several weeks in the brain.20 Whereas prior studies have
transplanted fetal grafts, single cell suspensions, or cells in 3-D matrices, our method is
considerably different in that the final cytoarchitecture of the micro-TENN – mimicking
the architecture of brain pathways – is created in vitro and transplanted en masse.133,194–200
Moreover, the miniature form factor allows for minimally invasive, stereotactic delivery
into the brain.
In the current dissertation, we will ascertain if custom-built dopaminergic microTENNs (fabricated with both embryonic rat dopaminergic neurons and a cell source
optimized for dopaminergic neuron purity) are capable of synaptically integrating with
striatal neurons and modulating their function through dopamine release in vitro. This
strategy is premised on the plasticity of endogenous as well as tissue engineered neural
networks, whereby neurons intrinsically have the ability to sense and respond to local
26

activity.56,201–203 It has been shown that transplanted neurons are capable of receiving
synaptic input from local networks as well as propagating action potentials.204,205
Furthermore, we will gain new knowledge regarding the feasibility of using these
preformed, tissue-engineered constructs to repair circuitry and reconstruct the nigrostriatal
pathway in rats. If the technology proves successful in the studies outlined in this
dissertation, we will be one step closer to testing micro-TENNs in large animal models
followed by clinical trials. We ultimately foresee the development of autologous human
micro-TENNs as a paradigm changing strategy to treat the source of PD motor symptoms
rather than the symptoms themselves.

1.4.2 Innovation
Our proposal to use tailored dopaminergic micro-TENNs to ameliorate the motor
symptoms of PD challenges the current clinical approach to PD because it represents a shift
from assuaging the overt symptoms of PD to reconstructing the underlying neural circuitry.
Our innovative strategy is one of the few approaches capable of replacing the nigrostriatal
pathway, thereby allowing implanted micro-TENNs to be subject to the normal cellular
modulation that dopaminergic SNpc neurons are subject to in vivo to “close the loop” and
restore a crucial circuit for motor control feedback. Contrary to current standards of care,
including dopamine replacement drugs and DBS, our technology could restore both the
neurons and axons lost to PD in order to improve motor function. Therefore, the proposed
therapeutic offers the chance to treat the cause of the PD motor symptoms instead of just
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treating the symptoms over a limited timeframe. The novel treatment could also be coupled
with existing therapies to bolster dopamine production.
Micro-TENNs emulate proven tissue grafts, but with the added advantage of
physically restoring the nigrostriatal pathway. Our custom process to generate microTENNs enables a precisely engineered structure where the number of neurons and
generation of dopamine can be known prior to implantation. Thus, our method avoids the
limitations of fetal tissue grafts, which are functionally inconsistent and require scarce fetal
source material. Micro-TENNs may surpass both cell-based and scaffold methods by
simultaneously restoring neurons and their long-distance axons to the striatum. Thus, as
micro-TENNs are more targeted than systemically delivered drugs, are less invasive than
DBS electrodes, and provide the opportunity to reconstruct lost neuroanatomy, they have
the potential to revolutionize PD treatment and dramatically improve patient outcomes.

1.4.3 Specific Aims and Hypotheses
The overall objective of this proposal is to utilize novel preformed micro-TENNs
mimicking the architecture of brain pathways to restore function in models of PD-like
neurodegeneration. Our central hypothesis is that micro-TENNs comprised of
dopaminergic neurons and long-projecting axonal tracts will survive, synaptically
integrate, and thereby physically reconstruct the nigrostriatal pathway to restore motor
function in models of PD. This hypothesis will be tested across three specific aims: (1)
Determine optimal in vitro techniques to fabricate dopaminergic micro-TENNs; (2)
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Examine the in vitro functionality of the micro-TENNs; (3) Assess micro-TENN
capabilities to reconstruct the nigrostriatal pathway, restore dopaminergic inputs, and
ameliorate motor symptoms in a rat model of PD. These aims are highly integrated and
complimentary, as Aim 1 will advance techniques to create preformed micro-TENNs with
an architecture emulating the nigrostriatal pathway, and Aim 2 will assess how these novel
micro-TENNs behave functionally using an in vitro paradigm featuring a surrogate striatal
end target. Lastly, in Aim 3 these preformed micro-TENNs will be stereotactically
microinjected into rats following PD-like neurodegeneration, after which nigrostriatal
pathway reconstruction and motor symptom amelioration will be assessed based on
behavioral, functional, and histological outcomes. This integrated proposal will advance
micro-TENNs as the first strategy to facilitate nervous system repair by simultaneously
providing neuronal replacement and physically re-creating long-distance axonal
connections in the brain.

Specific Aim 1: Create a novel class of dopaminergic micro-TENNs with structural
characteristics to mimic the systems-level architecture of the nigrostriatal pathway. In Aim
1A, we will determine the optimal in vitro techniques to generate micro-TENNs utilizing
dopaminergic neurons from embryonic rats, while in Aim 1B we will determine the optimal
in vitro techniques to generate micro-TENN utilizing a cell source optimized for
dopaminergic purity. We will capitalize on our existing knowledge to optimize survival
and axonal outgrowth of embryonic rat dopaminergic neurons within micro-TENNs.
Neuronal seeding method, media formulation (various growth factors), micro-TENN
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directionality, as well as hydrogel-ECM characteristics (various types/density) will be
explored. We hypothesize that dopaminergic micro-TENNs will demonstrate high
neuronal viability (>70%), axonal length >5 mm, and micro-TENN cytoarchitecture
exhibiting distinct separation between the neuronal somata and axonal regions. If
successful, these studies will establish the feasibility of fabricating a tissue engineered
construct that recapitulates the structural features of the nigrostriatal pathway.

Specific Aim 2: Determine the functional characteristics of the dopaminergic microTENNs in vitro. In Aim 2, we will examine the in vitro functionality of micro-TENNs
generated with the cell source optimized for dopaminergic purity. We will use fast scan
cyclic voltammetry to examine dopamine release from the micro-TENNs both with and
without a surrogate striatal end target, with the latter paradigm allowing determination of
whether the micro-TENNs are capable of synaptically integrating with and/or functionally
modulating striatal neurons. Integration with a striatal end target will also be assessed via
immunocytochemistry and optical techniques. We hypothesize that dopaminergic microTENNs will release dopamine and demonstrate histological and/or optical evidence of
integration with striatal neurons. If successful, these studies will establish the feasibility of
micro-TENNs to emulate both the structural and functional characteristics of the
nigrostriatal pathway.
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Specific Aim 3: Transplant fully formed dopaminergic micro-TENNs into a rat model of
PD for reconstruction of the nigrostriatal pathway. In Aim 3 we will assess the ability of
the next-generation micro-TENNs to reconstruct the nigrostriatal pathway. We will utilize
a 6-hydroxydopamine (6-OHDA) rat model of PD, which is characterized by PD-like
neurodegeneration and deafferentation of the nigrostriatal pathway. GFP+ micro-TENNs
will be implanted to span the SNpc and striatum, and behavioral, functional, and
immunohistological testing will be performed in order to assess construct neuron survival,
synaptic integration, and amelioration of motor deficits. We hypothesize that dopaminergic
micro-TENNs will integrate with native brain tissue and alleviate motor symptoms in
rodents with nigrostriatal deafferentation. If successful, these studies will determine the
capacity of dopaminergic micro-TENNs to reconstruct the nigrostriatal pathway and
ameliorate PD symptoms by restoring lost neuronal/axonal populations.

1.5 Chapter Overview
Chapter II will discuss the in vitro development and optimization of both the growth
and health of the dopaminergic micro-tissue engineering neural networks. Chapter III will
discuss the in vitro functional testing and characterization of the dopaminergic microTENNs. Chapter IV will discuss the transplantation of the dopaminergic micro-TENNs
into a rat model of Parkinson’s disease followed by in vivo functional and histological
analyses. Chapter V will provide of a summary of the conclusions of the previous chapters,
as well as discuss future research directions.
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CHAPTER 2: IN VITRO FABRICATION OF DOPAMINERGIC MICRO-TISSUE
ENGINEERED NEURAL NETWORKS

2.1 Introduction
As thoroughly reviewed in Chapter 1, current treatments strategies for Parkinson’s
disease only minimize symptoms; there is no approach capable of replacing the lost
nigrostriatal pathway. As a strategy to physically reconstruct lost long-distance axonal
pathways in the brain, we have developed micro-tissue engineered neural networks (microTENNs), a novel class of transplantable, anatomically-inspired three-dimensional (3D)
cylindrical constructs comprised of discrete neuronal population(s) spanned by internalized
long-projecting axonal tracts.1–6 Despite being only several hundred microns in diameter,
micro-TENNs may feature axonal extension of at least several centimeters to reconstruct
long-distance brain pathways lost due to trauma or neurodegenerative disease.1–6 We
employ novel micro-tissue engineering techniques to create the neuronal-axonal constructs
within a miniature tubular hydrogel featuring an interior extracellular matrix (ECM) core
that supports neurite extension in vitro. The miniature form factor allows for minimally
invasive delivery into the brain,2 while the biomaterial encasement protects the preformed
cytoarchitecture and gradually degrades over several weeks.6 In rat models, we have
previously demonstrated that allogeneic micro-TENNs comprised of cerebral cortical
neurons maintained their axonal architecture, and structurally integrated into the native
nervous system.6
In the current work, we have significantly advanced this micro-tissue engineering
approach by creating transplantable constructs that mimic the general cytoarchitecture of
the nigrostriatal pathway (Figure 2.1). Specifically, we report the construction of the first
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micro-TENNs comprised of a discrete population of dopaminergic neurons with longprojecting, unidirectional axonal tracts within transplantable miniature tubular hydrogels.
We advanced our micro-fabrication techniques by seeding tubular micro-columns with
engineered neuronal aggregates generated from primary embryonic rat midbrain neurons.
We systematically varied both ECM constituents and growth factors, and assessed neuronal
viability. These micro-constructs mimic the cytoarchitecture of the nigrostriatal pathway,
while providing the first evidence of dopaminergic axonal extension >6 mm.
However, as embryonic rat midbrain preparations contain a relatively low
percentage of dopaminergic neurons (<10%), following these initial feasibility studies with
midbrain preparations we investigated other cell sources for higher dopaminergic purity.
Specifically, we bred transgenic rats expressing green fluorescent protein (GFP) in their
dopaminergic neurons and performed fluorescent activated cell sorting (FACS) to improve
the purity of the population. Using this method, we found we could generate dopaminergic
micro-TENNs containing more than 50% dopaminergic neurons. We also optimized ECM
constituents and growth factors to maximize the health and outgrowth of the micro-TENNs
fabricated with the purified populations. Following our optimization studies, these microTENNs demonstrated lengths of over 5 mm at 21 days in vitro (DIV), and an average cell
viability of over 85%. Lastly, we showed proof of concept for clinical translation by
generating micro-TENNs with dopaminergic neurons differentiated from human
embryonic stem cells (hESCs), revealing at least several millimeters of unidirectional
axonal extension within implantable hydrogel micro-columns.
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Figure 2.1: Reconstruction of the Nigrostriatal Pathway Using Micro-Tissue
Engineered Neural Networks. A diffusion tensor imaging representation of the longdistance axonal tracts that connect discrete populations of neurons in the human brain. This
conceptual rendition shows how a unidirectional micro-TENN – consisting of a population
of dopaminergic neurons extending long, aligned processes – can be used to recreate the
nigrostriatal pathway (yellow) that degenerates in Parkinson’s disease. Axons in the
substantia nigra pars compacta (SNpc) are expected to functionally integrate with the
transplanted dopaminergic neurons in the micro-TENN, while the transplanted
dopaminergic axons are expected to functionally integrate with neurons in the striatum.
After receiving appropriate inputs from the SNpc, the transplanted neurons will release
dopamine in the striatum, thereby recreating the circuitry lost in Parkinson’s disease.

2.2 Methods
All procedures were approved by the IACUCs at the University of Pennsylvania
and The Michael J. Crescenz Veterans Affairs Medical Center and were carried out in
accordance with Public Health Service Policy on Humane Care and Use of Laboratory
Animals (2015).
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2.2.1 Three-dimensional Micro-TENN Fabrication
All supplies were from Invitrogen, BD Biosciences, or Sigma-Aldrich unless
otherwise noted. Micro-TENNs were comprised of an agarose (Sigma; A9539) ECM
hydrogel molded into a cylinder through which axons could grow. The outer hydrogel
structure consisted of 1% agarose in Dulbecco’s phosphate-buffered saline (DPBS). The
agarose cylinder, with an outer diameter of 398 µm, was generated by drawing the agarose
solution into a capillary tube (Drummond Scientific) via capillary action. An acupuncture
needle (diameter: 160 µm) (Seirin) was inserted into the center of the agarose-filled
capillary tube in order to produce an inner column. Cured micro-columns were pushed out
of the capillary tubes using a 30 gauge needle (BD; 305128) and placed in DPBS where
they were cut to 6 – 12 mm in length and sterilized under UV light (1 hour). 5 µL of the
appropriate ECM cocktail was added to each micro-column. ECM cocktails included: rat
tail type 1 collagen, 1.0 mg/mL; rat tail type I collagen, 1.0 mg/ml mixed with mouse
laminin, 1.0 mg/ml; mouse laminin, 1.75 mg/ml; and rat tail type 1 collagen, 1.0 mg/mL in
11.70 mM N-(3-Dimethylaminopropyl)-N’-ethylcarboiimide hydrochloride, 4.3 mM NHydroxysuccinimide, and 35.6 mM sodium phosphate monobasic. These micro-columns
were then incubated at 37°C for 15-30 minutes, after which DPBS was added to the petri
dish.

2.2.2 Neuronal Cell Culture
Female Sprague-Dawley rats (Charles River) were the source for primary ventral
mesencephalic neurons, a midbrain region previously shown to be enriched in
dopaminergic neurons 7. Carbon dioxide was used to euthanize timed-pregnant rats
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(embryonic day 14), following which the uterus was extracted. The brains were removed
in Hank’s balanced salt solution (HBSS) and the ventral midbrain was isolated 8. The
ventral midbrains were dissociated in accutase for 10 minutes at 37°C. The cells were
centrifuged at a relative centrifugal force (RCF) of 200 for 5 minutes and resuspended at
1-2 million cells/mL in standard media consisting of Neurobasal medium + 2% B27 + 1%
fetal bovine serum (Atlanta Biologicals) + 2.0 mM L-glutamine + 100 µM ascorbic acid +
4 ng/mL mouse basic fibroblast growth factor (bFGF) + 0.1% penicillin-streptomycin).
Enriched dopaminergic neuron populations were attained utilizing fluorescent
activated cell sorting (FACS). Here, transgenic male Sprague-Dawley rats (NTac:SDTg(TH-EGFP)24Xen; Taconic model # 12141-M) expressing GFP in their dopaminergic
neurons were bred with wild-type Sprague-Dawley female rats. Carbon dioxide was used
to euthanize timed-pregnant Sprague-Dawley rats (embryonic day 14), following which
the uterus was extracted. The brains were removed in Hank’s balanced salt solution
(HBSS) containing 20 mM glucose and 100 µM ascorbic acid. The ventral midbrains were
dissociated in accutase for 10 minutes at 37°C. The cells were centrifuged at a relative
centrifugal force (RCF) of 200 for 5 minutes and resuspended at 6 million cells/mL in a
sorting buffer consisting of HBSS + 20 mM glucose + 100 µM ascorbic acid + 0.1%
penicillin-streptomycin + 1.4% bovine serum albumin + 25 mM HEPES. Next fluorescent
activated cell sorting was performed on a BD Influx cell sorter to isolate the GFP+ cells.
These cells were collected in a buffer containing standard conditioned media + 4% bovine
serum albumin + 25 mM HEPES. Following sorting, the collected cells were resuspended
at 1-2 million cells/mL in standard conditioned media. Standard conditioned media was
generated by placing 12.5 mL of Neurobasal + 1% fetal bovine serum (Atlanta Biologicals)
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in a T-75 flask containing cortical astrocytes for 24 hours. Next, it was removed from the
flask and the following components were added: 2% B27 + 2.0 mM L-glutamine + 100
µM ascorbic acid + 4 ng/mL mouse basic fibroblast growth factor (bFGF) + 0.1%
penicillin-streptomycin.
Custom-built arrays of inverted pyramidal wells were fabricated using
polydimethylsiloxane (PDMS) (Sylguard 184, Dow Corning) cast from a 3D printed mold
and placed in a 12-well plate. 12 µL of the midbrain or dopaminergic cell suspension was
transferred to each pyramidal well, and the 12-well plate was centrifuged at 1500 rpm for
5 minutes, after which 2 mL of standard media was placed on top of each array. The
centrifugation resulted in forced aggregation of neurons (approximately 3,200 cells per
aggregate) (Figure 2.2). Dopaminergic neuron aggregates were created based on protocols
adapted from Ungrin et al.9 The wells were then incubated overnight. At the time of plating,
the DPBS was removed from the dishes containing the micro-columns and replaced with
media. Using forceps, the aggregates were inserted into one (unidirectional) or both
(bidirectional) ends of the micro-columns, and the cultures were placed in an incubator
(Figure 2.3).
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Figure 2.2: Neuronal Aggregate Fabrication and Planar Outgrowth. (A) A customdesigned, 3D printed mold was used to generate the inverted PDMS wells. (B)
Representation of PDMS wells used to aggregate cells. Each individual well measured 4
mm wide by 4 mm long by 3.46 mm deep. (C) An array of PDMS wells inserted into a 12well culture plate. (D) Concentrated neuronal cell suspensions were pipetted into inverted
pyramidal wells. The wells were centrifuged to aggregate the neurons by force, after which
the wells were incubated overnight to allow the pelleted cells to adhere to each other. (E)
A neuronal aggregate pelleted at the bottom of a custom-fabricated inverted PDMS well.
(F) A dopaminergic aggregate plated in planar culture was labeled via
immunocytochemistry to denote dopaminergic neurons/axons (TH; purple). Aggregates
achieved neurite outgrowth of over 5000 µm in length by 8 DIV. Scale bar (E) = 150 µm.
Scale bar (F) = 500 µm.
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Figure 2.3: Fabrication of Dopaminergic Axonal Tracts. In order to create the cell
aggregates, cells are first obtained from either the ventral mesencephalon of transgenic rat
embryos or from stem cell colonies. In order to enrich the cell population for dopaminergic
neurons, the cells are dissociated and run through a flow cytometer where fluorescent labels
can be used to perform fluorescent activated cell sorting. The purified cells are then
centrifuged in custom, inverted PDMS wells to create cell aggregates. In order to generate
the biomaterial micro-columns, agarose is gelled in a capillary tube containing a needle.
Once the agarose has hardened, the needle is removed to create a hollow agarose tube
which is then filled with an ECM core. Lastly, the aggregates are inserted into the ends of
the tubes, where they extend neurites over days to weeks in vitro.

High concentration growth media consisted of Neurobasal medium + 2% B27 +
1% fetal bovine serum (Atlanta Biologicals) + 2.0 mM L-glutamine + 100 µM ascorbic
acid + 0.1% penicillin-streptomycin + 12 ng/mL mouse bFGF + 10 ng/mL brain-derived
neurotrophic factor (BDNF) + 10 ng/mL glial cell-derived neurotropic factor (GDNF) +
10 ng/mL ciliary neurotropic factor (CNTF) + 10 ng/mL cardiotrophin.
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H9 human embryonic stem cells (passages 90-100, NIH code WA09; Wicell,
Madison, WI) were maintained on mouse embryonic fibroblast feeder cells (CF-1; MTIGlobalstem, Gaithersburg, MD), and cultured in human embryonic stem cell (hES) media
containing the following components: DMEM/F12 (Invitrogen, Carlsbad, CA), 20%
KnockOut serum replacement (Invitrogen), 1 mM non-essential amino acids (Invitrogen),
1X GlutaMax (Invitrogen), 0.1 mM b-mercaptoethanol (Sigma-Aldrich, St. Louis, MO),
100 U/mL penicillin/100 µg/mL streptomycin (Invitrogen), and 6 ng/mL bFGF (R&D
Systems, Minneapolis, MN). The stem cells were differentiated into dopaminergic neurons
using the protocol outlined in Kriks, et al.9 Differentiated dopaminergic neurons (Day 45)
were then dissociated using accutase, after which aggregates were created and inserted into
micro-columns as described above (total micro-TENNs created with differentiated
dopaminergic neurons: n=5). They were maintained in media consisting of Neurobasal
medium + 2% B27 + 2.0 mM L-glutamine + 0.2 mM ascorbic acid + 20 ng/mL BDNF +
20 ng/mL GDNF + 1 ng/mL transforming growth factor type b3 + 0.5 mM dibutyryl cAMP
+ 10 nM DAPT.
For micro-TENNs containing dissociated cells with no ECM core, dopaminergic
cells were suspended in standard media at 10 million cells/mL and 5 µL of this cell
suspension was added to each micro-column. The micro-TENNs were incubated for 60
minutes, after which media was added. For micro-TENNs containing dissociated cells with
an ECM core, dopaminergic cells were suspended in rat tail type 1 collagen, 1.0 mg/mL
(10,000,000 cells/mL) at the time of plating and 5 µL of this mixture was added to each
micro-column. The micro-TENNs were incubated for 15 minutes, after which media was
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added. Pre-warmed media was used to replace the culture media every 3-4 days in vitro
(DIV).

2.2.3 Immunocytochemistry
Micro-TENNs were fixed in 4% formaldehyde for 35 min and permeabilized using
0.3% Triton X100 plus 4% horse serum for 60 minutes. Primary antibodies were added (in
phosphate-buffered saline (PBS) + 4% serum) at 4°C for 12 hours. The primary antibodies
were the following markers: (1) β-tubulin III (1:500, Sigma-Aldrich, cat # T8578), a
microtubule element expressed primarily in neurons; (2) tyrosine hydroxylase (TH; 1:500,
Abcam, cat # AB113), an enzyme involved in the production of dopamine; (3) microtubuleassociated protein 2 (MAP-2) (1:500, Millipore, cat # AB5622), a microtubule-associated
protein found in neuronal somata and dendrites; (4) vesicular glutamate transporter 2
(VGLUT2) (1:500, Abcam, cat # AB79157), a protein expressed in glutamatergic neurons,
(5) Parvalbumin (1:500, Abcam, cat # AB11427), a protein expressed in GABAergic
neurons, (6) glutamic acid decarboxylase 65 (GAD65) (1:500, Abcam, cat # AB49832), a
protein expressed in GABAergic neurons, and (7) glutamic acid decarboxylase 67
(GAD67) (1:500, Abcam, cat # AB49832), a protein expressed in GABAergic neurons.
Appropriate fluorescent secondary antibodies (Alexa-488, -594 and/or -649 at 1:500 in
PBS + 30 nM Hoechst + 4% serum) were added at 18-24°C for 2 hours.
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2.2.4 Microscopy and Data Acquisition
For in vitro analyses, micro-TENNs were imaged using phase-contrast and
fluorescence on a Nikon Eclipse Ti-S microscope with image acquisition using a QiClick
camera interfaced with Nikon Elements. In order to determine the length of neurite
penetration, the longest observable neurite in each micro-TENN was measured from the
proximal end of the neuronal aggregate after fixation. For in vitro immunocytochemistry
analyses, cultures and micro-TENNs were fluorescently imaged using a Nikon A1RSI
Laser Scanning Confocal microscope. All micro-TENN confocal reconstructions were
from full thickness z-stacks. In order to determine dopaminergic purity, the number of TH+
neurons was divided by the number of β-tubulin III+ neurons at 14 DIV.

2.2.5 Live/Dead Assay
Calcein AM (Sigma-Aldrich) and ethidium homodimer (Life Technologies) were
used to perform Live/Dead assays on micro-TENNs and control cultures at 14 DIV.
Cultures were rinsed with DPBS, after which they were incubated in a solution of 4 mM
calcein AM and 2 mM ethidium homodimer for 30 min at 37C. Following incubation, the
cultures were rinsed three times with DPBS.

2.2.6 Statistical Analyses
No method was used to pre-determine the sample sizes of groups. Due to obvious
visual differences between experimental groups (e.g. dissociated versus aggregate neuron
micro-TENNs), in many cases it was not possible for investigators to be blinded to
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treatment group during experiments or data assessment. The normality of all data was
examined, and adjustments were made for non-normal data. An unpaired, parametric twosided t-test was performed to determine if there were statistically significant differences in
axonal outgrowth between uni-directional versus bi-directional micro-TENNs containing
a dopaminergic end target. Unpaired, non-parametric, two sided Mann-Whitney tests were
performed to determine if there were statistically significant differences in axonal
outgrowth between the following treatment pairs: dissociated versus aggregated cells and
high versus regular growth factor concentration. An unpaired, non-parametric, two sided
Mann-Whitney test was performed to determine if there were statistically significant
differences between the lengths of TH+ axons as a percentage of total axonal length with
collagen I versus collagen I-laminin cocktail inner cores. ANOVA was performed for the
extracellular matrix studies. When differences existed between groups, post-hoc Tukey’s
pair-wise comparisons were performed. An unpaired, non-parametric, two sided MannWhitney test was performed to determine if there were statistically significant differences
between the purity of the standard and enriched dopaminergic populations. For all
statistical tests, p < 0.05 was required for significance. Data are presented as mean ±
standard deviation.

2.3 Results
2.3.1 Micro-TENNs Plated with Dissociated Neuronal Suspensions
Dopaminergic neurons were isolated from the ventral mesencephalon of embryonic
rats. In planar culture, these neurons demonstrated a healthy neuronal morphology, the
presence of dopaminergic neurons (based on TH expression), significant neurite outgrowth
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(based on β-tubulin III expression), and network formation out to 28 DIV (Figure 2.4 AC). To create dopaminergic micro-TENNs, we initially seeded micro-columns using
dissociated neuronal suspensions. These dissociated cells infiltrated the length of the inner
lumen and generally did not produce the desired cytoarchitecture of a discrete cell body
region projecting axons across the length of the inner core (Figure 2.4 D-H). However, the
dissociated neurons within the micro-tissue constructs presented a healthy morphology,
and occasionally self-organized into the desired cytoarchitecture by chance (Figure 2.5).
In these cases, unidirectional axonal projections achieved lengths of several millimeters,
and, importantly, the health of these constructs was also maintained out to 28 DIV (Figure
2.5). In order to see if the inclusion of additional ECM in the inner core increased the
consistency with which the correct architecture was generated, we suspended dissociated
cells into collagen, and injected the mixture to gel inside the micro-columns. Unfortunately,
the presence of the collagen did not aid in producing the desired cytoarchitecture, and the
dissociated cells continued to spread throughout the length of the inner core (Figure 2.6
A1-A3). While these results demonstrated our ability to culture midbrain neurons that
formed extensive neurite networks within hydrogel micro-columns, these techniques were
not sufficient to consistently generate our desired cytoarchitecture.
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Figure 2.4: Dissociated Ventral Mesencephalon Neurons in Planar Culture and Within
Micro-Columns. Neuronal cultures labeled via immunocytochemistry to denote all neurons/axons
(β-tubulin III; green) and dopaminergic neurons/axons (TH; red), with nuclear counterstain
(Hoechst; blue). (A-C) Dopaminergic neurons in planar culture showing significant neurite
outgrowth and random network formation out to 28 DIV. (D-G) Representative micro-TENN at 7
DIV initially plated as a cell suspension. The single cell suspension infiltrated the length of the
inner core of the micro-column and did not demonstrate the desired cytoarchitecture requiring
separate cell body and axonal regions. (H1-H3) Higher magnification reconstructions from
demonstrative regions in (D-G). Neurons and neurites present in a micro-TENN plated with a cell
suspension show a lack of organization and directionality. Scale bar (C)= 250 µm. Scale bar
(G)=200 µm. Scale bar (H3)=125 µm.
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Figure 2.5: Chance Cell Aggregation in Micro-TENNs. Micro-TENNs plated with
single cell suspensions labeled via immunocytochemistry to denote all neurons/axons (βtubulin III; green) and dopaminergic neurons/axons (TH; red), with nuclear counterstain
(Hoechst; blue). (A-D) At 14 DIV, a micro-TENN showed the desired cytoarchitecture due
to chance re-aggregation of the dissociated neurons. (E-H) At 28 DIV, a micro-TENN
exhibiting chance re-aggregation of dissociated neurons; however, axonal extension had
only reached ~2800 µm in length. (I,J) Higher magnification reconstructions from
demonstrative regions in (E-H) showing that chance re-aggregation created discrete
regions of (I) cell bodies and (J) axons in some cases. Scale bar (D) = 100 µm. Scale bar
(H) = 250 µm. Scale bar (I,J) = 125 µm.
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2.3.2 Forced Neuronal Aggregation Method
As our previous micro-TENN fabrication methods did not reliably generate the
desired cytoarchitecture, we adapted a method to mechanically group cells into
aggregates.9 After dissociating embryonic tissue into a single cell suspension, this solution
was centrifuged in inverted pyramidal wells in order to pellet the neurons at the bottom of
the wells. The wells were left in the incubator overnight, during which the pelleted cells
became aggregated spheres of neurons (Figure 2.2). Once formed, the aggregates were
inserted into the ends of the agarose micro-columns. This method consistently produced
micro-TENNs with distinct cell body and axonal regions. Furthermore, we found that based
upon the depth and placement of the aggregate within the micro-column, we could create
micro-TENNs that exhibited either an externalized or internalized cell body region (Figure
2.6 B-D). Moreover, this technique produced long-projecting unidirectional axonal tracts,
as demonstrated based on TH and β-tubulin III immunoreactivity (Figure 2.6 E-F). Indeed,
as measured by the length of the longest neurite in each micro-TENN, it was determined
that the axons projecting from the aggregates grew approximately 10x longer than
analogous axons extending within micro-columns seeded with dissociated neurons (Figure
2.6 G).

2.3.3 Optimization of Micro-TENN Length (Standard Midbrain Population)
Once we were able to consistently produce micro-TENNs with the desired
cytoarchitecture, we optimized micro-column features and environmental conditions to
produce micro-TENNs with the longest possible axonal outgrowth. As the nigrostriatal
pathway measures approximately 5 mm in the rat, we attempted to generate micro-TENNs
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at least 5 mm in length. Here we tested the effects of the ECM constituents in the inner
lumen, presence of growth factors, and the micro-TENN directionality on outgrowth. At
14 DIV, it was found that collagen I and collagen I + laminin resulted in the longest axonal
outgrowth, as measured by the length of the longest neurite in each micro-TENN (Figure
2.7). The average axonal outgrowth for the collagen I and collagen I + laminin cores was
4892 ± 703 μm and 4686 ± 921 μm respectively. In contrast, it was found that crosslinked
collagen (1227 ± 481 μm), laminin-coated (205 ± 615 μm), and empty cores (~0 μm)
resulted in significantly reduced neurite outgrowth. For the two highest performing groups
(lumen comprised of collagen or collagen + laminin), it was determined that TH+
dopaminergic axonal projections attained at least 60% of the maximal axonal length
(Figure 2.7 F).
We also tested the effect of the media growth factor concentration on axonal
outgrowth within the micro-columns. A media containing a relatively low concentration of
bFGF (4 ng/mL) was compared to media containing high concentrations of growth factors
previously shown to increase dopaminergic neuron outgrowth and survival 10. At 14 DIV,
we found that the high growth factor concentration media did not result in denser or longer
axonal outgrowth compared to the low concentration media (n=14 micro-TENNs in each
group; Figure 2.8). Lastly, we investigated whether the use of a target population of
dopaminergic cells would increase axonal outgrowth. Bidirectional dopaminergic microTENNs were plated by inserting dopaminergic aggregates into both ends of the microcolumns. Since the two dopaminergic neuron populations were separated by 1.2 cm, we
sought to assess whether chemotactic signaling between the populations would increase
outgrowth. However, at 14 DIV we determined that the axonal outgrowth in bidirectional
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micro-TENNs was not greater than axonal outgrowth in unidirectional micro-TENNs
(n=14 micro-TENNs in each group; Figure 2.8).

Figure 2.6: Improved Micro-TENN Cytoarchitecture Using Forced Aggregation
Method. Phase contrast and confocal reconstructions of micro-TENNs plated with primary
dopaminergic neurons at 14 DIV. (A) Representative micro-TENN plated with dissociated
neurons labeled via immunocytochemistry to denote neurons/axons (β-tubulin III; green)
and cell nuclei (Hoechst; blue). Dissociated micro-TENNs did not demonstrate the desired
cytoarchitecture as they showed cell infiltration throughout the entire length of the inner
core. (B,C) Phase contrast images depicting micro-TENNs plated with engineered
dopaminergic neuron aggregates. Based upon plating technique, aggregates either (B)
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attached directly outside the agarose micro-column, or (C) inside the inner core. Higher
magnification images from demonstrative regions in (B,C) show that while the (D1,D3)
cell body regions differed between the two aggregate plating techniques, their (D2,D4)
axonal regions were similar. (E) Representative aggregate micro-TENN labeled via
immunocytochemistry to denote all neurons/axons (β-tubulin III; green) and dopaminergic
neurons/axons (TH; red), with cell nuclei counterstain (Hoechst; blue). Aggregate microTENNs demonstrated the ideal cytoarchitecture, with (E1) discrete cell body regions and
(E2,E3) axonal regions. (F) A higher magnification reconstruction from a demonstrative
region in (E) depicts the aggregated cell bodies. (G) Micro-TENNs generated using
aggregates demonstrated a greater extent of axonal outgrowth than micro-TENNs plated
with dissociated neurons (n=13 micro-TENNs each group; Mann-Whitney test, p<0.0001).
Data are presented as mean ± standard deviation. Scale bar (A) = 250 µm. Scale bar (B,C)
= 500 µm. Scale bar (D1) = 200 µm. Scale bar (D2-D4) = 100 µm. Scale bar (E) = 250 µm.
Scale bar (F) = 50 µm.

Figure 2.7: Effect of Extracellular Matrix on Axonal Outgrowth within MicroTENNs. Representative confocal reconstructions of dopaminergic micro-TENNs plated
with different ECM cores. At 14 DIV, all micro-TENNs were labeled via
immunocytochemistry to denote all neurons/axons (β-tubulin III; green) and dopaminergic
neurons/axons (TH; red), with nuclear counterstain (Hoechst; blue). The type of ECM
strongly influenced axonal outgrowth, with (A) collagen I (n=12 micro-TENNs) and a (C)
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collagen I + laminin cocktail (n=12) supporting the longest axonal outgrowth. MicroTENNs with (B) empty cores (n=9) or (D) crosslinked collagen cores (n=11) demonstrated
significantly less outgrowth. (a-d) Higher magnification reconstructions from
demonstrative regions in (A-D) show similar expression of TH across groups. (E) A one
way ANOVA (p<0.0001) followed by a post-hoc Tukey’s test determined that collagen I
and collagen I-laminin cocktail cores were statistically equal (p=0.8590), and that they each
supported axonal outgrowth that was statistically longer then outgrowth in empty
(p<0.0001), laminin-coated (p<0.0001), or crosslinked collagen (p<0.0001) cores (*
denotes significance). (F) As determined by a Mann-Whitney test, the lengths of TH+
axons as a percentage of total axonal length were statistically equivalent between the
collagen I (n=12) and collagen I+ laminin (n=12) inner cores (p=0.9723). Data are
presented as mean ± standard deviation. Scale bar (A,C,D) = 500 µm. Scale Bar (B) = 250
µm. Scale bar (E-H) = 50 µm.

Figure 2.8: Effects of Growth Factor Concentration and Target Neuronal Population
on Axonal Outgrowth within Micro-TENNs. (A) Micro-TENNs cultured in media
containing high growth factor concentrations did not result in longer axonal outgrowth than
micro-TENNs cultured using standard media (n=14 micro-TENNs each group; MannWhitney test, p=0.9851). (B) Micro-TENNs plated bi-directionally (n=14) did not result in
longer axonal outgrowth than micro-TENNs plated uni-directionally (n=14 each group; ttest, p=0.5219). Data are presented as mean ± standard deviation.

Overall, we found that the use of engineered neuronal aggregates and specific ECM
constituents were critical factors in axonal extension, while high growth factor media and
the presence of a target neuron population did not affect axonal outgrowth. Of note, the
mean neuronal aggregate length at 14 DIV was 1165 ± 212 μm; therefore, the total micro79

TENN length (neuronal aggregate + axon length) attained using dopaminergic aggregates
in collagen was >6 mm by 14 DIV – suitable to span the nigrostriatal pathway in rats.
Following these optimization studies, we fabricated dopaminergic micro-TENNs
with an inner core of collagen I and allowed them to grow over 28 DIV to ascertain if
axonal extension progressed further within the micro-columns. We found continued axonal
extension out to 28 DIV, with lengths of 6046 ± 670 μm for dopaminergic axons, 7697 ±
1085 μm for all axons, and 8914 ± 1187 μm for total aggregate + axon lengths. In some
cases, maximum total micro-TENN lengths at this time point were over 10 mm, well
beyond what would be required to span the nigrostriatal pathway in rats (Figure 2.9).

Figure 2.9: Long-Projecting Dopaminergic Micro-TENNs. (A-F) Confocal
reconstructions of a representative micro-TENN plated with a dopaminergic aggregate and
collagen I inner core at 28 DIV. Micro-TENN labeled via immunocytochemistry to denote
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all neurons/axons (β-tubulin III; green) and dopaminergic neurons/axons (TH; red), with
nuclear counterstain (Hoechst; blue). (A-D) Long-term dopaminergic micro-TENNs
showed robust survival and axonal extension over 28 DIV. (E-F) Higher magnification
reconstructions from demonstrative regions in (C) show healthy TH+ neurons and axons,
with apparent axonal varicosities suggesting sites of dopamine release. (G) Micro-TENN
length measurements taken at 28 DIV (n=7 micro-TENNs) demonstrated TH+ axons
measuring 6046 ± 670 µm, and a total TH+ length of 7264 ± 672 μm with the inclusion of
the dopaminergic aggregate. Importantly, these lengths are more than sufficient to span the
nigrostriatal pathway in rats. Data are presented as mean ± standard deviation. Scale bar
(A-D) = 250 µm. Scale bar (E-F) = 50 µm.

2.3.4 Micro-TENNS Fabricated with Enriched Dopaminergic Population
As the primary midbrain neuron preparation yielded a relatively low percentage of
dopaminergic neurons (<10%) (Figure 2.10 A), we used a transgenic rat model in
combination with fluorescent activated cell sorting (FACS) to produce an enriched
dopaminergic population. Transgenic male rats expressing green fluorescent protein (GFP)
in their dopaminergic neurons ((NTac:SD-Tg(TH-EGFP)24Xen; Taconic model # 12141M)) were bred with wild-type females. At embryonic day 14, the standard midbrain neuron
preparation was performed, followed by FACS to selectively isolate the GFP+
dopaminergic neurons. This protocol yielded a neuronal population containing an average
of ~ 60% dopaminergic neurons (N=5 micro-TENNs) (Figure 2.10 A). Utilizing the forced
neuronal aggregation technique we optimized with the standard population, we were able
to fabricate dopaminergic micro-TENNs displaying the correct cytoarchitecture with the
enriched population (Figure 2.12 B). These micro-TENNs extended robust processes
along the length of the micro-column and remained healthy for weeks in culture. Indeed, a
LIVE/DEAD assay performed at 14 DIV revealed an average viability of over 85% (N=5
micro-TENNs). We also labeled the enriched dopaminergic micro-TENNs with markers
of excitatory and inhibitory neurons to ascertain the phenotype of the non-dopaminergic
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neurons. We found that, in addition to the dopaminergic neurons, the enriched population
contained both glutamatergic and GABAergic neurons (Figure 2.11).

Figure 2.10: Optimization of Enriched Dopaminergic Micro-TENNs. (A) Micro-TENNs
generated using fluorescent activated cell sorted aggregates demonstrated a higher percentage of
dopaminergic neurons in comparison to micro-TENNs plated with aggregates made from the
standard midbrain isolation at 14 DIV (n=5 micro-TENNs each group; Mann-Whitney test,
p<0.05). (B) A one way ANOVA (p=0.3297) determined that all ECM cores as well as high growth
factor media resulted in statistically equivalent micro-TENN length at 14 DIV. Data are presented
as mean ± standard deviation.

Figure 2.11: Phenotype of Enriched Dopaminergic Aggregates. (A-D) Confocal reconstructions
of Fluorescent activated cell sorted aggregates at 35 DIV labeled via immunocytochemistry to
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denote all dopaminergic neurons/axons (TH; green), and glutamatergic neurons (VGLUT; red),
GABAergic neurons (Parvalbumin + GAD65 + GAD67; purple), with nuclear counterstain
(Hoechst; blue). Scale Bar (D) = 20 µm. Following maturation over weeks in vitro, sorted
aggregates demonstrated the presence of dopaminergic, GABAergic, and glutamatergic neurons.

2.3.5 Optimization of Micro-TENN Length (Enriched Midbrain Population)
As with the standard dopaminergic neuron population, we tested the effects of
various ECM constituents, as well as growth factors, on the axonal outgrowth of the
enriched dopaminergic micro-TENNs. It was found that the use of 1 mg/mL rat tail
collagen as the inner core produced the longest micro-TENNs at 14 DIV. Neither the
addition of laminin to the core (N=6 micro-TENNs), nor the use of crosslinked collagen
(N=6 micro-TENNs) resulted in statistically superior axonal outgrowth. Likewise, the use
of the media containing high concentrations of growth factors (N=6 micro-TENNs) did not
result in improved axonal outgrowth (Figure 2.10 B). As the majority of the enriched
constructs did not measure 5 mm (the length of the nigrostriatal pathway in rats) by 14
DIV, we monitored their growth out to 21 DIV. Here, we found that the average length of
the constructs was 4590 µm, with a standard deviation of 1111 µm (N=6 micro-TENNs).
Thus, at 21 DIV, many of the enriched dopaminergic micro-TENNs exceeded the 5 mm
length necessary to span the nigrostriatal pathway in rats.
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Figure 2.12: Dopaminergic Axonal Tracts Generated with Standard and Enriched
Dopaminergic Neuron Populations. (A-B) Confocal reconstructions of representative
constructs at 14 DIV labeled via immunocytochemistry to denote all neurons/axons (βtubulin III; purple) and dopaminergic neurons/axons (TH; red), with nuclear counterstain
(Hoechst; blue). Both constructs demonstrated the desired cytoarchitecture consisting of
discrete cell body and axonal regions. (A) A construct generated with neurons isolated from
the ventral mesencephalon. (B) A construct containing a neuronal population that was
enriched for GFP+ dopaminergic neurons using FACS. Scale bar (A) = 500 µm. Scale bar
(B) = 250 µm.

2.3.6 Generation of hESC-Derived Dopaminergic Micro-TENNs
As our eventual goal is to enable translation of this strategy, we sought to assess
the feasibility of generating micro-TENNs with dopaminergic neurons derived from human
sources. As such, we assessed the ability to fabricate micro-TENNs with dopaminergic
neurons differentiated from human embryonic stem cells (hESCs). hESCs were
differentiated following the protocol outlined in Kriks, et al., after which they were lifted
from two-dimensional culture (Figure 2.13 A), aggregated, and inserted into the microcolumns.11 At 14 days following plating in the micro-columns, it was found that these
micro-TENNs displayed the correct cytoarchitecture of a discrete somatic zone with
unidirectional axonal tracts within the lumen of the hydrogel micro-column. These axonal
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extensions measured over 4 mm in length at this time point (Figure 2.13 B). These human
dopaminergic micro-TENNs co-labeled for the axonal marker β-tubulin III and the
dopaminergic marker TH, and showed a purity of roughly 50% dopaminergic neurons (data
not shown).

Figure 2.13: Micro-TENNs Generated with Human Embryonic Stem Cell-Derived
Dopaminergic Neurons. H9 human embryonic stem cells were differentiated into
dopaminergic neurons and labeled via immunocytochemistry to denote all neurons/axons
(β-tubulin III; green) and dopaminergic neurons/axons (TH; red), with nuclear counterstain
(Hoechst; blue). (A) Differentiated dopaminergic neurons shown in two-dimensional
culture. (B) Differentiated dopaminergic neurons were dissociated, aggregated, and
inserted into micro-columns, were they extended robust processes measuring over 4 mm
by 14 days post plating. Scale bar (A) = 100 µm. Scale bar (B) = 225 µm.

2.4 Discussion
Current treatments for Parkinson’s disease, including the use of dopamine
replacement strategies and DBS, are aimed at alleviating motor disabilities rather than
correcting the underlying cause of the motor symptoms. Furthermore, while dopaminergic
neuron and/or fetal graft implants into the striatum may provide a local source of dopamine,
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these approaches do not recreate the nigrostriatal circuit and thus do not provide
appropriate feedback control of dopamine release. To address these gaps, we sought to
develop a tissue-engineered solution that could be precisely delivered to physically restore
lost dopaminergic neurons in the SNpc and their axonal projections to the striatum. To
achieve this objective, we built upon our lab’s previously developed micro-tissue
engineering platform to generate micro-TENNs utilizing primary embryonic dopaminergic
neurons.
Dopaminergic micro-TENNs were first generated using a population of ventral
mesencephalic neurons that contained roughly ~8% dopaminergic neurons when cultured
in 3D. While these studies were extremely important for optimization of the fabrication
protocol, delivery of an estimated 1200 dopaminergic neurons12 will be necessary to
provide sufficient concentrations of dopamine for recovery of motor function in a rat model
of Parkinson’s disease. Therefore, it was necessary to select a cell source with a greater
purity of dopaminergic neurons. Potential options included post-natal rat neurons, human
embryonic stem cell-derived (hESC-derived) neurons, induced pluripotent stem cell
derived (iPSC-derived) neurons, or embryonic rat neurons enriched for dopaminergic
neurons through immunopanning and/or FACS. While our successful generation of microTENNs using dopaminergic neurons derived from hESCs demonstrated feasibility of using
human cell sources, we ultimately chose to explore the use of a rat embryonic FACSpurified population. This cell source will match the species of our future rat animal model.
More importantly, the ability of these cells to release dopamine in response to electrical
stimulation has been well documented and well characterized.13–18 This attribute will be
necessary to evaluate the efficacy of the constructs both as a test bed in vitro, and following
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implantation in vivo. The purity of the fluorescent activated cell sorted population was
roughly 60% and this population was able to maintain a viability of over 85% out to 14
DIV. It was also found that this enriched population contained both glutamatergic and
GABAergic neurons. The presence of these additional neuronal phenotypes may or may
not matter functionally following transplantation, as both glutamate and GABA are coreleased with dopamine in some cases.19,20
Our method to plate micro-TENNs with dopaminergic “aggregates” alleviated the
lack of separation between the neuronal somata and neurites that we observed in some
cases when micro-TENNs were plated with dissociated cells. It was particularly important
to ensure that the micro-TENNs demonstrated the desired cytoarchitecture of a discrete cell
body region projecting axons through the length of the inner core since separate somatic
and axonal regions is a key feature of the nigrostriatal pathway. We believe that better
approximation of the cytoarchitecture of the nigrostriatal pathway will lead to improved
functional outcomes following micro-TENN implantation to reconstruct the degenerated
dopaminergic neurons in the SNpc and their projections to the striatum. In particular, the
dopaminergic neurons in the SNpc synapse directly onto striatal neurons without exerting
their effects through intermediate synapses and/or neurons. Therefore, in order for the
connectivity and timing of our micro-TENNs to be correct upon integration with the host,
our micro-TENNs will likely need to achieve modulation of striatal neurons by propagating
signals from the SNpc through a mono-synaptic pathway. Since we were able to create
dopaminergic micro-TENNs that approximate the architecture of the nigrostriatal pathway,
this increases the likelihood that functional integration in vivo will emulate the native
mono-synaptic pathway.
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By utilizing the neuronal aggregates as well as optimizing the inner core ECM, we
confirmed that the micro-TENNs were capable of spanning the length of the nigrostriatal
pathway in rats, which is approximately 5 mm. In fact, as far as we know, our microTENNs exhibit the longest in vitro dopaminergic axonal outgrowth recorded in the
literature.21–31 The standard (non-enriched) dopaminergic cell aggregates produced neurite
outgrowth that was approximately 10X longer than projections from individual cells. This
may be influenced by the fact that the cellular density within the neuronal aggregates is
more representative of the density within the brain. This higher cell density may give the
aggregated neurons better control over their 3D microenvironment than dissociated cells,
which in turn promoted better cell viability and health and therefore enhanced axonal
extension. Moreover, the gene expression of cells in the aggregates may also be more
representative of cells in the brain and allows the cells to tap into developmental programs
to initiate axonal outgrowth 9. Furthermore, many neuronal subtypes are programmed for
either short or long distance communication.32 In dissociated micro-TENNs, “long
distance” axons likely meet synaptic partners at intermediate distances along the length of
the micro-column. In contrast, for the aggregate micro-TENNs the absence of any
intermediate neighbors may have prompted the “long distance” neurons to up-regulate
proteins for long distance outgrowth and thus project the length of the micro-columns.
Lastly, the aggregates give rise to grouped and fasciculated axonal projections, which may
produce a sustained drive for axonal extension due to concentrated and persistent progrowth signaling, and/or physical/structural advantages. The rates and lengths of
dopaminergic axonal extension from the neuronal aggregates were unprecedented,
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although clearly further studies are required to elucidate the mechanisms of ultra-long
axonal projections from the aggregates.
In our attempts to maximize axonal outgrowth in both the standard and enriched
dopaminergic micro-TENNs, we found that collagen I and a collagen I + laminin cocktail
produced the longest outgrowth when used as the biomaterial for the inner core. We believe
this occurred because, unlike the laminin coating and empty cores, the collagen I and
collagen I + laminin cocktail both provided a continuous, 3D scaffold that supported axonal
outgrowth. While the crosslinked collagen also provided a continuous scaffold, it was
much stiffer and likely more resistive to enzymatic degradation upon growth cone
extension. Interestingly, utilizing media enriched in growth factors did not increase axonal
outgrowth. As engineered growth factor gradients were not employed, our results suggest
that the axons may be relatively non-responsive to global changes in growth signals.
Likewise, the use of a dopaminergic neuron end target did not increase axonal outgrowth
in the standard micro-TENNs, which does not support our hypothesis that chemotactic cues
generated from an end target would accelerate axonal outgrowth. Potentially, suprathreshold peak growth factor concentrations and adequate chemotaxic gradients could not
be established due to the significant diffusional distance (1.2 cm) required to span the two
populations.
Our in vitro optimization studies demonstrated that we were capable of generating
dopaminergic micro-TENNs with a neuronal population comprised of over 60%
dopaminergic neurons. These micro-TENNs exhibited the ideal cytoarchitecture of discrete
somatic and axonal regions, with axons projecting the length of the tube. The utilization of
the neuronal aggregation method, in combination with an extracellular matrix (collagen)
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core, supported dopaminergic cytoarchitecture measuring over 5 mm in length by 21 DIV,
and displaying a viability of over 85% out to 14 DIV. Thus, these studies demonstrated the
feasibility of generating healthy, purified dopaminergic micro-TENNs with sufficient
length to span the nigrostriatal pathway in a rat model of Parkinson’s disease.
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CHAPTER 3: IN VITRO CHARACTERIZATION OF DOPAMINERGIC MICROTENNS
3.1 Introduction
The nigrostriatal pathway consists of axonal projections to the striatum that
originate from the dopaminergic neurons in the substantia nigra pars compacta (SNpc).
Specifically, these axonal projections synaptically integrate with medium spiny neurons
and striatal interneurons in the striatum via a range of dopamine receptors (D1-D5). In the
direct pathway, the terminals synapse with medium spiny neurons expressing D1receptors, and in the indirect pathway, the terminals synapse with medium spiny neurons
expressing D2-receptors. Long-projecting axons from SNpc dopaminergic neurons exhibit
an exquisite arbor in the striatum to release dopamine at highly dense varicosities along the
axon, which are organized en passant with neighboring neuronal compartments.1
Furthermore, previous studies have shown that in addition to synapsing with dopamine
receptors on medium spiny neurons and interneurons, dopaminergic neurons self-regulate
via dopamine autoreceptors on their own axons, dendrites, and somata.1
During release, dopamine generally overflows beyond the presynaptic terminal
and the amount of extrasynaptic dopamine is influenced predominantly by the amount of
exocytotic release as well as the amount of reuptake via the plasma membrane dopamine
transporter (DAT).1 DAT is densely located on dopaminergic neuron cell bodies and axons,
and clears extrasynaptic dopamine in order to recycle it back into the cell’s releasable pool
of dopamine.1 As such, the half life of dopamine in the striatum – only 60 ms – is relatively
short.2 Prior studies have estimated that the range of the tonic concentration of dopamine
in the striatum of rats is between 50 nM and 100 nM.3
95

The way in which dopamine release modulates striatal activity is complex and
dependent upon which dopamine receptor is being activated. In line with the two pathways
(direct and indirect) model, it has been shown that activation of D1 receptors increases the
firing of striatal neurons while activation of D2 receptors decreases the firing rate of striatal
neurons. However, conflicting results have been recorded regarding the overall effects of
dopamine modulation on striatal circuits.4–7 One theory for this is that medium spiny
neurons simultaneously express dopamine receptors from separate classes that are known
to yield opposing effects. For example, neurons expressing D1 receptors can
simultaneously express the D3 receptor, which is categorized as a D2-like receptor.
Another theory is that striatal interneurons expressing dopamine receptors are important in
the regulation of medium spiny neurons, which results in an indirect response to the overall
dopamine activity. Regardless, several studies have observed that dopamine can influence
the synchronization of striatal networks.8–11 Reid et al. utilized calcium imaging to observe
that activation of both D1 and D2 receptors resulted in increased synchrony in rat
corticostriatal slices.9 Computational modeling has also predicted that dopamine alters the
synchronization of the striatum.10,11
The stereotypical neurodegeneration that occurs in Parkinson’s disease deprives the
striatum of these crucial dopaminergic inputs, and thereby interrupts important motor
feedback pathways. Therefore, while generating our micro-TENNs for the reconstruction
of the nigrostriatal pathway, it was of utmost importance to insure that they could release
dopamine and synaptically integrate with striatal neurons. Prior to implanting
dopaminergic micro-TENNs into a rat model of PD, we believed it would be advantageous
to examine these relevant measures of function in vitro. Thus, we created an in vitro test
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bed consisting of a dopaminergic micro-TENN containing a surrogate striatal end target at
the opposite end of the tube. We co-cultured these two populations for weeks in vitro, and
then used fast scan cyclic voltammetry (FSCV), immunocytochemistry, and calcium
imaging to examine the functional integration of the two populations. Using these
techniques, we confirmed that the dopaminergic micro-TENNs exhibited evoked dopamine
release and found both immunocytochemical and functional evidence that they formed
synapses with striatal neurons.

3.2 Methods
3.2.1 Micro-TENN Fabrication and Neuronal Cell Culture
Dopaminergic micro-TENNs fabricated with the standard dopaminergic population
and the enriched dopaminergic population were generated as described in Chapter 2. In
some instances, constructs were transduced with adeno-associated virus (AAV) vectors.
Here, at 3 DIV the micro-TENNs were incubated overnight in media containing the vector
and the cultures were rinsed with media the following day. The vectors included the
calcium indicator GCaMP6f (AAV1.Syn.GCaMP6f.WPRE.SV40,UPenn Vector Core,
~3x109

genome

copies/mL),

green

fluorescent

protein

(GFP)

(AAV2/1.hSynapsin.EGFP.WPRE.bGH, UPenn Vector Core, ~3.2x1010 genome
copies/mL),

and

the

channelrhodopsin

ChR2,

with

a

GFP

reporter

(AAV1.hSyn.ChR2(H134R)-eYFP.WPRE.hGH, UPenn Vector Core, ~3x109 genome
copies/mL).
Female Sprague-Dawley rats (Charles River, Wilmington, MA) were the source for
primary striatal neurons. Carbon dioxide was used to euthanize timed-pregnant rats
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(embryonic day 18), after which the uterus was extracted. To isolate striatal neurons, the
brains were removed in HBSS and striata were isolated. The striata were dissociated in
trypsin (0.25%) + ethylenediaminetetraacetic acid (EDTA) (1 mM) for 12 minutes at 37°C.
The trypsin-EDTA was then removed and the tissue was triturated in HBSS containing
DNase I (0.15 mg/mL). The cells were centrifuged at 1000 rpm for 3 minutes and
resuspended at 1-2 million cells/mL in Neurobasal medium + 2% B27 + 0.4 mM Lglutamine. Striatal aggregates were created and inserted into micro-TENNs as previously
described. The striatal aggregates were inserted into the vacant ends of the dopaminergic
neurons between 3 DIV and 10 DIV.

3.2.2 Immunocytochemistry
Micro-TENNs were fixed in 4% formaldehyde for 35 min and permeabilized using
0.3% Triton X100 plus 4% horse serum for 60 minutes. Primary antibodies were added (in
phosphate-buffered saline (PBS) + 4% serum) at 4°C for 12 hours. The primary antibodies
were the following markers: (1) β-tubulin III (1:500, Sigma-Aldrich, cat # T8578), a
microtubule element expressed primarily in neurons; (2) tyrosine hydroxylase (TH; 1:500,
Abcam, cat # AB113), an enzyme involved in the production of dopamine; (3) microtubuleassociated protein 2 (MAP-2) (1:500, Millipore, cat # AB5622), a microtubule-associated
protein found in neuronal somata and dendrites; (4) dopamine-and-cAMP-regulated
neuronal phosphoprotein (DARPP-32) (1:250, Abcam, cat # AB40801) a protein found in
striatal medium-sized spiny neurons; (5) synapsin 1 (1:1000, Synaptic Systems, cat #
106001), a protein expressed in synaptic vesicles of the central nervous system; (6)
dopamine transporter (1:500, Abcam, cat # AB111468), a plasma membrane protein the
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recycles extrasynaptic dopamine back into the cell, (7) dopamine receptor 1 (1:500, Novus
Biologicals, cat # NB110-60017), (8) bassoon (1:500, Synaptic Systems, cat # 141011), a
presynaptic scaffolding protein, (9) RIM 1 (1:500, Synaptic Systems, cat # 140003), a
protein in the active zone of neurotransmitter release, and (10) NeuN (1:500, Millipore, cat
# ABN91), a neuronal nuclear antigen. Appropriate fluorescent secondary antibodies
(Alexa-488, -594 and/or -649 at 1:500 in PBS + 30 nM Hoechst + 4% serum) were added
at 18-24°C for 2 hours.

3.2.3 Microscopy and Data Acquisition
For in vitro analyses, micro-TENNs were imaged using phase-contrast and
fluorescence on a Nikon Eclipse Ti-S microscope with image acquisition using a QiClick
camera interfaced with Nikon Elements. In order to determine the length of neurite
penetration, the longest observable neurite in each micro-TENN was measured from the
proximal end of the neuronal aggregate after fixation. For in vitro immunocytochemistry
analyses, cultures and micro-TENNs were fluorescently imaged using a Nikon A1RSI
Laser Scanning Confocal microscope. All micro-TENN confocal reconstructions were
from full thickness z-stacks.

3.2.4 Fast Scan Cyclic Voltammetry
At 24-35 DIV, micro-TENNs were transferred to a testing chamber and flushed
with culture media. A carbon fiber electrode (150-200 µm length x 7 µm diameter) was
inserted into the dopaminergic aggregate, the dopaminergic axon terminals, or the striatal
end target and a bipolar stimulating electrode (Plastics One, Roanoke, VA) was placed
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across the same location. Dopamine release was elicited using electrical pulse trains (2030 Hz, 5 ms pulse width, 0.5-1 s, monophasic) every 5-15 minutes and recorded using
Demon Voltammetry and Analysis Software.12 The potential of the carbon fiber electrode
was linearly scanned from −0.4 to 1.2 V and back to −0.4 V vs. Ag/AgCl. A
voltammeter/amperometer (Chem-Clamp; Dagan Corporation) was used to scan at a rate
of 400 V/s, and cyclic voltammograms were recorded every 100 ms. Electrode calibrations
of known concentrations of DA (1–10 μM) were used to calculate the concentration of
electrically evoked dopamine release at the peak oxidation potential for dopamine in
consecutive voltammograms.
For the standard (non-enriched) dopaminergic micro-TENNs, the culture media
contained 100 µm L-DOPA.
For the dopaminergic micro-TENNs transduced with channelrhodopsins, the
culture

media

contained

100

µM

L-DOPA.

For

optical

stimulation,

a

PlexBright® Optogenetic Stimulation System was used to deliver a 0.5 s pulse of 465 nm
light every 15 minutes.
For the dopaminergic micro-TENNs treated with the DAT inhibitor GBR12909,
increasing concentrations of GBR12909 were perfused through the testing chamber.
Concentrations of GBR12909 included 0.0 µM, 0.02 µM, 0.2, µM 2.0 µM, and 20 µM.
Dopaminergic neurons incubated in each concentration for 30 minutes before evoked
dopamine release was recorded.
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3.2.5 Calcium Imaging of Unidirectional Micro-TENNs
At 12 DIV, unidirectional micro-TENNs were placed in a live incubation chamber
on an N-STORM super-resolution fluorescent microscope system. The calcium activity of
unidirectional dopaminergic constructs transduced with the calcium indicator GCaMP6f
was recorded using this microscope system, after which calcium transients from the
recordings were identified in NIS Elements AR 4.50.00 (Nikon Instruments). The
intensities of selected aggregate-sized regions of interest (ROIs) of the constructs were
plotted over time. In some instances, a bipolar stimulating electrode (Plastics One,
Roanoke, VA) was placed across the aggregate, and calcium activity was evoked using
electrical pulse trains (20 Hz, 0.5 s, monophasic) every 5 minutes.

3.2.6 Calcium Imaging & Analyses of Bidirectional Micro-TENNs Containing Striatal
end Targets
At 35 DIV, bidirectional micro-TENNs were placed in a live incubation chamber
on an N-STORM super-resolution fluorescent microscope system. The calcium activity of
bi-directional dopaminergic constructs transduced with the calcium indicator GCaMP6f
was recorded using this microscope system, after which calcium transients from the
recordings were identified in NIS Elements AR 4.50.00 (Nikon Instruments). Neurons in
the striatal aggregate demonstrating changes in fluorescence were targeted as regions of
interest (ROIs), and the intensities of these ROIs were recorded under several conditions.
First L-DOPA (100 µM) and N-Methyl-D-aspartic acid (NMDA) (8 µM) were applied to
the cultures. After 30 minutes, the baseline calcium activity of the striatal aggregate was
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recorded for 3 minutes. Next, a bipolar stimulating electrode (Plastics One, Roanoke, VA)
was placed across the dopaminergic aggregate, and the aggregate was stimulated with an
electrical pulse train (20 Hz, 0.5 s, monophasic). 30 minutes later, the calcium activity of
the striatal aggregate was recorded for 3 minutes. Lastly, dopamine (3 µM) was applied to
the cultures, and after 30 minutes the calcium activity of the striatal aggregate was recorded
for 3 minutes.
The first 40 seconds of fluorescent intensity data was trimmed from each ROI trace,
after which the data was fed into a previously published and validated fluorescence single
neuron and network analysis package called FluoroSNNAP.13 This analysis package
calculated the normalized fluorescence (ΔF/Fo) for each ROI, and then compared this
normalized fluorescence to a library of known calcium transient waveforms. A correlation
coefficient was used to calculate the similarity between the input fluorescence and the
known waveforms; a calcium transient event within the input data was identified when the
correlation coefficient was greater than 0.85. Following detection of calcium transients, the
package performed a synchronization analysis by first calculating the instantaneous phase
of each fluorescent trace, which emphasizes the timing of the calcium events.13 Next, the
phase difference was calculated for each pair of neurons (each pair of ROIs) identified
within the network. Finally, the phase difference was used to calculate a synchronization
index between each pair of neurons; if the calcium events across the two traces were
completely synchronized, this index value=1 and if the events across the two traces were
completely independent, this index value=0.13 All of the pairwise synchronization indices
were placed into a matrix (matrix S), and eigen decomposition was used to cluster the
neurons.13–15 The minimum number of neurons to define a cluster was set to n=3 neurons.
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The number of unique activity patterns was determined by the number of large eigenvalues,
and a single global synchronization index was generated for each neuronal network under
each condition (baseline, post stimulation, or positive control) based upon the largest
eigenvalue of the matrix S.

3.2.7 Statistics
An unpaired, non-parametric, two sided Mann-Whitney test was performed to
determine if there was a statistically significant difference in axonal outgrowth between
unidirectional versus bi-directional micro-TENNs containing a striatal end target. A one
way ANOVA was used to determine if there was a statistically significant difference in the
synchronization of the striatal aggregate following electrical stimulation and the
application of dopamine (positive control) in comparison to the baseline. Data are
presented as mean ± standard deviation.

3.3 Results
3.3.1 Dopaminergic Neuron Machinery for Dopamine Uptake and Release
Immunocytochemistry was used to label dopaminergic neurons for markers of
machinery involved in dopamine uptake and release. As previously mentioned, the
dopamine transporter (DAT) is expressed heavily along dopaminergic neuron cell bodies
and neurites, and plays a large role in recycling dopamine from the extrasynaptic space
back into the cell’s releasable pool of dopamine.1 Immunocytochemistry confirmed the
expression of DAT on the embryonic dopaminergic neurons used to generate the microTENNs, suggesting they contain the machinery for dopamine re-uptake (Figure 3.1).
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Furthermore, Liu et al recently reported that the presynaptic scaffolding proteins bassoon,
RIM, and Elk form active-zone like release sites for dopamine.16 Within these sites, they
found that RIM was essential to dopamine release, while ELKS is dispensable for
dopamine release.16 Immunocytochemistry labeling of the dopaminergic micro-TENNs
confirmed both the expression and co-localization of the scaffolding proteins bassoon and
RIM with the dopaminergic neuron marker tyrosine hydroxylase along dopaminergic
neurites (Figure 3.2). Furthermore, such sites of co-localization appear at putative
dopaminergic varicosities.

Figure 3.1: Dopaminergic Neurons Express the Plasma Membrane Dopamine
Transporter. Representative confocal reconstruction at 14 DIV of a standard midbrain
population containing dopaminergic neurons labeled via immunocytochemistry to denote
dopaminergic neurons/axons (TH; red), the dopamine transporter protein (dopamine
transporter; green), and all neurons/axons (β-tubulin III; purple). Dopaminergic neurons
exhibit expression of the dopamine transporter (DAT), a protein involved in dopamine
recycling. Scale bar = 20 µm.
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Figure 3.2: Axons from Enriched Dopaminergic Neuron Micro-TENNs Exhibit
Expression of Bassoon and RIM Proteins. Representative confocal reconstruction at 14
DIV of an enriched dopaminergic micro-TENN labeled via immunocytochemistry to
denote dopaminergic neurons/axons (TH; green), RIM proteins (RIM1; red), and bassoon
proteins (Bassoon, purple). The RIM and bassoon proteins colocalize on putative
dopaminergic varicosities. Scale bar = 25 µm.

3.3.2 Formation of Synapses with Striatal Population
As the dopaminergic axons comprising the nigrostriatal pathway synapse with
striatal neurons in the brain, we probed the ability of our tissue engineered nigrostriatal
pathway to synapse with a population of striatal neurons in vitro. Dopaminergic microTENNs were generated and, after 3-10 DIV, embryonic rat striatal aggregates were inserted
into the vacant ends of the micro-columns. After 14 DIV, immunocytochemistry was
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performed in order to assess potential synaptic integration between the two populations.
Both standard (non-enriched) dopaminergic micro-TENNs, and enriched dopaminergic
micro-TENNs were investigated for synapse formation with the striatal target. This
analysis confirmed the presence of the appropriate neuronal sub-types in the two aggregate
populations, specifically TH+ dopaminergic neurons and DARPP-32+ medium spiny
striatal neurons (Figure 3.3 and Figure 3.4). Moreover, confocal microscopy revealed
extensive axonal-dendritic integration and putative synapse formation involving the
dopaminergic axons and striatal neurons (Figure 3.3 D,E,G,H and Figure 3.4 B,D). In
some instances, neurites from enriched dopaminergic aggregates demonstrated a
concentrated network of outgrowth within the striatal aggregate, representative of the dense
arborization of dopaminergic axons in the striatum in vivo (Figure 3.4 A-B).

Figure 3.3: Synapse Formation Between Axons from Standard Dopaminergic Micro-TENNs
and Striatal Neurons In Vitro. (A) Representative confocal reconstruction at 14 DIV of a standard
dopaminergic micro-TENN plated with an aggregated striatal end target. The micro-TENN was
labeled via immunocytochemistry to denote dopaminergic neurons/axons (TH; pink), striatal
(medium spiny) neurons (DARPP-32; green), and synapses (synapsin; purple), with nuclear
counterstain (Hoechst; blue). (B-E) Higher magnification reconstructions from demonstrative
regions in (A) depict the (B) dopaminergic neuron aggregate, (C) robust, aligned TH+ axons, and
(D) neurite outgrowth from the striatal neuron population. (E) A high degree of synapsin labeling
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(purple) along the trajectory of TH+ axons (pink) suggests that dopaminergic axons formed
synapses with the striatal neurons. (F) Micro-TENNs containing striatal end targets did not result
in statistically longer axonal outgrowth when compared to unidirectional dopaminergic microTENNs with no end target (n=9 micro-TENNs each group; Mann-Whitney test, p=0.9182). Data
are presented as mean ± standard deviation. (G-H) Synapsin+ puncta (purple) can be seen
decorating putative dendrites projecting from striatal neurons (green) shown with dopaminergic
axonal varicosities (pink), further suggesting synaptic integration. Scale bar (A) = 250 µm. Scale
bar (B-E) = 50 µm. Scale bar (G-H) = 20 µm.

Figure 3.4: Synapse Formation Between Axons from Enriched Dopaminergic Micro-TENNs
and Striatal Neurons In Vitro. (A) Representative confocal reconstruction at 14 DIV of an
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enriched dopaminergic micro-TENN plated with an aggregated striatal end target. The microTENN was labeled via immunocytochemistry to denote dopaminergic neurons/axons (TH; green),
striatal (medium spiny) neurons (DARPP-32; red), and synapses (synapsin; purple), with nuclear
counterstain (Hoechst; blue). (B) Higher magnification reconstructions from a demonstrative
region in (A) depict dense dopaminergic neurite outgrowth, containing a high degree of synapsin
labeling (purple) within the striatal aggregate. (C) Representative confocal reconstruction at 14
DIV of a striatal aggregate end target within a bidirectional, enriched dopaminergic micro-TENN.
The micro-TENN was labeled via immunocytochemistry to denote dopaminergic neurons/axons
(TH; green), striatal (medium spiny) neurons (DARPP-32; red), and synapses (synapsin; purple),
with nuclear counterstain (Hoechst; blue). (D) Higher magnification reconstructions from a
demonstrative region in (C) depict synapsin+ puncta (purple) decorating putative dendrites
projecting from striatal neurons (red) shown with dopaminergic axonal varicosities (green). Scale
bar (A) = 250 µm. Scale bar (B) = 20 µm. Scale bar (C)= 50 µm. Scale bar (D) = 25 µm.

Immunocytochemistry confirmed that the majority of the striatal (DARPP-32+)
neurites were also MAP-2+, suggesting that they were dendrites (data not shown).
Immunocytochemistry also confirmed that both the striatal neuron cell bodies and neurites
expressed the dopamine receptor D1R (Figure 3.5).

Figure 3.5: Expression of Dopamine Receptor D1R by Striatal Neurons.
Representative confocal reconstruction at 14 DIV of a striatal aggregate end target within
a bidirectional, enriched dopaminergic micro-TENN. The striatal aggregate was labeled
via immunocytochemistry to denote striatal neurons (DARPP-32; green), the D1 dopamine
receptor (D1R; red), and neuronal somata (NeuN, purple) with nuclear counterstain
(Hoechst; blue). As expected, striatal neurons express the dopamine D1 receptor on their
cell bodies, as well as along their neurites. Scale bar (A-B) = 20 µm.
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Lastly, in order to determine if chemotactic cues generated by the striatal population
influenced axonal outgrowth from the standard dopaminergic neuron aggregates, the length
of axonal outgrowth was quantified with and without the striatal end target. It was found
that the axonal outgrowth in dopaminergic micro-TENNs containing a target population of
striatal neurons was not statistically greater than axonal outgrowth in unidirectional
dopaminergic micro-TENNs (n=9 micro-TENNs in each group; Figure 3.3 F).

3.3.4 Dopamine Release In Vitro
In addition to immunocytochemical evidence of integration with striatal neurons,
we believed it was necessary to demonstrate that our dopaminergic neurons could release
dopamine in vitro. First, stimulation paradigms to evoke calcium activity without harming
unidirectional dopaminergic aggregates were explored. Dopaminergic micro-TENNs were
transduced with the calcium indicator GCaMP6f and calcium imaging of the dopaminergic
aggregate was performed while stimulating the dopaminergic aggregate with a bipolar
electrode. It was found that monophasic electrical pulse trains with a frequency of 20-30
Hz, pulse width of 5 ms, and duration of 0.5-1 s could be used to reliably evoke calcium
activity every 5-15 minutes over an extended period of time (>2 hours) (Figure 3.6).
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Figure 3.6: Controlled Stimulation of Dopaminergic Axonal Tracts. Dopaminergic
axonal tracts exhibit spontaneous and evoked Ca2+ oscillations as shown in constructs
transduced to express the genetically-encoded calcium indicator GCaMP6f. (A)
Fluorescent signal of a transduced dopaminergic construct before and after electrical
stimulation. (B) Quantitative intensity of the construct through-out the experiment.
Following electrical stimulation, the fluorescent intensity of the cell aggregate greatly
increased, indicating that the calcium activity of the construct could be controlled
electrically. Scale bar (A)= 50 µm.

FSCV was used to examine the capacity of both standard and enriched
unidirectional micro-TENNs to release dopamine in vitro. At 24-35 DIV, a carbon fiber
electrode was used to record evoked dopamine release in both the dopaminergic aggregate
as well as at the distal end of the micro-column containing the terminals of the axonal
tracts. It was found that dopamine release could be elicited in only the somatic region of
unidirectional micro-TENNs; evoked dopamine release in the axon terminals was not
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attained (Figure 3.7 and Figure 3.8). Furthermore, in order to record dopamine release in
the standard dopaminergic micro-TENNs, media containing L-DOPA was necessary.
Cyclic voltammograms recorded during dopamine release in the neuronal aggregate region
all demonstrated characteristic oxidation between 0.55 and 0.65 V, and reduction between
-0.20 and -0.30 V.17 Under the parameters used in these studies, the pattern of oxidation
and reduction may be used to correctly identify currents produced by action potential
dependent release of catecholamines. Current traces recorded in the aggregate region
across several micro-TENNs demonstrated an average peak extracellular dopamine
concentration of ~30 nM immediately following electrical stimulation in the standard
micro-TENNs (Figure 3.7), and an average peak extracellular dopamine concentration of
~280 nM immediately following electrical stimulation in the enriched micro-TENNs
(Figure 3.8) Of note, this protocol was also applied to multiple micro-TENNs at 9 DIV but
measurements of evoked dopamine release were not attained (data not shown), suggesting
the need for functional maturation of dopaminergic neurons/axons over long periods of
time in vitro.
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Figure 3.7: Evoked Dopamine Release from Standard Micro-TENNs In Vitro. (A)
Recording set up for FSCV in vitro following perfusion with L-DOPA. A carbon fiber
electrode (white) was used to attempt to record dopamine release both within the
dopaminergic aggregate (R1) and at the axon terminals (R2). A bipolar stimulating
electrode (red) was placed to span either the dopaminergic aggregate or the axonal tracts
within the micro-column. (B) Representative color plot displaying the current recorded as
the potential of the carbon fiber electrode was linearly scanned from −0.4 to 1.2 V and back
to −0.4 V vs. Ag/AgCl every 100 ms. The magnified cross section from the color plot
displays an individual cyclic voltammogram exhibiting an oxidation peak at 0.65 V and a
reduction trough at -0.3 V, which are characteristic of dopamine. (C) The averaged
concentration of dopamine released in the dopaminergic aggregate (R1) following
electrical stimulation. Scale bar A = 500 µm.
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Figure 3.8: Evoked Dopamine Release from Enriched Micro-TENNs In Vitro. Evoked
dopamine release was recorded from unidirectional enriched dopaminergic neurons; the
stimulating electrode was positioned to span the dopaminergic aggregate while the carbon
fiber recording electrode was placed within the aggregate. (A) Representative color plot
displaying the current recorded as the potential of the carbon fiber electrode was linearly
scanned from −0.4 to 1.2 V and back to −0.4 V vs. Ag/AgCl every 100 ms. (B) A cross
section from the color plot displays an individual cyclic voltammogram exhibiting an
oxidation peak at 0.65 V and a reduction trough at -0.3 V, which are characteristic of
dopamine. (C) Representative time versus concentration plot of the evoked dopamine
release. (D) Histogram displaying the range of maximum dopamine concentration values
recorded in the aggregate regions of enriched, unidirectional dopaminergic micro-TENNs
(n=5).

After confirming the ability of the dopaminergic aggregates to release dopamine in
response to electrical stimulation, the possibility of using optical stimulation to evoke
release was explored as well. A unidirectional, enriched dopaminergic micro-TENN was
transduced with the channelrhodopsin ChR2. At 35 DIV, both electrical and optical
stimulation (utilizing a PlexBright® Optogenetic Stimulation System) were used to evoke
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dopamine release at the same location within the dopaminergic aggregate. While it was
found that optical stimulation was capable of evoking dopamine release, the maximum
concentration of dopamine released via optical stimulation was much less than that of
electrical stimulation (Figure 3.9).

Figure 3.9: Optical and Electrical Evoked Dopamine Release from Enriched
Dopaminergic Micro-TENNs In Vitro. (A) Construct used for dopamine release studies.
(B) The construct was transduced with the genetically encoded channelrhodopsin ChR2,
containing a synapsin promoter and a GFP+ reporter. Fast scan cyclic voltammetry (FSCV)
using a carbon-fiber electrode was used to record evoked dopamine release in the
dopaminergic aggregate following perfusion with L-DOPA. (C-D) Color plots of
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recordings during electrical (C) and optical (D) stimulation that display the current
recorded as the potential of the carbon fiber electrode was linearly scanned from −0.4 to
1.2 V and back to −0.4 V vs. Ag/AgCl every 100 ms. (E-F) Cyclic voltammograms
recorded during electrical (E) and optical (F) stimulation exhibit oxidation peaks at 0.65 V
and reduction troughs at -0.3 V, which are characteristic of dopamine. (G-H) The
maximum concentrations of dopamine released during electrical (G) and optical (H)
stimulation were ~90 nM and ~4 nM respectively. Scale bar (A) = 250 µm. Scale Bar (B)
=100 µm.

To further demonstrate the expression of the DAT on the dopaminergic neurons,
evoked dopamine release was recorded from enriched dopaminergic micro-TENNs
following perfusion with increasing concentrations of the DAT inhibitor GBR12909.
Evoked release was recorded at baseline, as well as following perfusion with the following
concentrations of GBR12909: 0.0 µM, 0.02 µM, 0.2, µM 2.0 µM, and 20 µM. The
application of the DAT inhibitor resulted in higher maximum concentrations of evoked
dopamine release and longer release durations (Figure 3.10). During the initial application
of GBR12909, the maximum concentration of evoked dopamine rose rapidly; however, the
maximum concentration of dopamine essentially plateaued after the application of 20 µM
GBR12909 (Figure 3.11).
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Figure 3.10: Application of Dopamine Transporter Inhibitor to Enriched Micro-TENNs In
Vitro. Evoked dopamine release was recorded from a unidirectional enriched dopaminergic microTENN following perfusion with different concentrations of the DAT inhibitor GBR12909. The
stimulating electrode was positioned to span the dopaminergic aggregate while the carbon fiber
recording electrode was placed within the aggregate. The concentration of GBR12909 in (A,C,E)
was 0.0 μM, while the concentration of GBR12909 in (B,D,F) was 20 μM. (A-B) Representative
color plots displaying the current recorded as the potential of the carbon fiber electrode was linearly
scanned from −0.4 to 1.2 V and back to −0.4 V vs. Ag/AgCl every 100 ms. (C-D) Cross sections
from the color plots display individual cyclic voltammograms exhibiting an oxidation peaks at 0.65
V and a reduction troughs at -0.3 V, which are characteristic of dopamine. (E-F) Representative
time versus concentration plots of the evoked dopamine release. The application of the DAT
inhibitor GBR12909 increased both the maximum concentration of evoked dopamine, as well as
the duration of dopamine release.
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Figure 3.11: Dopamine Transporter Inhibition Increases Evoked Dopamine Release
from Enriched Micro-TENNs In Vitro. Evoked dopamine release was recorded from a
unidirectional enriched dopaminergic micro-TENN following perfusion with different
concentrations of the DAT inhibitor GBR12909. As the concentration of GBR12909 was
increased from 0.0 μM to 20 μM, the maximum concentration of evoked dopamine
increased rapidly and then plateaued at 20 μM.

While we were unable to record dopamine release in the axonal region of
unidirectional micro-TENNs, we tested the hypothesis that the presence of the surrogate
striatal end target would enable dopamine release from the dopaminergic axon terminals.
At 35 DIV, enriched bidirectional micro-TENNs containing surrogate striatal end targets
underwent FSCV; both the bipolar stimulating electrode and carbon fiber recording
electrode were placed in the striatal aggregate. It was found that dopamine release could
be evoked within the striatal aggregate and cyclic voltammograms recorded during
dopamine release demonstrated characteristic oxidation between 0.55 and 0.65 V, and
reduction between -0.20 and -0.30 V.17 Current traces recorded in the striatal aggregate
across several micro-TENNs demonstrated an average peak extracellular dopamine
concentration of ~375 nM immediately following electrical stimulation (Figure 3.12).
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Figure 3.12: Evoked Dopamine Release from Bidirectional Micro-TENNs In Vitro.
Evoked dopamine release was recorded from striatal aggregates within bidirectional
enriched dopaminergic neurons; the stimulating electrode was positioned to span the
striatal aggregate while the carbon fiber recording electrode was placed within the striatal
aggregate. (A) Representative color plot displaying the current recorded as the potential of
the carbon fiber electrode was linearly scanned from −0.4 to 1.2 V and back to −0.4 V vs.
Ag/AgCl every 100 ms. (B) A cross section from the color plot displays an individual
cyclic voltammogram exhibiting an oxidation peak at 0.65 V and a reduction trough at 0.3 V, which are characteristic of dopamine. (C) Representative time versus concentration
plot of the evoked dopamine release. (D) Histogram displaying the range of maximum
dopamine concentration values recorded in the striatal aggregate regions of enriched,
bidirectional dopaminergic micro-TENNs (n=6).

3.3.5 Calcium Imaging & Synchronization Analysis
Bidirectional micro-TENNs containing surrogate striatal end targets (n=5) were
transduced with the calcium indicator GCaMP6f. At 35 DIV, the constructs were placed
into a live incubation chamber and the fluorescent intensities of the constructs were imaged
at baseline, following electrical stimulation of the dopaminergic aggregate, and then
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following application of dopamine (3 μM). Recording media contained NMDA (8 μM) to
promote bursting activity within the striatal neurons and L-DOPA (100 μM) to amplify the
effects of the evoked dopamine. Neurons in the striatal end targets displaying calcium
fluctuations were targeted as regions of interest (ROIs), and fluorescent intensity traces of
these neurons under each imaging condition were processed through a validated
fluorescence network analysis package (Figure 3.13 A, C).13 Briefly, the package
normalized the fluorescent trace of each ROI and detected calcium transient events by
comparing the trace to known calcium event waveforms (Figure 3.13 B). This analysis
was performed for every neuron (ROI) within each striatal network (Figure 3.13 D).

Figure 3.13: Calcium Transient Event Detection within the Striatal End Target.
Bidirectional micro-TENNs containing a surrogate striatal end target were transduced with
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the calcium indicator GCaMP6f and imaged. (A) Neurons within the striatal target
exhibiting calcium fluctuations were targeted as regions of interest (ROIs). (B)
Representative plot of the normalized fluorescence of an individual ROI. Vertical bars
represent the onset of identified calcium transient events. (C) Representative plot of the
fluorescent intensity of every identified ROI within a network recorded during a 140
second time epoch. (D) Raster plot indicating the onset times of the calcium transient
events of each ROI in the network. Scale bar (A) = 100 µm.
The onset times of the detected calcium transient events were used to calculate the
instantaneous phase of each trace. The phase difference between each pair of neurons in
the network was then used to determine the index of synchronization for that pair.13 A
synchronization matrix (matrix S) containing the pair-wise synchronization indices for all
neurons in the network was generated (Figure 3.14 A). Lastly, eigen decomposition was
performed upon matrix S to determine the number of synchronized clusters and a global
synchronization index (GSI) for each network.13–15 We used a one way ANOVA to
compare the GSIs of the striatal networks across imaging conditions (baseline, post
stimulation, positive control). It was found that there were no statistically significant
differences in the synchronization of the striatal networks across imaging conditions
(Figure 3.14 B).

Figure 3.14: Striatal Aggregate Synchronization Analysis. The absolute phase difference
between every pair of neurons within a network was used to calculate a synchronization index
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between each pair. (A) Representative synchronization matrix displaying the synchronization
indices for each pair of neurons within a network. Eigen decomposition performed upon the
synchronization matrix determined the number of synchronized clusters, as well as a global
synchronization index for each network. (B) A one way ANOVA (p=0.3913) determined that all
three calcium imaging conditions (baseline, post stimulation, positive control) resulted in
statistically equivalent global synchronization indices for the striatal end target networks. Data are
presented as mean ± standard deviation.

3.4 Discussion
The nigrostriatal pathway is comprised of dopaminergic neurons in the SNpc that
project axons to the striatum, where they provide crucial dopaminergic inputs to motor
feedback pathways. Therefore, while seeking to reconstruct the nigrostriatal pathway with
our tissue-engineered dopaminergic micro-TENNs, it was important to demonstrate that
the micro-TENNs could release dopamine and integrate with a population of striatal
neurons. Prior to in vivo studies, we used immunocytochemistry, FSCV, and calcium
imaging to investigate the in vitro functionality of dopaminergic micro-TENNs.
Unidirectional micro-TENNs expressed machinery necessary for dopamine release
and re-uptake. Specifically, immunocytochemical labeling demonstrated the presence of
the dopamine transporter responsible for dopamine recycling, as well as two scaffolding
proteins necessary for dopamine release from active zone-like sites on dopaminergic
varicosities.16 Furthermore, FSCV confirmed the ability to evoke dopamine release within
the dopaminergic aggregate region of both standard and enriched dopaminergic microTENNs; cyclic voltammograms demonstrated oxidation between 0.55 and 0.65 V and
reduction between -0.20 and -0.30 V, which are characteristic of dopamine.17 Allowing the
dopaminergic neurons within the micro-TENNs to mature in culture was crucial, as it was
difficult to record dopamine release at earlier time points (data not shown). Enriched microTENNs exhibited an average peak extracellular dopamine concentration of ~280 nM
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immediately following electrical stimulation, whereas standard micro-TENNs required LDOPA in order to amplify the dopamine signal for ease of detection and exhibited only an
average peak extracellular dopamine concentration of ~30 nM immediately following
electrical stimulation. This disparity in dopamine concentration directly reflects the purity
of the two types of constructs, and the low concentration yielded by the standard microTENNs confirms our hypothesis that a dopaminergic neuron source of higher purity would
be necessary for sufficient dopamine release. Furthermore, the cyclic voltammograms of
standard micro-TENNs also displayed an oxidation peak around 0 V, which we believe is
a result of the release of neurotransmitters from non-dopaminergic neurons present in our
impure midbrain populations.
Our ability to record evoked dopamine release demonstrates that the machinery
necessary for dopamine synthesis and release was present within the dopaminergic microTENNs. The application of the DAT inhibitor GBR12909 also confirmed the presence of
functional DAT for dopamine recycling within the micro-TENNs. These studies
demonstrated an increase in the amplitude and half-life of evoked dopamine following
perfusion with GBR12909, consistent with other studies blocking dopamine re-uptake.18,19
Interestingly, the peak concentration of evoked dopamine initially rose rapidly with
increasing concentration of GBR12909, after which it plateaued around 20 μM of
GBR12909. We believe this diminishing release occurred because 20 μM of GBR12909
either blocked all the re-uptake locations, or was harmful to the dopaminergic neurons.
In contrast to electrical stimulation, optogenetic stimulation can be used to excite
specific types and/or groups of cells transduced with channelrhodopsins. This specificity
could be particularly advantageous following transplant in vivo where it may be necessary
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to excite engineered cells without exciting endogenous cells. Therefore, we transduced
enriched dopaminergic micro-TENNs with the channelrhodopsin ChR2 and used a
PlexBright® Optogenetic Stimulation System to confirm that dopamine release could be
evoked via optical stimulation. Optical and electrical stimulation were performed at the
same recording location within the dopaminergic neuron region of unidirectional microTENNs. Interestingly, the peak concentration of dopamine release evoked by electrical
stimulation was vastly greater (~20x greater) than the peak concentration evoked by optical
stimulation. As the dopaminergic aggregates are dense clusters of cells, it is possible that
the light from the optogenetic system was unable to penetrate through the entire aggregate.
While further optimization studies with the ChR2 viral vector need to be conducted for
improved expression, this study showed proof of concept for optogenetic stimulation of
micro-TENNs in future studies.
In order to further characterize the function of the dopaminergic micro-TENNs, we
created an in vitro test bed consisting of dopaminergic micro-TENNs containing a
surrogate striatal end target. As with use of a surrogate dopaminergic end target (discussed
in Chapter 2), the use of a surrogate striatal end target did not increase axonal outgrowth
in the standard micro-TENNs. Again, it is possible supra-threshold peak growth factor
concentrations and adequate chemotaxic gradients could not be established due to the
significant diffusional distance (1.2 cm) required to span the two populations. However,
our in vitro test bed did reveal extensive presynaptic puncta labeling in areas where the
dopaminergic micro-TENN axons grew into the striatal neurons. The striatal neurons also
expressed dopamine receptors along their cell bodies and neurites. These findings suggest
that the dopaminergic axons integrated with the striatal neuron population and provides
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proof of concept for our tissue engineered nigrostriatal pathway in vitro. Furthermore,
while we were unable to record evoked dopamine release in the axon terminals of
unidirectional micro-TENNs, we were able to record dopamine in the surrogate striatal end
target of the test bed. Current traces recorded in the striatal aggregate across several microTENNs demonstrated an average peak extracellular dopamine concentration of ~375 nM
immediately following electrical stimulation, which is larger than the estimated tonic
concentration of dopamine in the striatum of rats (50-100 nM).3 It is possible that presence
of a synaptic target and synapse formation was necessary for dopaminergic axons to
upregulate the necessary machinery for dopamine release. Consistent with this theory,
autaptic synapses would be responsible for the evoked release from the dopaminergic
aggregates. However, it is also possible that axons terminals within unidirectional microTENNs were simply not concentrated enough to create a detectable dopamine signal. The
striatal end target could have provided an impetus for dense axonal outgrowth capable of
generating a larger dopamine signal.
As several reports have suggested that dopamine is capable of increasing the
synchronization of striatal circuits, we applied calcium imaging techniques to our in vitro
test bed to look for evidence of striatal modulation. Following transduction with calcium
indicator CaMP6f, we recorded the fluorescent intensity of neurons within the striatal
aggregate at baseline, following electrical stimulation of the dopaminergic aggregate, and
then after adding dopamine (3 µm) to the cultures as a positive control. We included
NMDA (8 µM) within the media because it has been shown to produce recurrent bursting
activity within the inhibitory medium spiny neurons.9 Furthermore, we also included LDOPA (100 µM) within the media to amplify the dopamine signal. We used a validated
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image analysis program to detect calcium events and calculate a global synchronization
index for each network. It soon became apparent that several crucial aspects of the analysis
were relatively subjective, including: (1) the threshold to establish a calcium event had
occurred and (2) the number of neurons required to constitute a synchronized cluster. While
we did utilize various values for these variables, our synchronization analysis did not
indicate that there were any statistically significant changes in the synchronization of the
neurons within the striatal aggregate following stimulation with dopamine (either
electrically evoked or applied to the media).
In addition to the subjectivity of the analysis, it is possible our analysis did not
yield statistically significant results because our striatal populations were impure. As
shown in Figure 3.5, non DARPP-32 positive neurons existed within the striatal
aggregates, which were impossible to discern from medium spiny neurons during calcium
imaging. The aggregates are also three-dimensional, which limited us to recording the
fluorescent intensity of neurons in the outer layer of the aggregate. Furthermore, as our
striatal neurons were dissociated and re-aggregated prior to culturing, they no longer
existed in their original in vivo microcircuits. Previous reports of dopaminergic modulation
of striatal synchronization have only utilized either real or modeled in vivo circuits.
Therefore, it is entirely possible that the striatal circuits in the re-formed aggregates are
simply not subject to the same patterns of modulation as established in vivo circuits, or they
require more time for maturation in vitro. Regardless, this worked established the
framework for optical probing of input-output relationships in the engineered circuit, which
can be further optimized and validated in future work.
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Our functional characterization studies have demonstrated that our dopaminergic
micro-TENNs contain the necessary machinery to release and re-uptake dopamine.
Furthermore, our in vitro test bed containing a surrogate striatal end target has shown
immunocytochemical evidence of synaptic integration between the dopaminergic and
striatal populations. In fact, in some instances the striatal aggregate appeared to recruit
dense dopaminergic axonal outgrowth and arborization. While the results of the calcium
imaging analysis may be attributed to an impure and/or artificial circuit, our ability to
record dopamine release in the striatal end target, and not in the axon terminals of
unidirectional micro-TENNs, provides strong evidence that functional integration occurred
with the striatal neurons. Furthermore, the average concentration of evoked dopamine
recorded in the striatal target exceeded our goal of 100 nM (the estimated tonic
concentration of dopamine in the striatum of rats).
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CHAPTER 4: DOPAMINERGIC MICRO-TENN RECONSTRUCTION OF THE
NIGROSTRIATAL PATHWAY IN VIVO

4.1 Introduction
Pathologically, Parkinson’s disease is characterized by the selective loss of
dopaminergic neurons in the substantia nigra pars compacta (SNpc), and degeneration is
believed to be caused by the presence of Lewy bodies and Lewy neurites within the
cytoplasm and processes of dopaminergic neurons. Lewy bodies and neurites are abnormal
protein aggregates that are predominantly comprised of a-synuclein filaments.1,2 As SNpc
neurons send long-projecting axons to the striatum, this stereotypical neurodegeneration
deprives the striatum of crucial dopaminergic inputs and thereby renders an important
motor feedback pathway ineffective. Resulting motor symptoms include resting tremor,
bradykinesia (slowness of movement), and akinesia (impairment of voluntary
movement).3,4
Significant effort has been invested in creating rodent models of Parkinson’s
disease to allow for screening and/or evaluation of PD therapeutics and treatments. One
class of rodent models utilizes neurotoxins such as 6-hydroxydopamine (6-OHDA), 1methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), rotenone, and paraquat to selectively
destroy dopaminergic neurons and processes within the nigrostriatal pathway. These
models mostly reflect the degeneration of PD, demonstrate classic PD motor symptoms
(akinesia in the forelimb), and the extent of the loss of the nigrostriatal pathway can be
controlled by neurotoxin dose.5 However, these toxin-induced models do not reflect the
pathological signature of PD – the formation of Lewy pathology within the dopaminergic

128

neurons. While both unilateral and bilateral lesion models exist, the unilateral lesion allows
for direct comparison of dopaminergic innervation between the healthy and lesioned sides
of the brain. Furthermore, established behavioral tests, including the “apomorphine
challenge”, have been validated to indicate the severity of the lesion and/or reveal
alterations in motor function within the unilateral lesion model. The apomorphine
challenge involves administering the dopamine agonist apomorphine to the lesioned rats.
Due to a lack of dopaminergic inputs, the lesioned striatum is extremely sensitive to
apomorphine; the administration of apomorphine causes the rat to rotate towards the intact
side of the brain.5 The number of turns the rat makes is a rough indicator of the severity of
the lesion, and in instances where dopaminergic inputs are created and/or restored, the
number of turns will decrease.
For our in vivo transplantation studies, we chose to use a unilateral lesion, 6-OHDA
rat PD model so that we could utilize the apomorphine challenge as well as compare
dopaminergic innervation between the lesioned side of the brain and the intact side. For
these early proof of concept studies, we did not think it was necessary to use a model
exhibiting Lewy pathology. Furthermore, as we ultimately envision fabricating microTENNs using dopaminergic neurons derived from a patient’s own cells, we chose to
perform the unilateral 6-OHDA lesion within an athymic rat model to minimize the
immune response to the constructs following implantation. In particular, these athymic rats
lacked T-cells, but not B-cells and have been shown to support long-term survival of grafts
transplanted into the striatum without immunosuppression.6
As previously reviewed in Chapter 1, regenerative medicine strategies for the
treatment of Parkinson’s disease have included the use of tissue grafts, cell transplants, and
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scaffold-based methods. Therefore, within the athymic, 6-OHDA rat model, we compared
the performance of the enriched micro-TENNs to solitary neuronal aggregates, neuronal
aggregates within hydrogel micro-columns, micro-columns containing collagen (no cells),
and impure and/or pure micro-TENNs. We also included a lesioned, non-repaired group.
All constructs were stereotactically micro-injected to approximate the nigrostriatal
pathway, or in the case of the solitary aggregate groups, injected into the SNpc and
striatum; animals were survived for 1 week, 1 month, or 3 months. Building upon our
techniques from the previous two aims, we used histological analyses to evaluate construct
survival and outgrowth, FSCV to evaluate dopamine release within the striatum, and we
performed the apomorphine challenge to look for behavioral recovery. We found that the
enriched dopaminergic micro-TENNs outperformed the other construct groups in both
histological and functional metrics; however, behavioral improvements were not observed
for any of the treatment groups.

4.2 Materials and Methods
4.2.1 Sheath Fabrication
Protective “sheaths” were fabricated to prevent the implantation needle from coring
out the brain and damaging the micro-TENNs during insertion into the brain. The sheaths
were generated by using an electrical bag sealer to seal the end of a 2 cm piece of tubing
(Microspec, Isoplast 2510, ID: 559 µm, OD: 686 µm). The seal created by the bag sealer
was then cut to a length of 0.5 mm and three cuts parallel to the tubing were also created
through the seal. These cuts enabled the escape of air when the sheath was slid over the
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insertion needle. The cuts also weakened the seal, which allowed the seal to be ripped
following insertion of the implantation needle into the brain.

4.2.2 Transplantation of Micro-TENNs
Male athymic rats lesioned via the neurotoxin 6-hydroxydopamine were procured
from Charles River (n=55). These rats (205-270g) were anesthetized with isoflurane and
mounted in a stereotactic frame. The scalp was cleaned with betadine, bupivacaine was
injected along the incision line, and a midline incision was made to expose Bregma. A 5
mm craniectomy was centered at the following coordinates in relation to Bregma: +5 mm
(AP), 2.1 mm (ML). The micro-TENN (21 DIV) was loaded into a needle (OD: 534 µm,
ID: 420 µm; Vita Needle, Needham, MA), a protective sheath was slid over the needle,
and the needle was attached to a Hamilton syringe mounted on a stereotactic arm. The
stereotactic arm was positioned at 38° relative to the horizontal plane, the dura was opened,
and the needle lowered into the brain to a depth of 12.0 mm. The needle was rigidly affixed
in place by the stereotactic equipment. A pair of forceps was used to grab the exposed
section of sheath and pull the sheath upwards; this action ripped through the seal on the
end of the needle and exposed the micro-TENN within the brain. A stationary arm was
positioned to contact the plunger of the Hamilton syringe and hold the plunger in place as
the needle was withdrawn from the brain. This implantation method “laid out” the microTENN within the brain, rather than expelling it from the needle. The scalp was sutured
closed and buprenorphine was provided for postoperative analgesia. Acellular microcolumns, and micro-columns containing aggregates (utilized at 1-3 DIV) were transplanted
following the same procedure. Solitary aggregates (21 DIV) were transplanted using the
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same procedure with a different needle (OD: 534 µm, ID: 152 µm). Aggregates
transplanted into the striatum were lowered to a depth of 5 mm within the brain, rather than
12 mm. Animals were survived for 15 minutes, 1 week, 1 month, or 3 months. At the time
of sacrifice, animals not being used for functional dopamine release studies were
anesthetized and underwent transcardial perfusion with heparinized saline followed by
10% formalin.

4.2.3 Immunohistochemistry
After 24 hour post-fix in 4% paraformaldehyde, brains were prepared for optical
clearing, parafin processing, or cryosectioning. For optical clearing, a combination of
Visikol Inc.’s histology protocol7 and the iDISCO protocol were followed.8 Briefly, brains
were cut into 2 mm sections using a vibratome, dehydrated in a series of methanol washes,
incubated in dichloromethane (66%), treated with hydrogen peroxide, and then rehydrated.
Sections were permeabilized in a buffer containing PBS, 0.2% Triton X-100, 0.3 M
glycine, and 20% DMSO for two days. Sections were blocked with 6% horse serum for
two days, and then incubated in primary antibodies (Sheep anti-TH, 1:100, Abcam, cat #
ab113; Chicken anti-GFP, 1:100, Aves Labs, GFP-1020; Mouse anti-synapsin, 1:100,
Synaptic Systems, cat # 106001) for seven days. Next they were incubated in secondary
antibodies (1:250) for seven days. They were then dehydrated, treated with Visikolâ
HISTO-1ä for 18 hours, and imaged in Visikolâ HISTO-2ä.
For paraffin processing, brains were blocked sagittally, processed through paraffin,
cut at 8 µm, mounted on slides, and processed for immunohistochemistry. Paraffin sections
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were deparaffinized and then rehydrated. Endogenous peroxidase was quenched using 3%
hydrogen peroxide in water (Fisher, cat #S25359) followed by heat-induced epitope
retrieval in TRIS-EDTA. Sections were blocked with horse serum (ABC Universal Kit,
Vector Labs, cat #PK-6200) for 30 min. Rabbit anti-TH (1:750; Abcam, cat #ab112) was
applied in Optimax buffer overnight at 4°C. The antigen of interest was visualized using
DAB (Vector Labs, cat # SK-4100).
For cryosectioning, brains were blocked sagittally, put into 30% sucrose until
saturated, and then frozen. Sections were cryosectioned at 35 µm, mounted on slides, and
processed for immunohistochemistry. Frozen sections were blocked with 5% normal horse
serum in 0.1% Triton-x/PBS for 30-45 minutes. Primary antibodies (Rabbit anti-TH, 1:750,
Abcam AB112; Mouse anti-Tuj1, 1:1000, Sigma T8578) were applied to the sections in
2% horse serum/Optimax buffer for two hours at room temperature. Secondary antibodies
(1:1000) were applied in 2% horse serum/PBS for one hour at room temperature. Sections
were counterstained with Hoechst.

4.2.4 Microscopy and Data Acquisition
For analysis of micro-TENNs post-transplant into the brain, micro-TENNs were
fluorescently imaged using either a Nikon A1RSI Laser Scanning Confocal microscope or
a Nikon A1R HD Multiphoton microscope. Each section was analyzed to assess the
presence, architecture, and outgrowth/integration of micro-TENN neurons/neurites. A
semi-quantitative scale ranging from 0-5 was used to rate both the somatic and axonal
density of the transplants during histological analysis. Transplants demonstrating no or

133

extremely sparse neuronal somata and axons were rated a “0”, while transplants
demonstrating extremely dense neuronal somata and axons were rated a “5”.

4.2.5 Fast Scan Cyclic Voltammetry in Brain Slices
At the time of sacrifice, carbon dioxide followed by decapitation was used to
euthanize the animals. Brains were removed and placed in ice cold artificial cerebrospinal
fluid (ACSF) containing, (in mM; NaCl (126), KCl (2.5), NaH2PO4(1.2), CaCl2(2.4),
MgCl2(1.2), NaHCO3(25), glucose (11), l-ascorbic acid (0.4), pH adjusted to 7.4).9 A
vibratome was used to cut the brain within the sagittal plane. At the depth containing the
transplanted micro-TENN (or micro-column, aggregate etc.), a brain slice 400 µm thick
encapsulating the micro-TENN was taken. The slice was transferred to a bath where it was
perfused with oxygenated aCSF at room temperature for 1 hour prior to recording studies.
Following this incubation period, the slice was transferred to a testing chamber at 32 °C,
where it was continuously perfused with oxygenated aCSF. A carbon fiber electrode (150200 µm length x 7 µm diameter) was inserted into the striatum and a bipolar stimulating
electrode (Plastics One, Roanoke, VA) was placed across the same location. Dopamine
release was elicited using electrical pulse trains (20-30 Hz, 5 ms pulse width, 0.5-1 s,
monophasic) every 5-15 minutes and recorded using Demon Voltammetry and Analysis
Software.10 The potential of the carbon fiber electrode was linearly scanned from −0.4 to
1.2 V and back to −0.4 V vs. Ag/AgCl. A voltammeter/amperometer (Chem-Clamp; Dagan
Corporation) was used to scan at a rate of 400 V/s, and cyclic voltammograms were
recorded every 100 ms. Electrode calibrations of known concentrations of DA (1–10 μM)
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were used to calculate the concentration of electrically evoked dopamine release at the peak
oxidation potential for dopamine in consecutive voltammograms.

4.2.6 Behavioral Studies
The commonly utilized “apomorphine challenge” was used to assess the behavioral
response of the animals to the dopamine agonist apomorphine. Animals were
subcutaneously injected with 0.5 mg/kg apomorphine HCl (Medisca), after which the
number of turns the animals made in the following 30 minutes was recorded in five minute
increments.

4.2.7 Statistics
One way ANOVAs were used to determine if there were statistically significant
differences in behavioral recovery between the different implantation groups at both the
one week and one month time points. An unpaired, non-parametric, two sided MannWhitney test was performed to determine if there was a statistically significant difference
in behavioral recovery between the animals implanted with enriched micro-TENNs at the
one month and three month time points. Unpaired, non-parametric, two sided MannWhitney tests were performed to determine if there were statistically significant difference
in the mean construct axonal and somatic densities between animals implanted with
enriched micro-TENNs and animals implanted with aggregates within tubes. Data are
presented as mean ± standard deviation
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4.3 Results
4.3.1 Optimization of Histological Techniques
Conventional histological techniques, including sectioning paraffin embedded
tissue and cryosectioning frozen tissue, sometimes damaged implanted micro-TENNs
and/or pulled implanted micro-TENNs from within the agarose micro-columns.
Furthermore, these sections did not have sufficient depth to enable continuous visualization
of an implanted micro-TENN from the SNpc to the striatum. Therefore, conventional
techniques prevented global characterization of the micro-TENNs (e.g. if their
implantation trajectory was correct, if they maintained their cytoarchitecture, if they
spanned the length of the agarose micro-column). To avoid these drawbacks, we moved
towards histological techniques involving tissue clearing that allowed us to label large
sections of tissue. We took 2 mm wide sagittal sections from the implanted animals so that
the micro-TENNs were fully encapsulated within sections. Next, we combined two
previously published clearing methods (iDISCO and Visikol) to optimize antibody
penetration and minimize the use of toxic chemicals.7,8 It was found that our optimized
clearing protocol allowed for characterization of the micro-TENNs on both macro and
micro scales (Figure 4.1). The technique enabled us to discern the implantation trajectory
of the construct and determine if the cytoarchitecture spanned the micro-column. However,
it also allowed us to visualize small structures such as neuronal somata and individual
neurites.
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Figure 4.1: Tissue Clearing Enables Ideal Immunohistochemistry Analyses of Implanted
Constructs. In comparison to conventional sectioning methods, the use of tissue clearing allowed
for complete visualization of the micro-TENNs in vivo while avoiding damage to the microTENNs. (A) Representative confocal reconstruction of an enriched dopaminergic micro-TENN
immediately following implantation labeled via immunocytochemistry to denote dopaminergic
neurons/axons (TH; red). Tissue clearing enabled a global perspective on the implant and it’s
trajectory. (B) Representative confocal reconstruction of an enriched dopaminergic micro-TENN
immediately following implantation labeled via immunocytochemistry to denote dopaminergic
neurons/axons (TH; red) and neuronal nuclei (NeuN; purple). In addition to the global perspective,
the tissue clearing methodology allowed for sharp imaging of the aggregate and axonal regions.
(C) Representative confocal reconstruction of an enriched dopaminergic micro-TENN immediately
following implantation labeled via immunocytochemistry to denote dopaminergic neurons/axons
(TH; red) and all neurons/axons (β-tubulin III; green). Structures as small as neuronal somata and
individual neurites could be imaged with ease using the tissue clearing methodology. Scale bar (A)
= 200 µm. Scale bar (B) = 100 µm. Scale bar (C) = 50 µm
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4.3.2 Optimization of Implantation Methodology
Following optimization of our histological techniques, we performed several
micro-TENN implantations followed by immediate sacrifice of the animals to ascertain the
efficacy of our implantation methodology. In several instances, evidence of aggregate and
axonal compression was observed (Figure 4.2). Further investigation determined that
although the implantation needle has a small ID (420 µm), it was capable of coring out the
brain, which then compacted the micro-TENN within the needle.

Figure 4.2: Micro-TENN Damage During Implantation Process. The original
implantation methodology frequently resulted in damage to the fragile micro-TENNs. (AB) Representative confocal reconstructions of enriched dopaminergic micro-TENNs
immediately following implantation labeled via immunocytochemistry to denote
dopaminergic neurons/axons (TH; red). The original delivery process was capable of
damaging the micro-TENNs due to the delivery needle coring out the brain. In these
instances, the cored brain was pushed up into the needle and compressed the structure of
the micro-TENNs. Scale bar (A-B) = 50 µm.
In order to prevent compression of the constructs, we developed a method to use a
“sheath” to cover the end of the implantation needle during insertion, but allow for microTENN ejection at the correct depth within the brain (Figure 4.3). The sheath was fabricated
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by sealing the end of a tube (ID: 559 µm, OD: 686 µm) using an electrical current. During
implantation, the sheath was slid onto the end of the implantation needle after the microTENN was loaded into the needle. The sheath stayed in place, protecting the end of the
needle and preventing coring of the brain, while the needle was stereotactically lowered to
the correct location within the brain. Finally, forceps were used to pull the sheath upwards,
which broke the seal on the end of the needle and exposed the needle/micro-TENN within
the brain. A plunger was used to hold the micro-TENN in place as the needle and sheath
were removed from the brain. It was found that this improved implantation method
prevented compression of the micro-TENNs and was capable of precisely delivering
micro-TENNs to span the nigrostriatal pathway (Figure 4.4). The sheath also only added
about 150 µm to the footprint of the implantation needle, keeping the footprint under 700
µm in diameter.

Figure 4.3: Improved Implantation Methodology Utilizing Needle Sheath. In order to
prevent the compression of the micro-TENN by the brain during implantation, a needle
sheath with a breakable seal was used to cover the end of the needle. This improved
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methodology consisted of the following steps: (1) the construct was loaded into the
implantation needle; (2) once loaded, the sheath was slid on to the needle; (3) the whole
apparatus (needle and sheath) was lowered into the brain to the correct depth (the dashed
line represents the brain surface); and (4) forceps were used to pull the sheath upwards,
which broke the seal on the end of the needle and left the construct exposed at the correct
depth in the brain. As with the original methodology, a plunger was used to hold the microTENN in place while the needle and sheath were removed from the brain.

Figure 4.4 Validation of Implantation Trajectory. Representative confocal
reconstruction of an enriched dopaminergic micro-TENN one month post-implant labeled
via immunocytochemistry to denote dopaminergic neurons/axons (TH; red). The aggregate
end of the micro-TENN was positioned at the beginning of the nigrostriatal pathway, while
the axonal end of the micro-TENN terminated in the striatum. Scale bar = 1 mm.

4.3.3 Validation of Lesioned, Athymic PD Rat Model
While Charles River was able to provide us with an athymic (T-cell deficient),
unilateral 6-OHDA rat model, this model had not previously been validated. Therefore, we
used histological, functional, and behavioral analyses to determine that this novel model
demonstrated a lack of dopaminergic innervation of the striatum and PD-like motor
function. Immunohistochemistry revealed dense TH labeling in the striatum of the
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unlesioned side of the brain, while the lesioned side displayed minimal TH labeling
(Figure 4.5). While the 6-OHDA lesion appeared to ablate the vast majority of the
dopaminergic staining within the SNpc of the lesioned side, a few sparse patches of staining
could be found. Previous work by our lab found that 90 ± 1.4% of dopaminergic neurons
were lost within this lesion model in wild-type rats.

Figure 4.5: Animals Lesioned via 6-OHDA Displayed Minimal Dopaminergic Axons
in the Striatum. Athymic rats lesioned by the dopaminergic neurotoxin 6-OHDA were
used as surgical subjects for the in vivo studies. (A) Representative confocal reconstruction
of the non-lesioned side of the rat brain labeled via immunocytochemistry to denote
dopaminergic neurons/axons (TH; red). As expected, the non-lesioned side demonstrated
significant TH labeling within the striatum. (B) Representative confocal reconstruction of
the lesioned side of the rat brain labeled via immunohistochemistry to denote dopaminergic
neurons/axons (TH; red). The lesioned side of the brain demonstrated barely any TH
labeling in the striatal region, validating the efficacy of the 6-OHDA lesion in destroying
dopaminergic neurons/processes within the nigrostriatal pathway. Scale bar (A-B) = 1 mm.
We also performed fast scan cyclic voltammetry (FSCV) in the striatum of the
lesioned side of the brain to confirm that dopamine release could not be evoked by
electrical stimulation. No discernable dopamine signal was found within the striatum of the
lesioned side, whereas the striatum in the unlesioned side demonstrated significant evoked
dopamine release (Figure 4.6). Lastly, the apomorphine challenge was performed to check
that the rats displayed typical PD-like sensitivity and rotational behavior in response to
apomorphine. We found that the athymic, lesioned rats displayed an average of 11.2
141

turns/minute, which is greater than the 2.2 turns/minute required to indicate that a rat’s
dopaminergic system has been completely lesioned.11

Figure 4.6: Animals Lesioned via 6-OHDA Exhibited No Dopamine Release in the
Striatum. Evoked dopamine release was investigated in slices from both the non-lesioned
and lesioned sides of the brain. (A,C,E) Representative color plot (A), cyclic
voltammogram (B), and time versus concentration plot (C) of the evoked dopamine release
recorded in the non-lesioned side of the brain (n=3) as potential of the carbon fiber
electrode was linearly scanned from −0.4 to 1.2 V and back to −0.4 V vs. Ag/AgCl every
100 ms. The cyclic voltammogram exhibited an oxidation peaks at 0.65 V and a reduction
trough at -0.3 V, which are characteristic of dopamine. The maximum concentrations of
142

dopamine released by the non-lesioned side (n=3) was over 300 nM. (B,D,F)
Representative color plot (B), cyclic voltammogram (D), and time versus concentration
plot (F) of the evoked dopamine release recorded in the lesioned side of the brain. The
cyclic voltammogram did not exhibit peaks or troughs representative of dopamine, and no
discernable concentration of dopamine was recorded. These findings validated the efficacy
of the 6-OHDA lesion in destroying dopaminergic neurons/processes within the
nigrostriatal pathway.

4.3.4 Histological Analyses
We sought to characterize survival, maintenance of cytoarchitecture, and
dopaminergic outgrowth following micro-TENN implantation into the brain. Using the
previously optimized transplantation methodology, purified dopaminergic micro-TENNs
(GFP+, 21 DIV) were stereotactically micro-injected to approximate the nigrostriatal
pathway in the validated athymic, unilateral 6-OHDA rat model. Other transplantation
groups, including solitary aggregates, aggregates within micro-columns, micro-columns
containing collagen, and impure micro-TENNs, were also included in the study. Animals
were sacrificed at either 1 week, 1 month, or 3 month time points, after which their tissue
was sectioned, labeled, and cleared using our optimized histological techniques. At the 1
week time point, evidence of survival was found in all of the animals implanted with microTENNs (n=3). However, no survival was found in the aggregates implanted into the SNpc
(n=2) or the aggregates implanted into the striatum (n=2) (Figure 4.7 D). Surviving microTENNs labeled for the dopaminergic marker TH, revealed the preservation of a robust
neuronal and dopaminergic axonal population (Figure 4.7 A-C). In particular,
longitudinally projecting TH+ axons were present, which confirmed that the micro-TENNs
were able to maintain their cytoarchitecture following transplantation into the brain.
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However, no evidence of dopaminergic neurite outgrowth was found at this early time
point.

Figure 4.7: Micro-TENNs Survived and Maintained their Cytoarchitecture at One
Week In Vivo. (A) Representative confocal reconstruction of an enriched dopaminergic
micro-TENN one week post-implant labeled via immunohistochemistry to denote
dopaminergic neurons/axons (TH; green). The micro-TENN maintained its
cytoarchitecture consisting of distinct cell body and neurite regions, with dopaminergic
neurites projecting longitudinally within the micro-column. Higher magnification
reconstructions from demonstrative regions in (A) depict the (B) dopaminergic neuron
aggregate and (C) robust, aligned TH+ axons. (D) At one week in vivo, survival was found
within 100% of the transplanted micro-TENNs. However, no evidence of survival was
found within the other transplant groups (solitary aggregates transplanted into the SNpc or
striatum). Scale bar (A) = 250 µm. Scale bar (B-C) = 50 µm.

As we did not see any surviving implanted aggregates at the 1 week time point, we
adjusted our controls and used the following transplantation groups for the 1 month
histological time point: enriched micro-TENNs (n=12), aggregates within micro-columns
(n=3), acellular micro-columns containing collagen (n=3), impure micro-TENNs (n=3),
and lesioned, non-repaired animals (n=3). It was found that the enriched micro-TENNs
demonstrated the highest rate of survival, maintained their cytoarchitecture, and were the
only group to exhibit dopaminergic projections spanning the entire length of the microcolumn. Impure micro-TENNs had a high rate of survival and also displayed discrete
somatic and axonal regions, but their dopaminergic neurites did not appear to span the
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length of the micro-column in any cases. Aggregates transplanted within micro-columns at
early time points (1-3 DIV) showed low rates of survival and little neurite outgrowth. While
acellular micro-columns showed the capability to support host neurite ingrowth, instances
of ingrowth measured < 250 µm in length (Figure 4.8, Figure 4.10 A-B). Neuronal somata
and axonal density were rated using a semi-quantitative scale ranging from 0-5, (0
indicating no neurons/axons and 5 indicating extremely dense neurons/axons). It was found
that the enriched micro-TENNs displayed the highest density of both neuronal somata and
axons, followed by impure micro-TENNs. Enriched micro-TENNs demonstrated a nonsignificant (p=0.2176), 3-fold increase in mean somatic density and a non-significant
(p=0.1011), 5-fold increase in mean axonal density in comparison to aggregates in microcolumns. (Figure 4.10 C-D). Importantly, enriched micro-TENNs demonstrated
morphologically healthy neuronal somata and axons (Figure 4.9 A-B). Lastly, enriched
and impure micro-TENNs were the only construct groups to exhibit dopaminergic neurite
outgrowth into the SNpc, with enriched micro-TENNs being the only group to demonstrate
outgrowth into the striatum (Figure 4.10 E). In these instances, robust TH+ neurites
projected out of the micro-column and concentrated synapsin labeling in the regions
containing outgrowth suggested synaptic integration with the host tissue (Figure 4.9 C-E).
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Figure 4.8: Cytoarchitecture of Constructs at One Month In Vivo. Representative confocal
reconstructions of implanted constructs one month post-implant labeled via immunohistochemistry
to denote GFP (GFP; green) and dopaminergic neurons/axons (TH; red). (A) Enriched microTENNs maintained their cytoarchitecture with discrete somata and axonal regions; they also
demonstrated neurites spanning the length of the micro-column. (B) Standard micro-TENNs (nonenriched) did not exhibit neurites spanning the length of the micro-column. (C) Enriched aggregates
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implanted within micro-columns did not display robust neurite outgrowth within the micro-column.
(D) While acellular micro-columns supported host neurite ingrowth, instances of ingrowth
measured less than 250 µm in length. Scale bar (A) = 250 µm. Scale bar (B-C) = 100 µm. Scale
bar (D) = 250 µm.

Figure 4.9: Characterization of Enriched Micro-TENNs at One Month In Vivo. Representative
confocal reconstructions of implanted enriched micro-TENNs one month post-implant labeled via
immunohistochemistry to denote GFP (GFP; green), dopaminergic neurons/axons (TH; red), and
synapses (synapsin; purple). (A) Dopaminergic neurons within the aggregate region displayed
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healthy morphologies. (B) Dopaminergic neurites maintained healthy projections longitudinally
within the tube. (C-D) Micro-TENNs exhibited neurite outgrowth into the host SNpc from the
aggregate region. In these instances, regions containing outgrowth displayed concentrated synapsin
labeling. (E) Micro-TENNs exhibited neurite outgrowth into the host striatum from the axonal
region. In these instances, thin neurites were observed projecting from areas of dense TH labeling
within the end of the tube. Scale bar (A-B) = 25 µm. Scale bar (C) = 50 µm. Scale bar (D-E) = 25
µm.

Figure 4.10: Micro-TENNs Outperformed Other Constructs at One Month In Vivo. (A)
Micro-TENNs (enriched and standard) exhibited the highest percentage of neuronal survival at the
one month time point. (B) Enriched micro-TENNs were the only construct group displaying
discrete neuronal somata and axonal regions, with projections spanning the length of the tube. (CD) A semi-quantitative score (ranging from 0-5, 0 indicating no neurons/axons and 5 indicating
extremely dense neurons/axons) was used to assess somatic and axonal density within the
constructs. (C) Enriched micro-TENNs demonstrated a non-significant (p=0.2176), 3-fold increase
in mean somatic density in comparison to aggregates in tubes. (D) Enriched micro-TENNs
exhibited a non-significant (p=0.1011), 5-fold increase in mean axonal density in comparison to
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aggregates in tubes. (E) Standard and enriched micro-TENNs were the only groups displaying
neurite outgrowth from the micro-column (either within the SNpc or the striatum).

Enriched micro-TENNs (n=4) were the only constructs transplanted for the 3 month
time point. It was found that 50% of these constructs survived, and two-photon imaging
revealed that the surviving micro-TENNs maintained their cytoarchitecture; we were able
to discern GFP+ neurites projecting longitudinally within the agarose micro-columns
(Figure 4.11). However, there was no evidence of dopaminergic neurite outgrowth into
either the SNpc or the striatum at this time point. Interestingly, our histology showed that
the 1% agarose micro-column had not fully degraded by this time point.

Figure 4.11: Enriched Micro-TENNs Maintained Their Cytoarchitecture at 3 Months
In Vivo. Representative two photon reconstruction of an implanted enriched micro-TENN
3 months post-implant that inherently expressed GFP (green). The micro-TENN
maintained the cytoarchitecture and demonstrated longitudinally projecting GFP+ neurites.
Scale bar = 200 µm.

4.3.5 Functional Analyses
In order to test the functionality of the constructs in vivo, fast scan cyclic
voltammetry was performed upon selected transplant groups at the 1 month and 3 month
time points. Transplanted animals were sacrificed, their brains were harvested, and a
vibratome was used to cut a 400 µm thick brain slice containing the transplanted construct.
A stimulating electrode was used to evoke dopamine release and a carbon fiber electrode
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was used to record the release within the striatum of the slice. At the 1 month time point,
evoked dopamine release was compared between lesioned, non-repaired slices (n=3), and
slices implanted with enriched micro-TENNs (n=8) and acellular tubes (n=3). Here,
enriched micro-TENNs were the only group to exhibit any discernable dopamine signal.
While dopamine release was only recorded in 1/8 of slices implanted with enriched microTENNs, the recorded dopamine signal demonstrated a release concentration of ~95 nM
(within the desired range of 50-100 nM) and a cyclic voltammogram displaying typical
dopamine oxidation and reduction troughs (Figure 4.12). At the 3 month time point, only
animals implanted with enriched micro-TENNs (n=3) underwent functional testing via
FSCV. No dopamine release recorded within the implanted slices at this time point.

Figure 4.12: Micro-TENN Exhibited Dopamine Release within the Striatum at One
Month In Vivo. Evoked dopamine release was investigated in slices from implanted
animals at one month in vivo. (A,B,C) Representative color plot (A), cyclic voltammogram
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(B), and time versus concentration plot (C) of evoked dopamine release recorded in the
striatum of an animal implanted with an enriched micro-TENN. The cyclic voltammogram
exhibited an oxidation peak at 0.65 V and a reduction trough at -0.3 V, which are
characteristic of dopamine. The maximum concentration of dopamine released by the
implanted slice was ~95 nM following electrical stimulation. (D) Evoked dopamine was
recorded in 1 out of 8 slices implanted with enriched micro-TENNs. No other construct
groups demonstrated any discernable dopamine release.

4.3.6 Behavioral Analyses
In order to assess the behavioral recovery of the transplant groups, the validated
apomorphine challenge was performed to assess changes in the rotational responses (and
therefore sensitivity) of the animals following administration of the dopamine agonist
apomorphine. The number of turns the animals completed in the first 30 minutes following
injection was counted at baseline (prior to construct implantation), and prior to sacrifice at
the 1 week, 1 month, and 3 month time points. The ratio of the number of turns post
treatment to the number of turns pre-treatment was used to gage behavioral recovery; here,
a ratio of 1 indicates no behavioral recover while a ratio of 0.1 indicates substantial
behavioral recovery. At the 1 week time point, animals implanted with enriched microTENNs (n=3) demonstrated a trend towards improved behavioral recovery in comparison
to animals with aggregates transplanted into the SNpc (n=2), and aggregates transplanted
into the striatum (n=2) (Figure 4.13 A). However, this difference was not statistically
significant and the trend appeared to disappear by the 1 month and 3 month time points. At
1 month, animals implanted with enriched micro-TENNs (n=6) showed equivalent
behavioral recovery to animals implanted with impure micro-TENNs (n=3), aggregates
within micro-columns (n=3), acellular micro-columns (n=6), and lesioned, no repair
animals (n=18) (Figure 4.13 B). Likewise, the enriched micro-TENNs showed no further
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behavioral improvement between the 1 month (n=18) and 3 month (n=4) time points
(Figure 4.13 C).

Figure 4.13: No Construct Group Exhibited Significant Behavioral Recovery. The
apomorphine challenge was used to discern behavioral recovery within the implanted
animals. (A) At the one week time point, a one way ANOVA (p=0.3363) determined there
were no statistically significant differences between animals implanted with enriched
micro-TENNs and animals implanted with solitary aggregates. However, animals
implanted with enriched micro-TENNs exhibited a trend towards improved behavioral
function. (B) At the one month time point, a one way ANOVA (p=0.1862) determined
there were no statistically significant differences in behavioral recovery between the
construct groups. (C) At the three month time point, an unpaired, non-parametric MannWhitney test (p=0.9654) determined enriched micro-TENNs showed no statistically
significant improvement in behavior in comparison to enriched micro-TENNs at the 1
month time point.
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4.4 Discussion
The final aim of this dissertation was to assess the ability of the dopaminergic
micro-TENNs to reconstruct the nigrostriatal pathway in a rat model of Parkinson’s
disease. In particular, an athymic rat model of PD was chosen to forgo the need for
immunosuppression; this paradigm is representative of the immune environment we would
expect to see clinically when iPSC derived neurons are generated on a per patient basis.
The performance of the micro-TENNs in vivo was compared to contemporary regenerative
medicine strategies for treatment of PD, including dopaminergic neurons implanted into
the SNpc, dopaminergic neurons implanted into the striatum, and acellular biomaterial
scaffolds. Histological, functional, and behavioral metrics were chosen to assess the
constructs’ ability to survive, maintain their cytoarchitecture, integrate with the host,
release dopamine, and improve motor function.
However, prior to actually performing the in vivo study, the framework to assess
the performance of the constructs needed to be established. Conventional histological
techniques proved harmful to the fragile micro-TENNs and did enable sufficient
visualization of the entirety of the constructs. Therefore, multiple established tissue
clearing and labeling protocols were combined to create an optimized histological method
capable of revealing both global and minute micro-TENN structures. Furthermore, the
capability to stereotactically transplant the constructs to span the correct brain regions
without damaging the micro-TENNs needed to be demonstrated. The development of the
needle “sheath” was instrumental in ensuring that the insertion process did not compress
the micro-TENN cytoarchitecture within the tube. Lastly, the novel, athymic unilateral 6153

OHDA rat model needed to be validated to confirm that it exhibited sufficient loss of the
nigrostriatal pathway, loss of dopaminergic innervation within the striatum, and PD-like
motor dysfunction. Performance of the chosen histological, functional, and behavioral
metrics both verified that the model showed PD-like degeneration and endorsed the
efficacy of the outcome metrics in the model.
At the one week time point, immunohistochemistry revealed that enriched microTENNs (delivered at 21 DIV) demonstrated a 100% survival rate and maintenance of their
cytoarchitecture. In contrast, solitary aggregates implanted into the SNpc and striatum (also
delivered at 21 DIV) showed no survival at the one week time point, which could be
attributed to the lack of a protective biomaterial encasement during the insertion process.
It is possible that, without protection, the mechanical forces present during the insertion
process disrupted the integrity of the aggregates. Likewise, we believe that the shell affords
a degree of protection from potentially detrimental aspects of the host micro-environment
(e.g.,

blood,

inflammatory

cells,

reactive

astrocytes)

immediately

following

transplantation. This hypothesis is supported by the survival of the aggregates implanted
within micro-columns, as described below. The mechanical support of the extracellular
matrix present within the micro-columns could have also improved cell integration in vivo.
Regardless, the vastly higher survival rate of the micro-TENNs in comparison to
aggregates alone demonstrates the superiority of tissue-engineered therapies in general,
and the micro-TENNs in particular, in comparison to purely cell-based treatments for PD.
At the one month time point, immunohistochemistry revealed that the enriched
micro-TENNs surpassed other transplantation groups, with higher rates of survival
(~70%), neuronal density, axonal density, and neurite outgrowth. In particular, enriched
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micro-TENNs demonstrated non-significant, 3-fold and 5-fold increases in mean neuronal
and axonal density, respectively, in comparison to aggregates implanted within microcolumns. The lack of statistical significance for these trends was a result of larger than
expected variability; in future transplants studies we would increase the number of animals
for improved statistical power. Enriched micro-TENNs were also the only group to exhibit
projections spanning the length of the micro-column and dopaminergic outgrowth into the
striatum. Impure micro-TENNs similarly outperformed other groups, but showed
decreased density of dopaminergic neurons/axons in comparison to the enriched microTENNs. As we labeled specifically for dopaminergic neurons/axons, it is likely that initial
low purity of the impure micro-TENNs was responsible for this trend. In vitro, impure
micro-TENNs also demonstrated that their TH+ outgrowth only represented about 65% of
their total length. This phenomenon could be responsible for the lack of dopaminergic
projections spanning the micro-column within the impure group. Aggregates implanted
within micro-columns (delivered at 1-3 DIV) demonstrated low rates of survival and little
dopaminergic outgrowth within the micro-columns. It is possible that the in vivo
environment did not provide the necessary trophic support to these embryonic neurons in
their growth phase, and/or that any growth signals were not directed appropriately. In
comparison, micro-TENNs in culture were provided with basic fibroblast growth factor (4
ng/mL), albeit absent any geometric gradient. Lastly, while acellular micro-columns
containing collagen demonstrated the ability to support dopaminergic neurite ingrowth
from the host, the short length of this ingrowth (<250 µM) could likely be attributed to the
low number of residual dopaminergic neurons present within the lesioned animals in
addition to the limited capacity of intrinsic central nervous system axons to regenerate.
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These findings showcase the advantages of the micro-TENN technology, in illustrating that
the micro-TENNs alone have the capacity to direct targeted axonal outgrowth between the
SNpc and the striatum. Furthermore, as the micro-TENNs are pre-fabricated in vitro, they
are able to integrate with the host brain soon after transplantation. In contrast, dopaminergic
transplantations into the SNpc require time in vivo to extend processes to the striatum while
also not having directed guidance to the striatum (potentially leading to aberrant
innervation).
At the three month time point, two photon-imaging revealed that micro-TENNs
maintained their cytoarchitecture; however, the rate of survival was only 50%. As
described below, this decreasing survival rate across the three time points was reflected in
both the progressing functional and behavioral data.
While no functional tests were performed at the 1 week time point, the enriched
micro-TENNs were the only group to demonstrate evoked dopamine release at the 1 month
time point. While only 1/8 micro-TENN implanted slices demonstrated evoked dopamine
release, the concentration of evoked dopamine fell within our desired range and the cyclic
voltammogram displayed typical dopamine oxidation and reduction troughs. At the 3
month time point, no discernable dopamine signal was recorded in the slices of animals
implanted with enriched micro-TENNs (n=4). However, it was difficult to cut brain slices
containing the micro-TENNs within the correct plane, and the number of 3 month animals
was small. Nevertheless, these results show the feasibility of using the micro-TENNs to
deliver dopamine to the striatum, and taken together with the histological evidence, suggest
that micro-TENNs could be used to reconstruct the nigrostriatal pathway and restore
dopaminergic innervation to the striatum. Furthermore, the long axons present within the
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micro-TENNs enable the signaling between the repaired SNpc and striatum to occur
through a minimal number of synapses. Such a paradigm closely mimics the structure of
the nigrostriatal pathway in vivo, and should support appropriately timed dopamine
signaling within the striatum in response to afferent signals to the SNpc. In contrast,
dopaminergic transplantations into the striatum are unable to close the loop to restore
proper signaling. Moreover, the use of multiple cell transplantations along the nigrostriatal
pathway requires signaling through a much larger number of synapses and may lead to
delayed and/or irregular dopamine signaling.
Behavioral testing conducted at the 1 week time point revealed a non-significant
trend towards improved recovery in animals transplanted with enriched micro-TENNs in
comparison to animals implanted with solitary aggregates. However, by the 1 month and 3
month time points, this trend towards recovery of animals transplanted with enriched
micro-TENNs was not sustained. At the 1 month time point, the enriched micro-TENN
group showed equivalent recovery to all other transplant groups, and at the 3 month the
point, the enriched micro-TENN group showed no further changes in behavioral recovery.
While we did not expect to find complete behavioral recovery (the striatum is a large brain
structure and complete recovery of behavior would likely require extensive dopaminergic
innervation over many months in vivo), we did expect to observe greater recovery in
animals implanted with enriched micro-TENNs in comparison to other groups.
Our data suggests that improvements need to be made to the transplantation
paradigm for better long-term health of the micro-TENNs. As previously mentioned, the
environment of the brain is hostile upon transplantation; primary and secondary
mechanisms of injury include the presence of blood, hypoxia, ischemia, inflammation,
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excitotoxicity, reactive astrogliosis, and the formation of a glial scar. As we observed a
100% survival rate of micro-TENNs at the one week time point, and the diameter of the
aggregates within the micro-TENNs is sufficiently small (<180 µm) to allow for mass
transport via diffusion in vivo, we do not believe that hypoxia within the constructs is
responsible for cell death. However, hypothermia treatment during micro-TENN injection
could still be used to reduce the harmful consequences of potential ischemia around the
insertion site; hypothermia has been shown to reduce the release of excitatory
neurotransmitters and decrease inflammation.14 In order to combat the formation of a glial
scar, we could also engineer the micro-column tube/hydrogel shell to provide controlled
delivery of chondroitinase ABC- an enzyme shown to break down the chondroitin sulfate
proteoglycans that represent a large component of the glial scar.15,16 Controlled release
could also be used to provide the dopaminergic neurons with growth factors if we
determine that micro-TENNs require enhanced trophic support upon transplantation for
sustained viability. For example, controlled release of glial derived neurotrophic factor
(GDNF) and basic fibroblast growth factor (bFGF) has shown to improve survival of
transplanted dopaminergic neurons and grafts.17,18 Lastly, we could increase the initial
number of dopaminergic neurons within the micro-TENNs to preempt high in vivo attrition
rates.
Our transplantation studies demonstrated that enriched micro-TENNs surpassed all
other construct groups in terms of survival, maintenance of cytoarchitecture, and both
neuronal and axonal density. They were the only construct group to demonstrate
dopaminergic cytoarchitecture spanning the length of the tube, dopaminergic outgrowth
into the striatum, and dopamine release within the striatum. This study showed proof of
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concept for the ability of the dopaminergic micro-TENNs to reconstruct the nigrostriatal
pathway, and feasibility of using micro-TENNs to deliver dopamine to the striatum.
However, the study also revealed that micro-TENNs suffer from attrition over-time, which
is likely responsible for the observed lack of behavioral recovery in animals implanted with
micro-TENNs. Neuroprotective measures, including hypothermia treatment during
transplantation and the controlled release of growth factors, could be used to improve longterm survival in future studies.
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CHAPTER 5: CONCLUSIONS, LIMITATIONS, AND FUTURE DIRECTIONS

5.1 Conclusions
Parkinson’s disease (PD) is a progressive neurodegenerative disease that affects 12% of people over 65, causing significant morbidity across a prolonged and escalating
disease course.1–3 The classic motor symptoms of PD result from selective degeneration of
dopaminergic neurons in the substantia nigra pars compacta (SNpc), and subsequently the
disruption of key motor control circuits. This circuit disruption results from loss of the
finely tuned dopamine delivery to the striatum via long-distance axonal projections. While
several Parkinson’s disease treatments have been developed, most options focus on
mitigating symptoms resulting from the neurodegeneration of the dopaminergic neurons
rather than treating the underlying pathology itself. Dopamine replacement therapies,
including 3,4-dihydroxy-L-phenylalanine (L-DOPA) and dopamine agonists, attempt to
correct the underproduction of dopamine due to neuron/axon loss.1 These dopaminerelated therapies provide symptom improvements, but side effects, such as dyskinesias and
motor fluctuations, may develop and efficacy declines over time.4 Alternatively, surgery
can be performed to implant deep brain stimulation (DBS) systems that modulate basal
ganglia network function to alleviate motor symptoms. While DBS improves motor
function, electrode stimulation can have unwanted side effects impacting cognition and
speech.5 Similar to pharmaceutical therapies, DBS efficacy decreases over time as the
disease progression continues. Newer treatments have focused on neuroprotection, but
trials have only slightly slowed progression of symptoms.6 Even if an effective
neuroprotective treatment could be developed, the treatment could not replace the ≥60%
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of SNpc neurons and their axonal projections to the striatum that have already degenerated
by the time of symptom onset.7
Significant effort has also been focused on replacing components of the
nigrostriatal pathway via (1) tissue grafts, (2) cell implantation, and (3) scaffold-based
methods. Trials have indicated beneficial functional results from tissue grafts when
methods sustain a novel population of at least 80,000 dopaminergic neurons.8 However,
while grafts and cells implanted into the striatum create new “factories” for dopamine,
these cells do not reconstruct the nigrostriatal pathway and thus lack normal feedback
signals that target the SNpc. As a result, striatal neurons still do not receive appropriately
timed dopamine signals.9,10 Alternatively, implantations into the SNpc have largely failed
because axonal regrowth to the striatum is limited and techniques to coax axonal outgrowth
do not ensure specific outgrowth to the correct and/or distant target(s).11–13 Stem cell
implantations have been limited by cell loss, nonspecific cell type differentiation, and
neoplastic transformation. Lastly, while biomaterial scaffolds have facilitated axonal
regrowth, these treatments do not restore the loss of neural cells and underlying circuitry
that is the cause of the motor symptoms.14–16
To address these gaps in treatment, emerging regenerative medicine solutions are
being pursued to replace lost neurons and axonal circuitry in PD. Indeed, the ultimate goal
is to replace the nigrostriatal pathway—dopaminergic neurons in the SNpc and their axonal
projections to the striatum—thereby allowing implanted cells/tissue to be subject to the
normal cellular regulation that dopaminergic SNpc neurons are subject to in order to “close
the loop” and restore this crucial circuit for motor control feedback. Reconstructing the
pathway from the SNpc to the striatum is the most promising means to provide
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dopaminergic inputs that can be tuned and controlled by natural feedback mechanisms
present within the brain.
This dissertation explores our research team’s tissue engineering based strategy to
reconstruct the nigrostriatal pathway. Chapter 2 discussed our in vitro optimization studies
conducted to assess the feasibility of generating dopaminergic micro-tissue engineered
neural networks (micro-TENNs) that mimic the architecture of the nigrostriatal pathway:
a discrete population of dopaminergic neurons with unidirectional, long-projecting axonal
tracts. While dopaminergic micro-TENNs were initially generated using an impure,
midbrain population containing <10% dopaminergic neurons, we believed it would be
necessary to select a cell source with a greater purity of dopaminergic neurons for sufficient
release of dopamine in functional studies. Therefore, we developed a paradigm to breed
transgenic rats expressing green fluorescent protein (GFP) in their dopaminergic neurons
and then perform fluorescent activated cell sorting upon their isolated midbrain neurons to
obtain a population with enhanced dopaminergic purity (>60%). We found that, in contrast
to plating micro-columns with dissociated dopaminergic neurons, plating micro-columns
with 3D engineered cell aggregates produced our desired cytoarchitecture of discrete
somatic and axonal regions. This cytoarchitecture mimics the intrinsic structure of the
nigrostriatal pathway in vivo, in which dopaminergic neurons in the SNpc synapse directly
onto striatal neurons without exerting their effects through intermediate synapses and/or
neurons. As a result, we believe micro-TENNs will promote appropriate timing of
dopamine signaling within the striatum in response to afferent signals entering the SNpc.
The cell aggregates also produced neurite outgrowth that was approximately 10X
longer than projections from individual cells. Such superior growth may be attributed to
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the increased cellular density of the aggregates, upregulation of developmental
mechanisms, and/or a sustained drive for axonal extension due to concentrated and
persistent pro-growth signaling, and/or physical/structural advantages within the
fasciculated axonal projections. We also assessed the effects of various extracellular matrix
cores, several growth factors in the micro-TENN media, and the presence of a surrogate
striatal end target neurite outgrowth. We found that we were able to produce unidirectional
dopaminergic micro-TENNs of sufficient length to span the nigrostriatal in rats (5 mm)
using a collagen core and our standard growth media. Moreover, as far as we know, our
micro-TENNs exhibit the longest in vitro dopaminergic axonal outgrowth recorded in the
literature.17–26 These micro-TENNs exhibited a viability greater than 85% at 14 DIV. Thus,
this worked confirmed the feasibility of consistently generating healthy, purified
dopaminergic micro-TENNs displaying the correct cytoarchitecture; these micro-TENNs
were also of sufficient length to span the nigrostriatal pathway in a rat model of Parkinson’s
disease.
Chapter 3 discussed our in vitro studies to characterize the functionality of the
purified dopaminergic micro-TENNs. As the nigrostriatal pathway terminates in
dopaminergic innervation of the striatum, we sought to show that the dopaminergic neurons
could release dopamine, recycle dopamine, and functionally integrate with a population of
striatal neurons. Immunocytochemistry and fast scan cyclic voltammetry (FSCV) were first
performed upon unidirectional micro-TENNs and revealed that the micro-TENNs
contained the machinery necessary for dopamine release and re-uptake within the
dopaminergic aggregate. Interestingly, we were unable to record a discernable dopamine
signal within the axonal terminals of the unidirectional micro-TENNs. We then created an
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in vitro test bed to study the interactions of the dopaminergic micro-TENNs with a
population of striatal neurons. While this population was confirmed to contain medium
spiny

neurons,

it

also

contained

a

number

of

other

neuronal

subtypes.

Immunocytochemistry revealed synapsin labeling in areas where dopaminergic axons grew
along striatal neurites, suggesting synaptic formation between the two populations. In some
instances, dopaminergic neurites formed concentrated networks of outgrowth within the
striatal aggregate, representative of the dense arborization of dopaminergic axons in the
striatum in vivo. Significantly, we were able to record dopamine release within the striatal
aggregates of bidirectional micro-TENNs, and the average concentration of this release
exceeded our goal of 100 nM (the estimated tonic concentration of dopamine in the
striatum of rats). These data strongly suggests that the dopaminergic neurons required
integration with a synaptic target for functional dopamine release, and implies that the
dopaminergic neurons did indeed functionally integrate with the striatal neurons. We also
performed calcium imaging followed by network analysis to detect changes in the
synchronization of the striatal aggregate in response to evoked dopamine release. While no
changes in striatal synchronization were detected, this lack of response may be attributed
to heterogeneous neuronal populations, lack of critical component(s) in the engineered
circuit, and/or need for greater maturation in vitro. Overall, this worked demonstrated that
the enriched dopaminergic micro-TENNs could release sufficient concentrations of
dopamine, recycle dopamine, and synaptically/functionally integrate with striatal neurons.
Chapter 4 discussed our in vivo transplantation studies to investigate the ability of
the enriched dopaminergic micro-TENNs to reconstruct the nigrostriatal pathway in a 6OHDA rat model of PD. As we foresee clinical fabrication of micro-TENNs using neurons
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derived from a patient’s own cells, the lesions were performed in an athymic rat model to
minimize the immune response to the constructs following implantation. Prior to initiating
the transplant studies, the framework to assess the performance of the constructs needed to
be established. We combined two previously described tissue clearing protocols to create
an immunohistochemistry method that allowed for visualization of both the macro
cytoarchitecture of the transplants in vivo, as well as the micro cytoarchitecture consisting
of individual neurons and neurites. We also optimized our surgical strategy to include a
needle “sheath” that would protect the constructs by covering the end of the needle during
insertion, but then rupture in vivo to allow for ejection of the constructs at the correct depth.
Lastly, we also validated that the athymic, PD model demonstrated minimal dopaminergic
innervation of the striatum, no dopamine release within the striatum, and sufficient
rotational turning during the apomorphine challenge.
As previous PD regenerative medicine strategies have included the use of tissue
grafts and biomaterial scaffolds, we compared the performance of the dopaminergic microTENNs to solitary aggregates, aggregates within micro-columns, micro-columns
containing collagen, and impure micro-TENNs at 1 week, 1 month, and 3 month time
points. Immunohistochemistry revealed that the micro-TENNs surpassed all other groups
in terms of survival, maintenance of cytoarchitecture, and both somatic and neuronal
density. They were also the only construct group to demonstrate dopaminergic
cytoarchitecture spanning the length of the micro-column, and dopaminergic outgrowth
into the striatum. During studies utilizing FSCV to investigate dopamine release, enriched
micro-TENNs were the only group to exhibit dopamine release within the striatum. In
particular, the concentration of evoked dopamine fell within our desired range and the
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cyclic voltammogram displayed typical dopamine oxidation and reduction troughs.
However, behavioral recovery was not observed in animals implanted with micro-TENNs
or in animals implanted with the other constructs. While longer time points post-implant
may be required for sufficient dopaminergic outgrowth and innervation to facilitation
amelioration of motor deficits, the rate of micro-TENN survival trended towards a decrease
over time – from survival in 100% of micro-TENNs at 1 week, to 70% at 1 month, and
50% at 3 months. These data suggest that micro-TENNs suffered from attrition over time
in vivo, and that future optimization of the implantation paradigm will be necessary to
enhance long-term viability of the constructs. Such improvements may include the
controlled release of growth factors from the micro-column to provide trophic support to
the construct in vivo, or hypothermia treatment during micro-TENN injection to reduce
excitotoxicity and inflammation within the transplanted environment. Overall, this worked
showed proof of concept for the ability of the dopaminergic micro-TENNs to reconstruct
the nigrostriatal pathway, and feasibility of using micro-TENNs to deliver dopamine to the
striatum.

5.2 Limitations & Future Directions
5.2.1 In Vitro Fabrication Studies
While we met the fabrication goals of the dopaminergic micro-TENNs in Aim 1
(purity > 50%, length > 5 mm, and viability > 70%), there were still several limitations to
these studies. When testing the effects of media containing a high concentration of growth
factors, we were simply increasing the global concentration of growth factors, rather than
creating a gradient. It is well documented that gradients of growth factors not only direct
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axonal outgrowth, but also accelerate the growth of central nervous system (CNS) axons.
Indeed, one study reported a growth rate of ~ 1mm/day in response to a gradient of insulinlike growth factor 1.27 Therefore, in future studies it would be beneficial to test the growth
of dopaminergic micro-TENNs in response to gradients of growth factors, rather than
global increases in growth factors. Similarly, we tested the growth effects of surrogate
striatal end targets located ~ 1.2 cm from the dopaminergic aggregate. Instead, we could
test the growth effects of a surrogate striatal end target located closer to the dopaminergic
aggregate in case this long distance prevented the establishment of an adequate chemotaxic
gradient between the two populations. We also only tested a limited number of extracellular
matrix (ECM) biomaterials as the inner core. Other ECMs, including alginate, fibrin, and
gelatin, have shown to support robust axonal outgrowth and viability.28 In future studies,
we could compare the performance of these ECMs to the performance of the collagen type
I core we are currently utilizing.
Furthermore, our in vitro characterization studies were limited by our selected time
points of assessment. While we found a viability of ~85% at 14 DIV, we should assess
their health at later time points (e.g. 3+ months) to ensure that they remain viable for long
periods of time. In addition, while we were able to generate enriched micro-TENNs
consistently, our fabrication technique is time-consuming and this “one at a time”
manufacturing results in considerable variability between micro-TENNs. Therefore, it
would be extremely advantageous to develop an automated fabrication method. Advances
in biological 3D printing allow for the printing of both hydrogels and living cells in
complex 3D structures, with resolutions as small as 10 µm.29,30 In future studies,
bioprinting techniques could be used to print the micro-columns, fill the inner core with
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extracellular matrix, and deposit the engineered cell aggregates at one end of the column.
However, no bioprinter is capable of printing axonal tracts; axon growth will still need to
occur after the biomaterial and cell seeding have been performed. Bioprinting techniques
will improve the speed and consistency of bio-fabrication, in addition to laying the
groundwork for scalability.

5.2.2 In Vitro Functional Characterization Studies
Although Aim 2 provided immunocytochemical and functional evidence of
dopaminergic micro-TENN integration with the surrogate striatal end target, future studies
could improve upon this work. As with the viability assessment in Aim 1, in Aim 2 we
only investigated the ability of the micro-TENNs to release dopamine out to 35 days in
vitro (DIV). Future work should perform fast scan cyclic voltammetry (FSCV) at later time
points (e.g. 3+ months) to establish the relationship between dopamine release kinetics and
the maturation of the engineered nigrostriatal circuitry as well as to confirm that the microTENNs retain the ability to release dopamine over extended periods of time. Furthermore,
only one stimulation paradigm was used to evoke dopamine release. Future work should
utilize several stimulation currents of increasing amplitude to investigate the dose response
of the evoked dopamine release; such a study would lead to a better understanding of the
feasible range of dopamine release, including intrinsic and maximum release. Lastly, while
we showed that optogenetic stimulation of the micro-TENNs was possible, our data
demonstrated that the concentration of dopamine released following optogenetic
stimulation was significantly smaller than the concentration of dopamine released
following electrical stimulation. This study was limited by the fact that the micro-TENNs
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were only transduced with one viral vector concentration of the channelrhodopsin ChR2.
Future studies should employ a range of viral vector concentrations and provide more time
for ChR2 expression to determine if optogenetic stimulation has the capacity to provide
equivalent dopamine release to electrical stimulation.
Due

to

limitations

in

antibody

selectivity

and

spectral

overlap,

immunocytochemical labeling of the micro-TENNs was limited to the use of 3 antibodies,
which prevented identification of both pre-synaptic and post-synaptic proteins in the same
preparation. While our Aim 2 studies revealed the presence of the pre-synaptic protein
synapsin in areas where the dopaminergic axons grew in to meet the striatal dendrites,
labeling with both pre and post-synaptic markers would provide a more complete picture
of synaptic integration. While we did attempt to label with four antibodies and use a
spectral detector to differentiate between them, the presence of the agarose micro-column
appeared to undermine the spectral detection; the agarose micro-column acted as a lens and
diffracted light improperly. Therefore, in future studies we should either plate 2D
bidirectional cultures or develop a process to remove the agarose shell prior to imaging so
that we can utilize quadruple (or more) labeling in combination with spectral detection for
comprehensive visualization of synaptic integration. However, it is important to note that
only an estimated 20% of dopaminergic varicosities are associated with post-synaptic
specializations, indicating that many functional dopamine release sites may not even label
positively for post-synaptic markers.31,32
Our dopamine release studies in Aim 2 provided strong evidence to suggest that the
dopaminergic micro-TENNs functionally integrated with the surrogate striatal end target.
However, our analysis of striatal synchronization in response to dopamine was severely
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limited by the artificial and impure composition of our surrogate striatal end targets. The
striatal neurons were re-aggregated following dissociation, and therefore formed circuits
randomly. Furthermore, while labeling with DARPP-32 confirmed the presence of medium
spiny neurons, labeling with NeuN revealed the presence of other neuronal subtypes within
the striatal end targets. It is unclear how other neuronal subtypes, including striatal
interneurons, could affect striatal synchronization. In order to avoid these complications,
in future studies we should differentiate between D1R and D2R medium spiny neurons and
investigate straightforward qualities of individual neurons (e.g. firing rate). While
transgenic mice models exist that selectively express reporters in D1R or D2R neurons,
currently no such models exist in rats.33 Alternatively, following calcium imaging, microTENNs could be fixed and labeled with antibodies against both DARPP-32 and the D1R
receptor to identify D1R expressing medium spiny neurons. Calcium imaging analysis
could be restricted to these neurons; furthermore, since D1R neurons reliably increase their
firing rate in response to dopamine, the resulting data processing would be much simpler
with fewer objective variables.

5.2.3 In Vivo Transplantation Studies
While our in vivo data provided proof of concept for the ability of the dopaminergic
micro-TENNs to reconstructs the nigrostriatal pathway in a rat model of PD, limitations
existed within our analysis and future studies are necessary to characterize the in vivo
environment, improve the long-term survival of micro-TENNs, and investigate how microTENNs respond to Lewy pathology. Considerable variability was observed in the
histological metrics that we used to assess the performance of all construct groups.
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Therefore, in some instances it was difficult to achieve statistical significance despite large
trends in the data. In future work, the number of animals included in each group will need
to be increased for improved statistical power.
Another limitation within our analysis was the lack of survival within the solitary
aggregate group. Here, it is possible that our transplantation technique was harmful to the
solitary aggregates as they did not have the protection of an outer biomaterial encasement.
However, as fetal grafts transplanted into the striatum have been one of the most successful
regenerative strategies to treat PD,34–36 it is imperative that we are able to compare the
performance of the micro-TENNs to these grafts at long term time points. Therefore, in
future work we may need to develop a new transplantation technique for the solitary
aggregates or protect them with a temporary encasement to serve as an experimental
control group for comparison with our optimized micro-TENN transplantation
methodology.
Our transplantation technique was also restricted due to the linear nature of the
micro-TENNs. In vivo, the circuitry of the nigrostriatal pathway is complex, with
dopaminergic axons curving rather than projecting in a straight line from the SNpc to the
striatum. While our linear implantation trajectory was adequate to physically span the SNpc
and striatum, the trajectory should be refined in future studies to take into account relevant
sub-structures within these anatomical substrates. This will most likely involve the
development and fabrication of arched micro-TENNs that mimic the curvature of the
nigrostriatal pathway. Here, either molds or bioprinting techniques (discussed in section
5.2.1) could be employed to create micro-columns with a rounded architecture.
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While our optimized tissue clearing methodology was crucial to our ability to
analyze both the global and minute histological data, labeling the 2 mm thick slices of
tissue containing the micro-TENNs en masse severely limited the number of antibodies we
could use, as well as our ability to inspect the in vivo environment following
transplantation. In order to improve the long term survival of the constructs, it will be
necessary to have a comprehensive understanding of the cellular environment around the
micro-TENNs. As discussed in Chapter 4, the environment of the brain is hostile upon
transplantation; primary and secondary mechanisms of injury include the presence of
blood, hypoxia, ischemia, inflammation, excitotoxicity, reactive astrogliosis, and the
formation of a glial scar.37,38 Future exploratory studies should label implanted tissue to
assess the presence of blood, inflammation, B-cells, T-cells, reactive astrocytes,
microglia/macrophages, and glial scar formation. As discussed in the following section,
once we have knowledge of which mechanisms and/or processes could be harming the
micro-TENNs over time, we can further optimize the micro-TENNs and/or implantation
paradigm for improved survival in vivo.
Long term assessment of the performance of micro-TENNs in vivo was limited by
an apparent decreased survival rate at later time points. Therefore, increasing micro-TENN
survival rates at protracted time points (6+ months) will be a priority of future work. Such
work will be highly dependent upon which mechanisms and/or processes we believe are
damaging the micro-TENNs. In the case of blood, the slits cut into the sheath for escape of
air could be coated with a hydrophobic material to prevent the entrance of blood prior to
sheath removal. As mentioned in section 4.5, hypothermia treatment during the microTENN implantation procedure could be used to reduce the harmful effects of ischemia,
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including excitotoxicity and inflammation.39 Alternatively, micro-TENNs could be grown
in hypoxic cell culture conditions (as opposed to normal cell culture conditions with 21%
oxygen) to accustom micro-TENNs to a low oxygen environment. In the case of reactive
astrocytes, nonsteroidal anti-inflammatory inhibitory drugs (NSAIDs) have been shown to
reduce astrogliosis and decrease the upregulation of the glial fibrillary acidic protein
(GFAP) in both mice and in vitro models.40 Alternatively, treatment with inhibitors of
histone deacetylases (HDAC), such as valproic acid, has been shown to reduce
inflammation mediated by both reactive astrocytes and microglia.40–42 Both valproic acid
and NSAIDs are already used clinically, effectively cross the blood brain barrier (BBB),
and would not require local release at the transplantation site.43
In the event that we believed a glial scar was preventing micro-TENN outgrowth
into the host tissue, we could use the enzyme chondroitinase ABC to break down the
chondroitin sulfate proteoglycans that represent a large component of the glial scar.

44,45

Here, the micro-column could be engineered to provide sustained, controlled release of
chondroitinase ABC. Many hydrogels, including agarose, fibrin, collagen, and alginate,
have already successfully been used for controlled release within the nervous system of
animal models.46–48 In addition to combatting the glial scar, controlled release could be
used to provide the dopaminergic neurons with growth factors if we determine that microTENNs require enhanced trophic support upon transplantation for sustained viability. For
example, controlled release of glial cell line-derived neurotrophic factor (GDNF) and basic
fibroblast growth factor (bFGF) has shown to improve survival of transplanted
dopaminergic neurons and grafts.49,50
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Our studies were further limited to the use of only one biomaterial hydrogel for our
outer shell / micro-column. If histology revealed that there was a significant immune
response to the agarose, future studies could test the relative biocompatibility of other
hydrogels as the outer shell material. As mentioned above, several other hydrogels have
been successfully employed within neuroregenerative therapies for the nervous system.46–
48

Along these lines, the degradation rate of the micro-column biomaterial (whether agarose

or another hydrogel) could be adjusted for superior micro-TENN health. As shown in
Chapter 4, the 1% agarose micro-columns used within our studies had not fully degraded
by the 3 month time point. While the shell presumably provides the micro-TENN
neurons/axons with protection during and immediately following transplantation, a faster
degradation rate could reduce micro-TENN attrition in the event that the tube causes
ongoing inflammation, astrogliosis etc. A faster degradation rate could also enable
integration with the host at earlier time points. Among other properties, crosslinking
density and the inclusion of bonds subject to hydrolytic degradation can be used to tune
degradation within hydrogels.51,52 Therefore, future studies should fully characterize the
benefits and drawbacks of different degradation rates in relation to the micro-column’s
ability to protect the micro-TENNs, provide sustained delivery of chondroitinase
ABC/anti-inflammatory agents/growth factors, support integration with the host, and
instigate a minimal immune response.
Lastly, the number of surviving dopaminergic neurons and axons at long term time
points could potentially be raised simply by increasing the initial dose of dopaminergic
neurons. Here, either the size and/or purity of the dopaminergic aggregates could be
enhanced to initially deliver a greater number of dopaminergic neurons. Assuming
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consistent in vivo attrition rates, a higher initial dose could yield a sufficient number of
surviving dopaminergic neurons/axons. Furthermore, while we exceeded our dopamine
release goal of 100 nM within the striatal aggregates in vitro, the rat striatum has a
significantly larger volume than our striatal aggregates. Therefore, the dose of delivered
dopaminergic neurons may also need to be increased and/or optimized to promote
sufficient dopamine release throughout the entire striatal structure.
Once long-term in vivo survival is optimized for the dopaminergic micro-TENNs,
additional experimental animal groups should be added to future transplant studies. While
our work sought to compare the performance of micro-TENNs to previous regenerative
medicine strategies, L-DOPA and deep brain stimulation (DBS) are two of the most
common treatment strategies currently used clinically. Therefore, in order to demonstrate
superiority of the micro-TENNs, animal groups receiving treatment with L-DOPA and
DBS must be included.
While the 6-OHDA lesioned rat model provided a valuable in vivo environment for
the exploration of efficacy of the dopaminergic micro-TENNs, there were limitations to
this model. The ablation of the dopaminergic neurons in the 6-OHDA model was
representative of PD in that it mimicked dopaminergic loss in the SNpc and a lack of
dopaminergic innervation of the striatum. However, this model does not actually mirror
the underlying neuropathology of PD- the presence of Lewy bodies/neurites and activated
microglia that are believed to be responsible for the degeneration of the dopaminergic
neurons. Emerging animal models for neuroprotection studies have utilized
lipolysaccharide (LPS) and proteasomal inhibitors (PSIs) to trigger reactive microgliosis
and the formation of proteinous inclusions, respectively.53 Thus, while they are still being
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optimized, these models are representative of aspects of the PD process. Future studies
should transplant micro-TENNs into these neuroprotective models to assess if and how the
micro-TENN neurons are affected by the pathogenic mechanisms of PD. In conjunction,
we could also expose micro-TENNs in culture to alpha-synuclein fibrils (the primary
component of Lewy bodies) to see if they develop Lewy pathology and/or alter their
functional characteristics.54,55
Lastly, our in vivo assessment of dopamine release was limited by the thickness of
our cut brain slices. The maximum thickness of live brain slices used for FSCV recordings
is generally 400 µm.56–58 However, the outer diameter of the micro-TENN shell is 398 µm.
Therefore, it was extremely difficult to cut live brain slices containing the entirety of the
transplanted micro-TENNs; most sections cut through the micro-TENNs at some location.
In future studies, it may be worth attempting to use slices of greater thickness to avoid this
challenge. Conventional in vivo (live) voltammetry could avoid issues of mass transport,
but it would be hard to accurately target the end of the micro-TENN within the striatum
using this paradigm. Alternatively, our collaborators in neuroengineering are developing
micron-scale electrodes that could potentially be implanted within the micro-TENNs to
allow for continuous monitoring of dopamine release. However, such electrodes have not
yet been validated to record dopamine release, and could likely result in persistent and/or
exacerbated inflammation and fibrosis.

5.2.4 Clinical Translation
In order to supply the 80,000 dopaminergic cells and >3.0 cm axonal lengths needed
for functional improvement in humans, our micro-TENNs will eventually need to be scaled
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up considerably for clinical trials. Stem cells and other expandable, self-renewing cell
sources—whether allogeneic or autologous—are promising to address these needs. Such
methods, while presenting challenges in controlling differentiation, heterogeneity, and
maturity, amongst others, will avoid the limitations of fetal tissue grafts, specifically ethical
considerations and dearth of fetal source material. In particular, using emerging iPSC
methodology, a patient’s own cells could be efficiently differentiated into dopaminergic
neurons, thereby eliminating the need for immunosuppression.59 As a first step towards
this benchmark, our successful generation of micro-TENNs using dopaminergic neurons
derived from hESCs demonstrates feasibility of using human cell sources. While it is
possible that these autologous micro-TENNs would eventually degenerate similar to native
tissue, previous research has shown that dopaminergic neurons from tissue grafts can
survive decades in vivo despite ongoing degeneration of the native dopaminergic
system.10,60 Furthermore, we envision the development of Parkinson’s disease-resistant
micro-TENNs via genetic approaches to minimize α-synuclein (the primary pathological
protein in Parkinson’s disease) induced pathology to lengthen the micro-TENN lifespan.
For example, the dopaminergic neurons within the construct could be engineered to
overexpress GDNF, which has been shown to be neuroprotective in both animal and
cellular models of PD.61
In order to provide the >3.0 cm axonal lengths necessary to span the nigrostriatal
pathway in humans, the micro-TENN inner core material, outer shell hydrogel, and media
components will need to be optimized for the chosen clinical cell source. As mentioned in
section 5.2.1, a gradient of growth factors could also be employed to accelerate axonal
outgrowth within the tube. In the event that optimization of the micro-TENN fabrication
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methodology is not sufficient to produce the desired axonal lengths, the micro-TENN
technology may need to coalesce with other in vitro technologies to lengthen neurites via
mechanical tension. For example, Pfister et al. used a stepper motor to slowly separate two
populations of neurons, resulting in accelerated axonal growth rates of up to 8 mm/day
without harming the neuronal populations.62 Future work could employ a similar tactic to
stretch dopaminergic neurites within the micro-column.

5.3 Summary
Current clinically used treatments for Parkinson’s disease, such as levodopa and
DBS, result in unwanted side effects and their efficacy often decreases over time.
Furthermore, no regenerative medicine strategy is currently capable of simultaneously
replacing dopaminergic neurons in the SNpc while physically reconstructing their long
axonal tracts to the striatum. This dissertation explored the feasibility of using
dopaminergic micro-tissue engineered neural networks (micro-TENNs) to address the
current gaps in technology by restoring the circuit responsible for crucial motor control
feedback. Micro-TENNs could potentially be the first Parkinson’s disease treatment
capable of providing dopaminergic innervation to the striatum that is subject to the same
cellular modulation as the nigrostriatal pathway in vivo; crucially, in repairing the pathway,
micro-TENNs could restore the temporal characteristics of dopamine signaling in the
striatum.
This work confirmed that dopaminergic micro-TENNs demonstrating discrete
somatic and axonal regions could be fabricated to span the nigrostriatal pathway in rats.
These constructs demonstrated over 70% viability, over 50% dopaminergic purity, and
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lengths greater than 5 mm. Our worked showed that they had the machinery to release
dopamine, recycle dopamine, and functionally integrate with striatal neurons in vitro. Our
in vivo studies established that transplanted micro-TENNs could maintain their
cytoarchitecture, extend dopaminergic neurites into the host tissue, and release an
appropriate concentration of dopamine. This work also showed evidence of micro-TENN
attrition over time in vivo, which improved our knowledge of where future optimization
studies may be necessary for clinical translation.
Fabrication of micro-TENNs using autologous stem cell sources may enable the
construction of patient-specific constructs tailored to their particular extent of
degeneration. Such next-generation constructs may provide a transformative and scalable
solution to directly replace neurons in the SNpc, restore axon-based dopaminergic levels
in the striatum, and thereby alleviate the cause of motor symptoms in PD. In the coming
era of restorative neurosurgery, dopaminergic micro-TENNs have the potential to
revolutionize Parkinson’s disease treatment and dramatically improve outcomes for
millions of patients worldwide afflicted by PD.
In summary, we have established the first approach to physically replace the
nigrostriatal pathway and demonstrated proof of concept in a 6-OHDA lesion model of PD
in rats. This involved the development of novel techniques to bio-fabricate custom-length
dopaminergic micro-TENNs that were validated in vitro based upon robust dopamine
release and integration with striatal neurons. Micro-TENN implants restored dopamine
levels in the striatum, while demonstrating that neuronal survival and architecture were
improved in comparison to alternative implant paradigms, including purely cell-based and
biomaterial-based strategies. Given these promising results, future work should optimize
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dopaminergic micro-TENN bio-fabrication using a translatable human stem cell type, and
optimize the potency and consistency of this strategy.
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